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Heterogeneity: Comparing Clinical Trial Transport and Non-experimental Epidemiologic Methods  
(Under the direction of Jennifer Lund) 
 Oral anticoagulation is vital to the health of patients with atrial fibrillation at elevated risk of 
stroke. The first treatment for these patients, warfarin, was approved in the 1990s. Since 2010, 
dabigatran has been available for use after demonstrating non-inferiority to warfarin in a randomized 
controlled trial. Non-experimental studies comparing dabigatran to warfarin and censoring at treatment 
discontinuation have shown greater benefits than the original trial for all-cause mortality and 
attenuated harms for gastrointestinal bleeding.  
The goals of this dissertation, then, were to compute and compare 1) estimates of the absolute-
scale effects of dabigatran vs warfarin initiation on ischemic stroke (IS), death, and gastrointestinal 
bleeding (GIB) in trial-eligible older adults using non-experimental Medicare data and 2) estimates of 
those effects in the same populations using inverse odds of sampling weights to transport results from 
the Randomized Evaluation of Long-Term Anticoagulation (RE-LY) trial. 
First, we conducted a propensity score weighted non-experimental study with the new user 
active comparator design in a 20% random sample of Medicare beneficiares. We estimated on-
treatment two-year risk differences for IS (RD for dabigatran users, RDdabi: -0.67%, 95% CI -1.10%, -
0.24%), mortality (RDdabi: -2.98%, 95% CI -3.97%, -1.95%) and GIB (RDdabi: 0.51%, 95% CI -0.30%, 1.31%). 
Intention-to-treat estimates showed attenuation for mortality (RDdabi:    -1.65%, 95% CI -2.32%, -0.98%) 
and reversal for IS (RDdabi: 0.16%, 95% CI -0.20%, 0.52%). 
Next, we reweighted RE-LY to resemble the Medicare new users of warfarin or dabigatran 
(restricted to those with less than 15% predicted probability of frailty). After weighting, we estimated
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on-treatment two-year risk differences for IS (RDdabi: -0.77%, 95% CI -1.69%, 0.14%), death (RDdabi: -
0.57%, 95% CI -1.83%, 0.68%) and GIB (RDdabi: 1.75%, 95% CI 0.76%, 2.74%).
 These twin studies show non-experimental and weighted trial analyses comparing dabigatran to 
warfarin agree much better for IS than they do for mortality or GIB. This could be due to confounding in 
the non-experimental estimates, missing treatment effect modifiers, or outcome misclassification. 
Researchers should be cautious about comparing studies without considering treatment effect 
heterogeneity and differences in adherence across study populations.
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CHAPTER 1: SPECIFIC AIMS 
Atrial fibrillation affects 33 million adults worldwide.1 Even if individuals with atrial fibrillation 
are asymptomatic, stroke incidence in the atrial fibrillation population is much higher and resulting 
strokes are more frequently associated with death, hospitalization, and long-term disability than strokes 
in adults without atrial fibrillation.2,3 Warfarin, the standard treatment for preventing strokes in atrial 
fibrillation, is difficult to manage therapeutically due to its lengthy half-life and narrow therapeutic 
range. Warfarin overdose can also result in catastrophic bleeding events.4 Novel oral anticoagulants 
have been shown to be non-inferior to warfarin administered with systematic management protocols in 
clinical trial populations.5 One of the first novel anticoagulants to be approved in the United States, 
dabigatran, was shown to be more effective than warfarin at stroke and embolic event prevention (HR 
0.66, 95% C.I. 0.53-0.82) with no increase in bleeding (HR 0.93, 95% C.I. 1.07) in the RE-LY trial.6 
However, estimates of efficacy in these clinical trials are not estimates of effectiveness in clinical 
care.7,8 Patients selected into trials tend to be young with fewer comorbidities than the general 
population; this can modify the population average treatment effect.9,10 To address concerns about this 
potential treatment effect modification, studies have used observational claims data to directly estimate 
safety of novel oral anticoagulants compared to warfarin in clinical care and observed attenuated 
efficacy and differing safety profiles. Unfortunately, their results may be confounded by unmeasured 
variables.11-20 Furthermore, warfarin management protocols from trials do not necessarily represent the 
way warfarin is managed for patients in routine clinical care, making it difficult to know how consistent 
warfarin treatment is between trial and observational populations.21 
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The overarching goal of this dissertation is to estimate treatment effects in various Medicare 
populations of older adults, juxtaposing the estimates obtained from relatively novel methods for 
transporting treatment effects from a trial with estimates obtained using more standard propensity 
score weighting in those older adults. 
 
Specifically, I will: 
Specific Aim 1: Estimate the effect of dabigatran versus warfarin initiation on two-year risks of ischemic 
stroke, death, and gastrointestinal bleeding in Medicare beneficiaries with atrial fibrillation using non-
experimental data and propensity score methods. 
1.1: Estimate absolute effects of dabigatran versus warfarin on two-year risks of ischemic stroke, 
death, and gastrointestinal bleeding in warfarin and dabigatran new users with a new user 
active comparator design under both intention-to-treat and as-treated follow-up. 
 
Specific Aim 2: Estimate the effect of dabigatran versus warfarin initiation on the two-year risk of 
ischemic stroke, death, and gastrointestinal bleeding among Medicare beneficiaries with atrial 
fibrillation using transportability methods reweighting the RE-LY trial data. 
2.1: Compare risks of each outcome between the RE-LY and Medicare cohorts on each 
treatment before and after using inverse odds of sampling weights to standardize RE-LY to 
Medicare with respect to effect measure modifiers (EMM).  
2.2: Estimate the absolute effect of dabigatran versus warfarin on two-year risks of ischemic 
stroke, death, and gastrointestinal bleeding using inverse odds of sampling weights to 
standardize the RE-LY trial to the Medicare cohort in effect measure modifiers.  




CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
2.1: Atrial Fibrillation 
2.1.1: Pathophysiology 
Atrial fibrillation (AF) is a 
type of sustained disorder of 
cardiac rhythm in which the upper 
chambers of the heart beat 
irregularly due to abnormal 
impulse formation for any reason 
(see Figure 1).22 AF is typically 
divided into valvular and non-
valvular categories based upon the 
etiology of the rhythm disorder, 
with valvular diseases tracing back 
to rheumatic diseases of the mitral 
valve or valve replacement.23 In both types of AF the atria’s chaotic beat overwhelms the 
atrioventricular node until it is unable to create consistent ventricular contractions, creating irregular 
time intervals between heartbeats. This leads to the symptoms of AF including heart palpitations, 
lightheadedness, fatigue, shortness of breath, and chest pain, though these symptoms do not occur in 
everyone with an irregular heartbeat.22 Symptomatic episodes may be brought on by a 
Figure 1: A heart and EKG with and without AF-picture from 
PracticalClinicalSkills.com. Note the chaotic lines within the heart 
on the right and the irregular spacing between EKG peaks. 
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variety of stimuli, including caffeine, stress, poor sleep, and (for some individuals) exercise, but the 
chronic disease persists regardless. The best ways to relieve symptoms are the use of medications or 
procedures for rate or rhythm control, but neither of these strategies have substantive morbidity or 
mortality benefits.24  
Even when symptoms are controlled, the most devastating consequence of AF is stroke after an 
atrial blood clot, or thrombus, is dislodged and finds its way to the brain. Rudolf Virchow proposed a trio 
of risk factors for thrombotic events: abnormal changes in the walls of blood vessels, abnormal blood 
flow, and abnormal blood constraints.25 Research using modern imaging and other technology has 
shown that AF leads to long-term changes in the heart and blood’s structure that suffice to cover all 
three components of Virchow’s Triad to substantially promote thrombogenesis.25 As a result of these 
structural and chemical changes in the human body, AF increases an individual’s risk of stroke by a 
factor of 5 and creates associated increases in rates of dementia and mortality; the strokes themselves 
are also more harmful on average than strokes in individuals without AF.2,26 This is especially concerning 
because many of the risk factors for AF (high blood pressure, congestive heart failure, history of heart 
attacks, obesity, and diabetes) are also risk factors for stroke.27 While guidelines disagree about which 
AF patients merit oral anticoagulation to counteract this increased stroke risk, most agree that aging 







2.1.2: Population burden 
AF is one of the most common heart rhythm disorders, affecting 33 million adults around the 
world.1 In the United States, between 2.7 and 6.1 million people have atrial fibrillation, with it affecting 
2% of individuals under 65 and 9% of individuals over 65.22 As the world’s population ages the incidence 
and prevalence of atrial fibrillation is rising worldwide.29-31 The United States is no exception: analyses of 
the Framingham Heart Study have shown prevalent and incident AF increasing in the past 50 years in 
both men and women, and an analysis in Minnesota using ECG data showed the incidence of AF 
increasing by 12.3% from 1980 to 2000.32,33 If these trends continue, there will be 15.9 million U.S. 
adults with AF by 2050 rather than previous estimates of 5.6 million (Figure 2).32  These changes are 
hypothesized to be due to enhanced surveillance, reduced mortality from a host of risk factors for AF, 
and higher population life expectancy.33 This increased prevalence is paired with high economic costs: 
the annual adjusted per capita medical cost of individuals with AF using U.S. claims data is $10,355 
higher than that of individuals without AF for patients 18-65 and $3,600 higher for patients over 65, with 
Figure 2: Projected U.S. population with AF over time from Miyasaka et al’s work in Minnesota. 
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undiagnosed AF only adding to the overall cost to the U.S. healthcare system.34 By far the most costly 
cardiovascular outcome of AF is stroke, which imposes a large burden on both the patient and various 
caregivers. Direct costs to Medicare for AF-related strokes have been estimated at $2.6 billion.35 As 
more patients are diagnosed with AF and the population ages, identifying optimal pharmacologic 
treatments to reduce the cardiovascular AF outcomes of stroke and mortality is key to improving public 





2.2: Pharmacologic Treatment Options for Anticoagulation 
2.2.1: Warfarin 
Warfarin (also known as coumadin or coumarin) has been the 
treatment of choice for oral anticoagulation in patients with AF at 
high risk for stroke for more than 50 years.22 Initially used as a rat 
poison, potential health benefits as an anticoagulant were identified 
at the University of Wisconsin.36  Warfarin prevents the synthesis of 
several key vitamin K dependent clotting factors in the liver. This 
leads to reduced thrombolysis, stroke, and death. Unfortunately, 
warfarin features both a narrow therapeutic range and an extremely 
long and variable half-life between 20 and 60 hours.37 As a result, 
medical providers need to carefully titrate and monitor the dosing of individuals on warfarin to ensure 
their international normalized ratio for clotting (INR) stays within the therapeutic range (generally 
between 2 and 3 for non-valvular AF patients and slightly higher for patients with prosthetic heart 
valves) to prevent excessive bleeding events.37 These INRs are an estimate of the time it takes blood to 
clot and are typically taken at least weekly while doses are being initially adjusted. Even when a patient 
is stable with a consistent warfarin dose, guidelines recommend patients are monitored monthly 
(though extremely consistent and reliable patients may be suitable for monitoring every two months).22 
Further complicating matters, due to warfarin’s metabolism by multiple cytochrome P 450 (CYP) 
enzymatic pathways and mechanisms of action, serum concentrations of warfarin can be substantially 
altered by antibiotics, herbal remedies, and even the amount of green vegetables in an individual’s 
diet.38 This creates a panoply of interactions that can quickly result in subtherapeutic or 
supratherapeutic INRs unless dosing is carefully monitored, even when warfarin is being taken as 
directed. While antidotes to warfarin-induced bleeding are straightforward due to the low cost and ease 
Figure 3: Warfarin as it was 
available in the early 20th century. 
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of administering a vitamin K infusion, long-term damage from bleeding events can be severe and the 
hospitalizations still have a mean cost of $10,819.39 While many attempts have been made to identify 
optimal methods for initiating patients on warfarin using both randomized trials and observational data, 
including attempts to leverage pharmacogenomics, 40-42 the science of warfarin dosing remains 
challenging. Still, anticoagulation with warfarin is the definitive benchmark for thromboprophylactic AF 
treatment and all alternative medications must be able to demonstrate non-inferiority in safety and 
efficacy relative to warfarin to obtain regulatory agency approval in both the United States and 
internationally. 
 
2.2.2: Novel Oral Anticoagulants (NOACs) 
Due to advances in biological understanding and chemical engineering, the 21st century saw the 
advent of additional oral anticoagulant options.36 Instead of targeting vitamin K synthesis to reduce 
levels of circulating clotting factors, these agents either directly inhibit factor Xa or thrombin.43 NOACs 
possess a significantly shorter half-life compared to warfarin and a much wider space where doses are 
both efficacious and safe, making therapeutic monitoring much less necessary during the course of long-
term anticoagulation.43 Between these characteristics and their smaller suite of drug interactions, there 
is limited to no need for the patient-specific dosing characteristic of warfarin treatment beyond 
potential renal dose adjustment.22 Large-scale randomized controlled trials (RCTs) were performed to 
assess non-inferiority to warfarin with respect to both safety and efficacy, and the results were 
sufficiently positive to allow approval and marketing of many NOACs in the United States and 
elsewhere.44-47 Since their approval, NOACs have increased in market share in clinical cohorts to the 
point where warfarin is used in fewer than 50% of patients in some countries, allowing comparative 
studies of warfarin to the NOACs similar to the one proposed in the current study.48,49 Notably, NOACs 
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have generally only been approved for the treatment of non-valvular AF, so valvular AF is still treated 
with warfarin. 
2.2.2.1: Dabigatran 
Dabigatran (brand name Pradaxa) was the first of the 
NOACs to be approved in the United States for use in 
patients with non-valvular AF on October 10th, 2010. 
Dabigatran is a direct thrombin inhibitor, binding to 
thrombin to prevent thrombin’s conversion of 
fibrinogen to the fibrin used to bind together platelets 
and create blood clots. It has a half-life of between 12 
and 14 hours that is consistent across patients with 
normal renal function, resulting in twice-a-day dosing, 
and is eliminated renally, hepatically, and through P-glycoprotein pumps.50 Because it is not a CYP 
substrate, it possesses far fewer drug interactions than warfarin (though it interacts with P-glycoprotein 
inhibitors like proton-pump inhibitors) and because it acts on thrombin directly its effectiveness is not 
dependent on the amount of vitamin K a patient consumes. While the RE-LY trial examined both 110 mg 
and 150 mg dabigatran doses twice daily, only the 150 mg dosage was approved in the United States 
with a 75 mg dosage available for individuals with creatinine clearance between 15 and 30 mL/min. As 
of October 2015, Dabigatran is the first of the NOACs to have its own targeted reversal agent, 
idarucizumab, which binds with dabigatran at the molecular level with higher affinity than thrombin to 
rapidly reverse dabigatran’s effects.51-53 Boehringer Ingelheim has posted the trial on 
ClinicalStudyDataRequest.com, a site allowing investigators access to individual-level trial data. 
 
  
Figure 4: Dabigatran packaging. 
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2.2.2.2: Other NOACs 
Several other drugs have recently been discovered that fall under the umbrella of novel oral 
anticoagulants. Rivaroxaban (approved in the U.S. for AF on November 4th, 2011), apixaban (approved in 
the U.S. for AF on December 28th, 2012), and edoxaban (approved in the U.S. for AF January 8th, 2015) 
inhibit factor Xa of the clotting cascade, meaning they have a slightly different mechanism of action than 
dabigatran.54 Notably, rivaroxaban is the only one of these agents with once-daily dosing for prevention 
of stroke in AF. Each of these agents was approved after a randomized non-inferiority trial comparing 
them to warfarin: the ROCKET-AF trial by Bayer for rivaroxaban,47 the ARISTOTLE trial by Pfizer and 
Bristol-Myers Squib for apixaban,44 and the ENGAGE-AF trial by Daiichi Sankyo for edoxaban.46 In these 
trials, apixaban and edoxaban demonstrated superiority to warfarin with respect to both stroke 
prevention and major bleeding, rather than the stroke superiority and major bleeding non-inferiority 
shown by dabigatran and rivaroxaban. Andexanet alfa has been developed as an antidote for major 
bleeding associated with the use of any of these Xa inhibitors.55 Unfortunately, none of these trials are 
posted on ClinicalStudyDataRequest.com; individual-level or joint categorical trial data would need to be 
obtained through direct contact with the pharmaceutical company. Their later approval (particularly for 
apixaban and edoxaban) means that comparative effectiveness studies have a smaller sample size, 
particularly if data is only available through 2015 or the advent of ICD-10 codes, though there have still 





2.3: Existing Evidence on Dabigatran Safety and Efficacy 
 As with any approved drug, a great deal of research has been conducted in efforts to gauge the 
safety and efficacy of dabigatran. Several randomized controlled trials and multiple observational 
studies have sought to determine the relative merits of each potential pharmacologic treatment option. 
Table 1 at the end of section 2.3 lists the results of some of these pivotal studies; more specifics 
regarding methodology and potential reasons for differing results are given throughout Section 2.3, as 
are the results of a phase II randomized controlled trial and subgroup analysis results from RE-LY. 
 
2.3.1: Randomized Controlled Trials 
2.3.1.1: RE-LY Trial 
Dabigatran’s approval for the indication of stroke prophylaxis in AF was based on the RE-LY non-
inferiority trial.6 In RE-LY, more than 18,000 AF patients from 951 clinical centers in more than 44 
countries were randomized to receive warfarin under a standard dosing protocol, twice daily dabigatran 
110 mg, or twice daily dabigatran 150 mg. Patients were blinded to which dose of dabigatran they 
received, but use of warfarin was open-label. Patients were followed for a variety of outcomes in an 
intention-to-treat analysis. Markedly reduced hazards were observed for the primary efficacy outcome 
of stroke or systolic embolism for patients in the 150 mg dabigatran arm versus the warfarin arm (HR: 
0.66, 95% C.I. 0.53, 0.82) and major bleeding overall was also slightly lower (HR: 0.93, 95% C.I. 0.81, 
1.07), but much higher rates of gastrointestinal bleeding were observed (HR: 1.50, 95% C.I. 1.19, 1.89). 
Notably, the HR for ischemic stroke (rather than combined hemorrhagic and ischemic stroke) was 0.76 
(95% C.I. 0.60, 98) in the 150 mg arm. The 110 mg dose of dabigatran, on the other hand, had a larger 
decrease in major bleeding versus warfarin (HR: 0.80, 95% C.I. 0.69, 0.93) and a smaller increase in 
gastrointestinal bleeding (HR: 1.10, 95% C.I. 0.86, 1.41) but a much smaller improvement in the primary 
efficacy outcome (HR: 0.91, 95% C.I. 0.74, 1.11). Both the 110 mg and 150 mg dosage improved survival 
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versus warfarin with a HR of 0.91 (95% C.I. 0.80, 1.03) and 0.88 (95% C.I. 0.77, 1.00), respectively. The 
non-inferiority margins set by the investigators were all met, and the drug was approved for dosing at 
150 mg twice daily. It is not clear, however, how these tradeoffs might manifest in populations with 
differing distributions of risk factors for bleeding and stroke. 
 
2.3.1.2: Evidence for 
Heterogeneity in RE-LY 
Some trialists have taken the 
position that subgroup 
analyses (and effect 
heterogeneity) should be 
ignored and the population 
relative effect should simply 
be applied to the estimated 
risks of individuals in each 
subgroup.56,57 This represents 
a significant assumption that 
effectively ignores the 
potential for biological 
differences in dose or 
individual metabolism of the 
studied drug. There is some 
evidence for heterogeneity of dabigatran effect in the RE-LY trial on the multiplicative scale used for the 
main analyses (p < 0.25 for the interaction) with respect to ethnic group, amiodarone use, sex, body-
Figure 5: Sub-group treatment effect estimates from the RE-LY trial. 
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mass index, and PPI use at baseline, as seen in Figure 5. Furthermore, age was not examined in their 
efficacy subgroup analyses. All of these factors may differ between the population of RE-LY patients and 
the Medicare AF patients; see Section D.1 for additional details. In addition, if the other variables in the 
table are associated with AF outcomes and are indeed not effect modifiers on the multiplicative scale, 
they will be effect modifiers on the absolute scale and necessary for estimating a valid risk difference 
and number needed to treat (NNT) for the clinical cohort.58  Furthermore, subsequent analyses of the 
RE-LY trial specifically analyzing different types of bleeding risk demonstrated relative scale effect 
heterogeneity based upon age when categorized above and below 75, particularly for extracranial 
hemorrhages.59,60 Similar subgroup analyses were conducted for the stroke outcome in patients with 
heart failure,61 patients using other antiplatelet therapies,62 patients with history of stroke or transient 
ischemic attack,61 and patients with paroxysmal vs persistent vs intermittent AF,63 with none of the 
analyses finding substantial heterogeneity on the hazard ratio scale but typically preserving benefit. 
 
2.3.1.3: Other Trials of Dabigatran vs Warfarin 
There were two additional relevant trials for dabigatran that investigated its safety or efficacy, 
both showing roughly similar results to RE-LY: The PETRO trial and the RE-COVER trial. The PETRO trial 
was particularly relevant as the first trial evaluating dabigatran in patients with AF and showed similar 
bleeding risk between 150 mg of dabigatran twice daily and warfarin in the AF population.64 As a phase II 
trial, it was much smaller than the RE-LY trial, enrolling 502 patients and randomizing them to one of 
four trial arms: 50 mg of dabigatran twice daily, 150 mg of dabigatran twice daily, 300 mg of dabigatran 
twice daily, or warfarin with a target INR of 2-3, with the warfarin arm being open-label. If patients were 
randomized to one of the dabigatran groups, they were further randomized to take no aspirin, 81 mg of 
aspirin, or 325 mg of aspirin once daily as well. Like RE-LY, PETRO enrolled individuals with AF that were 
at high risk of thromboembolic events. Like RE-LY, PETRO was conducted in international study centers, 
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though the study centers were generally in European countries as well as the United States. Unlike RE-
LY, PETRO was a phase II study focused on determining a safe dose of dabigatran that would result in an 
acceptable level of bleeding events relative to warfarin. It also sought to identify efficacy by examining 
the anticoagulant activity biomarkers of activated partial thromboplastin time and inhibition of D-dimer 
generation. Study investigators did not test a formal statistical hypothesis, instead seeking mainly to 
measure data on pharmacodynamics to help decide which doses should be used in the RE-LY study. 
Major bleeding events only occurred in the 300 mg of dabigatran twice daily group taking 81 mg or 325 
mg of aspirin, and there were generally more bleeding events with higher doses of dabigatran and 
higher doses of aspirin. Of the groups, only the 50 mg dabigatran group had substantially lower 
incidences of bleed than warfarin; the 150 mg dabigatran group was comparable. Only the 50 mg group 
experienced any embolic events. Biomarker analyses bore out these results. The end result of the study 
was to move forward with the 150 mg twice daily dabigatran dose, rather than the 50 mg or 300 mg 
dose, due to its favorable bleeding and embolic profile. 
 The second study, the RE-COVER trial, was an investigation of the use of dabigatran when 
treating venous thromboembolism and showed some potential heterogeneity in bleeding effects.65 RE-
COVER enrolled 2,564 patients with acute venous thromboembolism from 228 clinical centers in 23 
countries and randomized them to receive dabigatran 150 mg twice daily or warfarin with a target INR 
of 2-3. RE-COVER assessed both safety and efficacy in the setting of venous thromboembolism, and 
since it used a similar dosage of dabigatran as RE-LY the safety information is particularly valuable. 
Unlike RE-LY, however, RE-COVER was a double-blind double-dummy trial, where individuals taking 
dabigatran were given placebo warfarin pills and even had placebo INRs and dose adjustments 
performed, and it had a shorter follow-up time (six months). Unlike the results of RE-LY, RE-COVER 
found strong reductions in major and clinically relevant bleeding for dabigatran 150 mg twice daily (HR: 
0.63, 95% C.I. 0.47, 0.84) and for any bleeding event (HR: 0.71, 95% C.I. 0.59, 0.85), though there were 
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more gastrointestinal bleeds in the dabigatran group than the warfarin group (53 vs. 35). Because RE-LY 
focused on including individuals with cardiovascular risk factors, including age and diabetes, RE-COVER’s 
population was generally younger (mean age 71.5 in RE-LY vs mean age 55.0 in RE-COVER), suggesting 
there may be some modification of bleeding effect by age or these other risk factors that could account 
for the improved overall bleeding profile in RE-COVER. 
 
2.3.2: Non-experimental Studies 
There have been several comparative effectiveness studies published using routintely collected 
claims data in an attempt to determine whether dabigatran and other NOACs are as or more effective in 
practice compared to their performance in clinical trials. Their results have varied, but all have differed 
from RE-LY in one way or another. On the whole they reinforce the need for additional studies and 
examination of potential treatment effect heterogeneity. 
Perhaps the largest study to date has been the FDA’s analysis using initiators of warfarin and 
dabigatran in the full Medicare sample from October 2010 to December 2012.15 They identified 67,494 
new initiators of dabigatran and 273,920 new initiators of warfarin including individuals with any 
inpatient or outpatient diagnoses for AF or atrial flutter and excluding individuals with other competing 
indications for warfarin treatment. They used propensity score matching to eliminate differences in their 
study variables; based upon standardized mean differences (SMDs) they were successful and all 
dabigatran individuals had a match. They used an as-treated design, censoring individuals from the 
analysis after switching anticoagulants or a gap in days’ supply of 3 days, though a sensitivity analysis 
examined the ramifications of allowing a grace period of up to 14 days. Their death outcome was not 
actually death; instead, they analyzed deaths not preceded by a study outcome or within 30 days of 
hospitalization for a study outcome, making it difficult to interpret. They estimated a hazard ratio of 
0.80 (95% C.I. 0.67, 0.96) for ischemic stroke, favoring dabigatran, and a hazard ratio of 0.97 (95% C.I. 
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0.88, 1.07) for major bleeding, with a heightened risk of gastrointestinal bleeding for dabigatran patients 
with a hazard ratio of 1.28 (95% C.I. 1.14, 1.44); when they looked at dosages of 150 mg specifically, 
rather than 75 mg, they found improved stroke reduction (hazard ratio of 0.70) but greater risk of 
gastrointestinal bleed (hazard ratio of 1.51) more in line with the results of the RE-LY trial. They did 
notice, however, that the increase in the risk of gastrointestinal bleeding was concentrated in older 
adults, particularly women over 75 and men over 85. Women over 85 were the only group with an 
increased risk of mortality from dabigatran, but other groups experienced an improvement in mortality 
with an overall hazard ratio of 0.76 (95% C.I. 0.67, 0.86) with the 150 mg dose, more pronounced than 
the 0.88 observed in the RE-LY trial. The fact that they implemented an as-treated design and used such 
a short gap in days supply despite the large variance in warfarin prescribing makes it difficult to interpret 
the extent to which their findings parallel those from RE-LY. Still, the results were largely similar to the 
trial results on the relative scale, with a lower hazard ratio for mortality and some evidence of bleeding 
effect heterogeneity based on age and sex. 
At the same time the FDA study was running on the full Medicare sample, Hernandez et al were 
investigating the question using the 5% Medicare sample.16 This study only used Medicare initiators 
from October 2010 to October 2011, limiting the population, and required two outpatient diagnoses for 
AF or atrial flutter to qualify an individual as an AF patient, as well as requiring individuals to fill within 
two months of their incident diagnosis (while the FDA merely required a diagnosis at any time before 
filling). The resulting cohort had only 1,302 Dabigatran users and 8,102 warfarin initiators, who they 
compared after using inverse probability of treatment weighting based on a propensity score. They also 
used an as-treated design but provided a 60 day grace period and censored individuals at death. They 
focused predominantly on bleeding outcomes, rather than stroke or systemic embolism. They provide p 
values rather than SMDs so it is difficult to determine how successful their weighting process was, but it 
seems to have performed well for most variables. While it would be quite useful to see the extent of the 
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propensity score overlap to compare the difference between the dabigatran user and whole population, 
they do not share this information in their paper or supplement. After adjustment, they identified an 
increased risk of major bleeding with a hazard ratio of 1.58 (95% C.I. 1.36, 1.83) and an increased risk of 
gastrointestinal bleeding with a hazard ratio of 1.85 (95% C.I. 1.64, 2.07), both higher than the original 
RE-LY trial. Despite being conducted on a subsample of the FDA data, their results looked quite a bit 
worse for dabigatran, suggesting that either the difference in grace period, the use of a different target 
population than the FDA (the whole population of initiators rather than the dabigatran patients targeted 
in a matched design), worse confounding control, or all three are to blame. 
Other U.S. governmental databases have been used to answer this question as well. Villines et al 
utilized the Department of Defense database, which provides uniform medical coverage and pharmacy 
benefits to nearly 10 million individuals receiving care at both military and non-military institutions, to 
find initiators of dabigatran and warfarin from October 2010 to July 2012 with at least one diagnosis for 
AF within 12 months of their initiation.17 They identified a cohort of 14,813 dabigatran users and 24,500 
warfarin initiators, with propensity score matching using a model built by backwards selection reducing 
it to 12,793 of each. These authors used a grace period of 30 days after the final prescription, with 
sensitivity analyses exploring the impact of a 45 and 60 day grace period and integrating INR 
measurements as a way to extend follow-up, though it is unclear how they identified INR 
measurements. They stopped following patients at death. Comparing dabigatran to warfarin, they 
estimated a hazard ratio for stroke of 0.73 (95% C.I. 0.55, 0.97), a hazard ratio for major bleeding of 0.87 
(95% C.I. 0.74, 1.03) and 0.82 (95% C.I. 0.71, 0.95) when restricting to 150 mg doses, and a hazard ratio 
for gastrointestinal bleeding of 1.13 (95% C.I. 0.94, 1.37). Additionally, they found a hazard ratio for 
myocardial infarction of 0.65 (95% C.I. 0.45, 0.95), much lower than that observed in RE-LY of 1.35 (95% 
C.I. 0.98, 1.87); similarly, the hazard ratio for death was 0.64 (95% C.I. 0.55, 0.74). The authors state 
none of their sensitivity analyses examining the impact of longer or INR-supplemented follow-up periods 
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changed results much. Overall, their results were more similar to the RE-LY results than the other non-
experimental studies, but the fact that the gastrointestinal bleeding, M.I. and death estimates were 
substantially better for dabigatran than those from RE-LY is notable. Unfortunately, it is impossible to 
determine whether these differences are because of poor confounding control or heterogeneity, 
measured or otherwise, between this and the RE-LY trial population. 
Other researchers examined private insurance databases. Seeger, Schneeweiss, et al performed 
an analysis using data from two commercial insurance databases (MarketScan from Truven and 
Clinformatics from Optum) focusing on both safety and efficacy.18 These investigators identified 41,103 
warfarin and 18,560 dabigatran initiators between October 2010 and December 2013. The authors 
matched on a propensity score with 78 investigator-specified covariates, resulting in a final cohort of 
15,529 initiators of each medication (with successful removal of imbalances in the covariates as 
measured by the SMD), with an additional analysis using high-dimensional propensity scores. They 
performed an as-treated analysis with a grace period of 14 days without any days supply on hand, but 
also performed a sensitivity analysis extending this period by 365 days in an imitation of an intention-to-
treat analysis. This study was the first to look at benefits on an absolute scale, rather than reporting 
purely hazard ratios. Individuals stopped follow-up at the time of death. Unlike many of the other 
studies, they combined ischemic and hemorrhagic strokes in their analysis. When contrasting dabigatran 
with warfarin, they found a hazard ratio of 0.77 (95% C.I. 0.54, 1.09) and one-year risk difference of -
0.0003 (95% C.I. -0.0006, 0.0002) for strokes and a hazard ratio of 0.75 (95% C.I. 0.65, 0.87) and risk 
difference of -0.018 (95% C.I. -0.025, -0.010) for major hemorrhages; they did not investigate 
gastrointestinal hemorrhages or mortality. P values for the proportional hazards assumption were 0.23 
and 0.18 for stroke and major bleeding. Despite their more pronounced hazard ratio for major bleed 
compared with the trial (0.75 vs. 0.93), they did not detect any “significant” heterogeneity in major 
bleeding across their subgroups. On the other hand, they noted some trends towards improved 
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dabigatran stroke reduction in adults over 75 and improved reduction in major hemorrhage in adults 
under 55. All of this suggests that an older population (such the warfarin users in their analysis) might 
experience a differing risk/benefit profile than that in this study on both the absolute and relative scale. 
Another large-scale study was conducted in Denmark, where both the 110 mg and 150 mg twice 
daily doses of dabigatran were approved for use in August 2011.66 They included dabigatran initiators 
after August 2011 and only allowed warfarin initiators to enter between August 2009 and July 2010, 
resulting in initial cohorts of 5,106 dabigatran and 13,548 warfarin patients. This was another 
propensity-score matched analysis (this time matched 2:1) that found matches for 4,978 dabigatran 
patients of either dosage and censored at treatment switching but not discontinuation with two levels 
of propensity score; they built their model for treatment choice using warfarin initiators after August 
2011 and then applied it to warfarin users from 2009 to 2010, and also built a model predicting which 
type of dabigatran an individual would initiate if they did initiate dabigatran. This latter step was 
designed to allow them to perform contrasts for each of the doses, but did not appear successful: quite 
a few of their covariates show SMDs greater than 10% for one or both of the dosages, including key 
confounders like renal function, sex, age, and some of the medication usages at baseline. Possibly as a 
result, they found large mortality benefits for both doses of dabigatran with hazard ratios of 0.79 (95% 
C.I. 0.65, 0.95) for the 110 mg dose and 0.57 (95% C.I. 0.40, 0.80) for the 150 mg dose compared to 
warfarin. They also found much lower risks of gastrointestinal bleeding comparing dabigatran 110 mg 
with warfarin with a hazard ratio of 0.60 (95% C.I. 0.37, 0.93) and only a slight increase for 150 mg with a 
hazard ratio of 1.12 (95% C.I. 0.67, 1.83), with favorable results for major bleeding with both dosages as 
well (HR: 0.82 (95% C.I. 0.59, 1.12) for the 110 mg dose and HR: 0.77 (95% C.I. 0.51, 1.13) for the 150 mg 
dose). Stroke benefits were also inconsistent with findings from other studies and with the logical 
assumption that higher doses will prevent more embolisms, with hazard ratios of 0.73 (95% C.I. 0.53, 
1.00) for the 110 mg dose and 1.18 (95% C.I. 0.85, 1.64) for the 150 mg dose. Given the large differences 
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between their cohorts even after propensity score matching and the strange trends between dabigatran 
doses (which could be the result of matching to different cohorts), their results are difficult to interpret 
but seem to show more pronounced benefits for dabigatran compared to the results from the RE-LY trial 
and other non-experimental studies. 
The final and most recent study focusing specifically on the contrast between dabigatran and 
warfarin in AF was conducted by the FDA with the Sentinel system in 2017.20 The Sentinel network 
collects data from a variety of administrative, clinical, and pharmacy dispensing databases for use in 
large-scale investigations of key medical questions in the United States.67 Using this system and data 
from November 2010 to May 2014, Go et al conducted an propensity-score matched analysis (with 
matching and model estimation performed within each of the data partners), identifying 25,289 
dabigatran initiators and finding matches for each one amongst the 83,034 warfarin initiators. They 
conducted an as-treated analysis with a grace period of 7 days between prescriptions and allowance for 
stockpiling on medications. Individuals were censored at death. Because they used many claims-based 
insurance sources, their mean age of 68.4 was lower than many of the Medicare-based studies or the 
RE-LY trial itself. Their propensity score was quite successful in removing the differences between all 
their measured covariates (as one might expect with such a large sample). They estimated a hazard ratio 
for ischemic stroke of 0.92 (95% C.I. 0.65, 1.28) and a hazard ratio for gastrointestinal bleeding of 1.04 
(95% C.I. 0.83-1.30), meaning their results showed both less benefit and less harm than the RE-LY trial. 
Interestingly, however, they did identify substantial heterogeneity in gastrointestinal bleeding with 
those under 65 having a hazard ratio of 0.59 (95% C.I. 0.32-1.07), those between 65 and 74 having a 
hazard ratio of 0.81 (95% C.I. 0.52-1.24), those between 75 and 84 having a hazard ratio of 1.47 (95% C.I. 
1.05, 2.14) and those over 85 experiencing a hazard ratio of 1.84 (95% C.I. 1.05, 3.20). There was also 
some heterogeneity by kidney function in both ischemic stroke and gastrointestinal bleeding risks, 
though this may be due to other concomitant factors associated with reduced kidney function like age, 
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hypertension, diabetes, and congestive heart failure. Overall, while they used an as-treated design that 
differed from RE-LY and included a younger patient population, these results reinforce that the overall 
benefits and risks of treatment with dabigatran may be quite heterogeneous across populations and 
that these heterogeneities in risk may only become apparent in large databases. 
There is another study focusing on several different NOACs with dabigatran as one of the 
potential options whose results also warrant discussion. Lip et al conducted a study in MarketScan 
examining NOAC initiators from January to December 2013 focusing specifically on major bleeding risk 
and using Cox proportional hazards with direct adjustment for a variety of variables and backwards 
selection at p < 0.2.11 These authors identified a decreased rate of  
major bleeding for dabigatran relative to warfarin (HR: 0.88, 95% C.I. 0.64-1.21). Their propensity 
matched analysis showed a slightly reduced rate of major bleeding with a hazard ratio of 0.69 (95% C.I. 
0.50-0.96), suggesting some potential treatment effect heterogeneity.12 In both analyses individuals 
were followed until discontinuation from their initial medication or switching, though the amount of gap 
or grace period they allowed is unclear. These results generally seem to agree with those of other 
studies in younger, claims- 
based cohorts. 
 Overall, there is still significant clinical uncertainty about the actual benefit/risk profile of 
dabigatran compared to warfarin; still, these studies have clearly shed light on the fact that there is 
likely heterogeneity in the safety and efficacy of dabigatran with respect to warfarin. While each of the 
studies added to our body of knowledge only one of them implemented an intention-to-treat analysis 
for comparison with RE-LY. Beyond this, almost all of the studies focused on estimating a treatment 
effect amongst dabigatran initiators who have characteristics that set them apart from the general 
patients included in RE-LY. Most stopped following individuals at their time of death while using Cox 
proportional hazards and Kaplan-Meier estimators that assume we can prevent competing risks; this can 
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be problematic, particularly when the competing event is roughly as common or more common than the 
event of interest.68 A new study in a Medicare cohort spanning more time using both IPTW and matched 
designs alongside an analysis using the trial data that conditions on staying on therapy would improve 
understanding of which medication performs better in an older population with a higher prevalence of 
comorbid conditions without assuming adherence patterns will be constant across the RE-LY and 
Medicare cohorts with respect to baseline modifiers. 
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2.4: Heterogeneity Between Trial and Clinical Cohorts 
RCTs have long been held up as the gold standard for assessing the effects of various 
interventions, and for good reason.58 Randomization of patients will in expectation prevent confounding 
of effect estimates and often allows for straightforward data analysis. Unfortunately, the non-random 
nature of trial inclusion can lead to differences between trial cohorts and source populations in key 
variables, limiting our ability to directly transport results from the trial to target populations.69 There are 
three main types of heterogeneity that are concerning when attempting to transport the estimates of 
the RE-LY trial: demographic characteristic heterogeneity, warfarin management heterogeneity, and 
medication adherence heterogeneity.  
 
2.4.1: Demographic Characteristic Heterogeneity 
Heterogeneity in demographic characteristics between trials and source populations is a 
common concern in the field of cardiology. A systematic review concluded that patients of advanced age 
and patients with complex comorbidity profiles are often not selected into randomized controlled trials 
in cardiovascular trials.10 Some studies have compared distributions of age, sex, race, and other baseline 
characteristics in trial patients compared to large-scale population estimates from stroke registries and 
found that trial populations are generally younger and more male.9 This is especially true when 
comparing to older populations of patients initiating dabigatran. For example, in the FDA study using 
Medicare, the mean age was more than 75 compared to the RE-LY trial’s mean age of 71, 51% of 
initiators were female rather than RE-LY’s 64% male, and 33% of patients had diabetes rather than the 
23% in RE-LY.15 Other researchers have assessed the proportion of patients seen in their clinic which 
would have been eligible for trial enrollment, finding that less than half of patients in a suspected stroke 
registry with AF were eligible for inclusion into the trials for the direct oral anticoagulants.7 The 
overwhelming consensus is that trial samples are not a representative sample of the clinic population. If 
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any of the differing factors amongst eligible patients alter the treatment effect observed in the trial, 
adjustment of effect estimates will be necessary to obtain an unbiased effect estimate in the eligible 
patients. 
 
2.4.2: Warfarin Management Heterogeneity 
An additional source of heterogeneity between trials and clinical populations unique to oral 
anticoagulation is differences in methods of initiating and altering dosages of warfarin between trial and 
clinical practice.21 For example, RE-LY’s suggested warfarin management protocol involved specific 
changes in warfarin management with INRs observed in specific ranges; variance from this protocol was 
associated with lower time in therapeutic range (TTR, the amount of time patients spent with a safe and 
effective INR and a common metric for evaluating warfarin management quality).70,71 As a result of these 
algorithms and potential for better care, TTRs observed in trial patients can vary compared to the TTRs 
observed in community practice.71-73 While the median TTR in the RE-LY trial across all centers was 66%, 
national estimates for TTRs in the United States are between 54% and 55%.74,75  
Outside trials, TTRs can vary depending on the type of provider managing anticoagulation, with 
cardiology clinics generally having higher TTRs than primary care at 61% vs 55% with only 10% of their 
time supratherapeutic rather than 15%.76 One analysis based in active anticoagulation clinics testing 
new methods for predicting effective warfarin management even showed TTRs above 75%.77 Even 
within the RE-LY trial, there was still substantial variation in INR control across the various centers that 
may have contributed to patients experiencing more or less benefit compared to being randomized to 
dabigatran.78 This is in part due to difficult to manage patients being excluded from trials, but different 
management methods are also likely to contribute. Dabigatran management and dosing is 
straightforward; it simply requires twice daily dosing with no target therapeutic range with some dosage 
adjustment based upon renal function, resulting in much better consistency than that observed with 
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warfarin. With all of these differences in warfarin management between the clinical trial and routine 
care setting, it becomes increasingly important to check the assumptions for generalizability when data 
does not exist to include warfarin management quality in the sampling model. 
 
2.4.3: Medication Adherence and Persistence Heterogeneity 
Adherence and persistence must also be considered in addition to management strategy. While 
estimating intention-to-treat effects ordinarily allows researchers to ignore adherence in the context of 
randomized controlled trials, if individuals outside the trial differ in their adherence to those included in 
the trial bias can be introduced into a transported effect estimate.79 Unfortunately, participation in a 
clinical trial also generally improves both adherence and persistence.80 
If adherence were not linked closely linked to outcomes with the two medications, this problem 
might be ignorable. Regrettably, adherence is a clear cause of heterogeneity for both NOACs and 
warfarin; poor adherence to NOACS may be associated with short-term spikes in stroke risk and warfarin 
has a long history linking missed doses to changes in INR and treatment effects.81 To make matters 
worse, the effects of trial participation may be differential depending on whether patients are taking 
warfarin or a NOAC, particularly if trials use placebo INR visits in the NOAC arm or see patients more 
frequently than is expected in clinical care (which is less likely to be the case with warfarin, which 
requires office visits even when managed well). Dabigatran adherence may also differ between trial and 
clinical populations due to the price of the medication. Studies conducted after the introduction of 
NOACs have generally shown much higher levels of non-persistence than in clinical trials, with up to 60% 
of individuals with AF in commercial insurance in the United States discontinuing warfarin after 1.1 years 
and more than 50% of patients discontinuing NOACs, compared to RE-LY’s 16% and 10% at one year.82 
Similar increases in NOAC and warfarin discontinuation compared to RE-LY were observed in Danish, 
Canadian, and UK populations, though they were not as extreme.83-85 Using methods to assess whether 
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patients in the trial are experiencing drastically different outcomes from individuals in the target 
population after controlling for known modifiers can help elucidate the degree to which treatment 
effect estimates are influenced by adherence and management concerns, as can making sure both trial 





2.5: Methods for Transporting Causal Effects 
Multiple methods exist for transporting and generalizing treatment effects from studies to 
differing populations. To give some perspective on the reasoning behind the methods that will be used 
in this study, we present here a brief summary of the oldest method for transporting results (direct 
standardization) as well as the advantages weighting methods have. 
 
2.5.1: Direct Standardization Methods 
Standardization is a potent and necessary tool for comparing results across different 
populations, whether to assure internal validity and remove confounding or to improve external validity 
and remove problems of effect measure modification. As such, standardization has been used in 
epidemiology for quite some time; the first examples involving standardizing rates of death can be 
traced back to the 18th century comparing observed to expected survival amongst various differing 
professions based upon age. It wasn’t until the 1970s that Miettinen published a paper describing the 
potential benefits of standardizing rate ratios to entire referent populations rather than using SMR 
weighting.86  
When dealing with a few levels of key categorical variables, standardization is straightforward 
and simple cases are presented in textbooks58 describing generalization or transportation of causal 
effects. In standardization, a specific standard is chosen that identifies the distribution of key strata in a 
population. Estimates of treatment effects within those key strata are calculated and the results 
averaged using weights identified from the standard. Creating age category-sex standards is 
commonplace when performing some epidemiologic calculations, but building three or four-variable 
standard becomes complex, as does attempting to incorporate continuous variables into the standard. 
When transporting results to target populations, we often need to deal with a large number of effect 
measure modifiers that may or may not change how one another modify the treatment effect, making 
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standardization incredibly cumbersome and potentially imprecise. Moreover, dealing with continuous 
variables improperly when standardizing (for example, by dichotomizing age) may misrepresent the 
modification of the treatment effect of exposure and cause bias in the resulting estimates of treatment 
effects, just as it can result in bias when attempting to control for confounding. 
2.5.2: Weighting Methods 
Weighting methods are a more flexible alternative to standardization when generalizing and 
transporting treatment effects, though they rely on more parametric assumptions.87,88 In weighting 
methods, the trial population is transformed into a pseudo-population that resembles the target with 
respect to selected variables and then re-analyzed using these weights (Figure 6). In the setting of small 
numbers of categorical variables that may be potential effect measure modifiers and fully saturated 
non-parametric weighting models, weighting methods and standardization yield identical results. With 
larger numbers of effect measure modifiers or continuous effect measure modifiers, however, weighting 
methods allow researchers to obtain treatment effect estimates under some parametric assumptions 
that are cumbersome to implement in standardization. 
The actual implementation of weighting methods is fairly straightforward. Rather than creating 
a standard and computing a weighted average of stratum-specific estimates based on that standard, 
researchers obtain data on the selected effect measure modifiers in both the trial or study population 
and target population, preferably at an individual level or tabular level. Aggregate information can also 
Figure 6. A graphic depicting the results of weighting. Because light blue patients were more likely to be 
included in the trial and gray patients were less likely, the light blue patients received lower weights 
while gray patients received higher weights. This means that light blue patients will be less influential in 
the final analysis of the trial than in the crude analysis. 
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be used, but this approach ignores the correlation of variables in the target population that could lead to 
interactions altering treatment effect. In order to transport both absolute and relative scale treatment 
effects (and thus transport the estimated risks), variables should be included in the sampling model that 
separate sampling and the outcome on a causal diagram.88,89  
Logistic regression can then be used to estimate the probability of being in the study population 
rather than the target population, conditional on the key effect measure modifiers with as few or as 
many interaction terms as are necessary. From this probability, researchers can construct either inverse 
probability of sampling weights (IPSW) or inverse odds of sampling weights (IOSW) based on whether or 
not they wish to consider the study population part of the target population and generalize treatment 
results (which requires IPSW) or whether they consider the target population its own discrete to which 
the study results should be transported (which requires IOSW). These weights can be further stabilized 
based upon the probability or odds of sampling ignoring the key effect measure modifiers such that the 
sum of the weights will be equal to the original number of trial participants. Mathematically, stabilized 
odds weights are calculated for individuals in the study population as follows (where “EMM” refers to 
effect measure modifiers on the scale of interest): 
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 		   ℎ () = 
 		(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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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)1 − #(	 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With individuals in the target population receiving weights of 0 so that they do not contribute to the 
analysis. Analyses of interest are then carried out on the trial data using the IOSW or IPSW weights. 
Notably, variance in estimates resulting from sampling of the target population will be ignored by 




2.6: Methods for Assessing Transportability 
 While these data transport methods exist and have existed in some form for quite some time, 
they have rarely been utilized. Part of this may be because of the lack of access to trial data, but some of 
it is surely due to difficulty in knowing when exactly they are necessary as well as how likely they are to 
actually work. After all, reweighting the trial population results in increased uncertainty that may lead to 
“non-significant” results, even if there is still evidence for some degree of causal effect. Techniques have 
been used to assess when we can’t transport trial results to a given target population, but they generally 
ignore the potential for effective use of a trial sampling model. Fortunately, an additional method has 
been theorized that helps assess performance of these weighting techniques. 
 
2.6.1: Comparing Marginal Variable Distributions 
Perhaps the most common method for assessing whether trial results are readily transported or 
generalized to “real-world” populations is simply comparing the proportion of individuals with a 
characteristic to the amounts in the real-world, akin to what we discussed in Section 2.4.1 describing 
demographic characteristic heterogeneity. These methods are at the heart of the debate around 
representativeness in randomized controlled trials.90,91 How does the age distribution in RE-LY compare 
to that of the general AF population, or the Medicare AF population? Are there more or fewer African 
Americans than in the general AF population in the United States? Do more or fewer of them have 
comorbidities like hypertension, diabetes, and other stroke risk factors?  
While these questions are all relevant, this metric is imperfect for assessing the overall external 
validity of trial results. First, if the variable in question is completely unrelated to the outcome, it cannot 
act as an effect measure modifier and thus will not need to be accounted for. Even if blue-eyed people 
were underrepresented in a study due to either quirks of enrollment or intensive recruitment, fewer 
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blue-eyed people in the study will not be a problem if the outcome is stroke and thus unlinked to eye 
color.  
Second, even if the variable is associated with the outcome, its paths may go through other 
variables that were balanced in the study and target populations; the amount of bias they induce is 
proportional to the degree to which their association with the outcome remains. Take the issue of age, 
where trial participants are on balance younger than the general population but age was only associated 
with stroke because of diabetes. If the prevalence of diabetes were the same between the trial and 
general population, age would no longer be relevant.  
Third, both standardization and weighting can be used to deal with variables that differ between 
the trial and target population, provided there are at least some individuals included with the 
characteristic (though uncertainty increases and there is an attendant loss of precision). In other words, 
marginal imbalance or lack of representativeness is not in and of itself an obstacle to the theoretical 
exchangeability of the trial and target population.92 It does, however, represents an indicator for when 
we may want to standardize or weight trial results. Overall, while this method can indicate when the 
unweighted trial estimate is likely to be biased, a difference in distribution for a variable alone does not 
necessarily mean that obtaining an externally valid estimate is impossible, and indeed may be helpful for 
transporting trial results to a given population.93 
 
2.6.2: Assessing Proportion of Patients Eligible for Trials 
Another common metric to assess transportability, and one with potentially more merit, is the 
proportion of patients in a routine care practice or other target population that could have been 
included in the trial based upon its eligibility criteria. This is essentially the extreme version of examining 
the marginal distributions of variables, simply looking at whether the prevalence of individuals with the 
characteristic in the target population is over 0% while it was 0% in the trial. As a result, the same 
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caveats apply as when comparing marginal distributions; if blue-eyed people were excluded completely 
from the trial, it is only relevant if being blue-eyed is associated with the outcome even after other 
variables have been accounted for.  
Unfortunately, this is very likely the case with many trial eligibility criteria. They frequently 
increase the expected number of events to improve power with lower sample sizes or decrease the risk 
of negative safety outcomes for patient protection. We cannot rely upon weighting and standardization 
by this discordant variable because lack of positivity makes rendering the trial and target population 
exchangeable impossible; the trial simply contains no information on individuals with that covariate 
pattern.88 Extrapolating past the eligibility criteria requires reliance on non-experimental effect 
estimates and “generalizability bias,” a heavily limited concept dependent on similar confounding 
structure for eligible and ineligible individuals,94 or the use of various exposure-variable modeling 
techniques if the eligibility criteria is a continuous variable. Because both of these methods have quite 
strong assumptions, a greater the share of the target population ineligible for the trial generally 
increases the potential for bias in transported effect estimates. Restricting the target population to trial-
eligible individuals as much as possible reduces the risk of this kind of bias substantially. 
 
2.6.3: Weighting Methods for Assessing 
Transportability 
There is another potential option that has 
been underutilized in epidemiology. Transport 
weights can identify whether outcomes are 
discordant between trial and target populations 
after utilizing sampling models. This method was 
first used in the transport literature by Stuart et al 
Figure 7: An example where the transport weights 
seems to work well until 30 months. Survival of the 
weighted RCT patients is much closer to the 
observational patients than the unweighted RCT. 
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using propensity scores in the setting of educational achievement95 and is analogous to the placebo-
checking perspectives used in some trial indirect comparison literature.96,97 Factors associated with the 
outcome of interest will be effect modifiers on the absolute scale, relative scale, or both if there is a 
non-null treatment effect.58 Thus, a weight specification model that accounts for all heterogeneity on 
both scales and is properly specified should predict the risk of the outcome in patients in the target 
population receiving a treatment when it is applied to the patients in the trial receiving that same 
treatment (in other words, sampling and outcome will be independent on the transport diagram, a 
requirement of the weighting methods to yield unbiased results).88 You can then compare the observed 
target survival curves to the trial survival curves with or without weighting visually (Figure 7), at specific 
time points, or using proportional hazards regression. If there are large residual differences after 
weighting, the sampling model is inadequate for fully transporting results on both scales. Because we 
are focusing on the risk differences with respect to ischemic stroke and gastrointestinal bleeding, we can 
examine their incidence at specified time points in the unweighted trial, weighted trial, and Medicare 
cohorts to assess if additional effect measure modifiers or consistency violations due to warfarin 
management or medication adherence makes our transported effect estimates likely to be biased. 
Importantly, this approach can only be implemented in one treatment group at a time; it can 
thus only assess transportability to the treated or untreated, not both at the same time. Because it can 
only be used on one treatment arm at a time, it is best thought of as a way to rule out the ability to 
transport treatment effects.  Attempts to weight to the entirety of the target population essentially 
require the removal of all confounding. We may be interested in whether we can transport treatment 
results to adopters of a new therapy but not all others continuing on the older therapy. Relationships 
between multiple unmeasured or incorrectly specified factors and the outcome could cancel one 
another out, resulting in matching outcomes for one treatment arm with remaining unmeasured effect 
measure modifiers. It is also possible for causes of treatment effect heterogeneity to be associated with 
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the outcome only in individuals receiving one of the two treatment arms. This approach is inherently 
retrospective and assesses whether trial results were transportable to a population that has already had 
a treatment decision made for it. This further solidifies its role as a method for ruling out 
transportability, as being able to transport to a claims-based population from 2010 to 2014 is no 
guarantee of transportability to a claims-based population from 2014-2018 while being unable to 





2.6: Public Health Significance 
Understanding the risk-benefit profile of dabigatran in older adults is important for public 
health. Oral anticoagulants, including warfarin and dabigatran are used frequently in patients with AF, 
especially as criteria have shifted over time and point-of-care and self-INR monitoring have become 
more common.98,99 Since their introduction to the market in 2010, novel oral anticoagulants (including 
dabigatran) account for a large share of oral anticoagulant prescriptions100-103 and an even larger share 
of anticoagulant cost in the United States and worldwide, with dabigatran ranking 88th in current sales 
rank for all U.S. pharmaceuticals with over 800,000 prescriptions quarterly in 2013.104 With a large 
patient population and such frequently prescribed drugs, it is vitally important to make sure that the 
benefit-risk distribution for the potential treatment options are being appropriately presented to 
stakeholders at the patient, provider, and insurer level.  
This is even more important when discussing older adults participating in Medicare with higher 
risks of both adverse outcomes from AF (strokes) and adverse outcomes from anticoagulants (bleeding). 
Additionally, if there are important differences in outcomes between warfarin patients in trials and 
warfarin patients in routine care, even after accounting for differing patient characteristics with 
weighting methods, both trials and target population data repositories may need to become more 
flexible and record more data on potential effect modifiers going forward in order to be relevant for 
public health. Synthesizing trial and non-experimental data represents an important step forward for 
patients with AF and public health by allowing better understanding of the potential risks and benefits of 
treatments with warfarin and novel oral anticoagulants. 
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CHAPTER 3: RESEARCH PLAN 
This research plan was designed to compare outcomes in older adults in routine care taking 
warfarin or dabigatran with risks in RE-LY trial participants, before and after adjusting for known risk 
factors; estimate effects of dabigatran compared to warfarin on ischemic stroke and gastrointestinal 
bleeding risk in older adults using transport weights; and assess how well estimates from various non-
experimental methods agree with these transported trial results. 
3.1: Overview 
The aims called for estimating safety and effectiveness of starting dabigatran compared to 
starting warfarin in the U.S. Medicare population with atrial fibrillation (AF) through transporting the 
results of the RE-LY trial to several target populations. Because non-experimental approaches and direct 
use of the trial estimate both have their limitations, we fused cohort data from the Medicare population 
with the RE-LY trial data. Combining these two data sources made it possible to estimate average 
treatment effects in the Medicare population that take advantage of the randomized nature of RE-LY. 
This estimate would be valid under the assumption that a sufficient set of causes of sampling into the 
trial that are risk factors for the outcome have been accounted for.105 The outcome data collected on 
patients in Medicare allowed us check this assumption using various weighting techniques as well as 
assess how different the results are from results obtained using non-experimental approaches. 
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3.2: Data Sources and Collection 
 This research used two data sources from two populations that were collected in very different 
ways: the RE-LY trial’s individual-level data and cohorts of initiators of dabigatran and warfarin in 
Medicare from 2010 to October 2015. 
3.2.1: RE-LY Population 
3.2.1.1: RE-LY Population Description 
Individual-level data for the RE-LY trial was obtained using Clinical Study Data Request (CSDR) 
and analyzed on the Clinical Trial Data Transparency (CTDT) platform, soliciting data access as soon as 
the analysis protocol is finalized. The RE-LY trial randomized 18,113 patients to warfarin, 110 mg 
dabigatran twice daily, and 150 mg of dabigatran twice daily. We focused primarily on the results for the 
150 mg dosage of dabigatran, since the 110 mg dose was not approved for usage in the United States. 
Eligible patients had documented AF during the six months before their enrollment, as well as at least 
one of five other risk factors for stroke including: age greater than 75; previous stroke, TIA, or systemic 
embolism; left ventricular ejection fraction under 40% in the past six months; a diagnosis of diabetes 
mellitus and age over 65; or hypertension requiring pharmaceutical treatment and age over 65; or 
documented coronary artery disease and age over 65. 
Key exclusions to assure either safety or efficacy of warfarin or dabigatran included reversible 
AF, prosthetic heart valves or other conditions for which dabigatran had not been tested, stroke within 
the past 14 days or severe stroke within the past 6 months, a variety of conditions associated with 
increased risk of bleeding, active infective endocarditis, active liver disease, anemia or 
thrombocytopenia, patients judged unreliable or having a life expectancy less than the expected trial 
duration, patients who received another investigational drug within 30 days, transaminase elevations in 
response to ximelagatran (another agent with a similar mechanism of action), and patients with severe 
renal impairment (creatinine clearance of equal to or less than 30 mL/min). The RE-LY trial was 
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conducted in a population from a variety of countries with a wide range of ages (mean age in dabigatran 
150 mg of 71.5 years, standard deviation 8.8) and collected data on multiple potential causes of 
heterogeneity including medication use, past stroke, and other medical diagnoses.  
As a randomized controlled trial there is no confounding in expectation in the baseline covariate 
distribution in RE-LY (and analyses suggested limited chance confounding). This allowed estimation of an 
internally valid intention-to-treat effect estimate in the target population using outcome data from RE-
LY in Aim 1 provided we have weighted the RE-LY data to match the distributions of measured effect 
modifiers in our target. It does not, however, guarantee that an estimate censoring at treatment 
discontinuation will be internally valid. We limited our population to patients over 65 from the RE-LY 
trial to ensure we are looking only at older adults; this was not problematic from a sample size 
perspective, as 85% of the initial RE-LY trial population was over the age of 65. 
 
3.2.1.2: Outcome Assessment in RE-LY 
 The RE-LY trial followed individuals for two primary outcomes after treatment initiation: first 
stroke or systemic embolism (efficacy) and first major hemorrhage (safety). These outcomes were 
reviewed and categorized by an international team of blinded adjudicators and patients were also 
provided symptom questionnaires at regular intervals; these symptom questionnaires were followed up 
on with medical record review. Stroke was defined as “sudden onset of a focal neurologic deficit in a 
location consistent with the territory of a major cerebral artery” and was divided into ischemic, 
hemorrhagic, and unspecified types. Major bleeding was defined as reduction in hemoglobin level of 20 
grams per liter or more, transfusion with at least 2 units of blood, or symptomatic bleeding in a critical 
area or organ. 
Within the context of our study, we used RE-LY’s outcome data on first ischemic stroke and 
ignored the systemic embolism outcomes (as it is difficult to compare these results given difficulties 
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capturing embolisms in claims data)106; risk of hemorrhagic stroke may be elevated with a more potent 
anticoagulant while risk of an ischemic stroke is lowered, so all stroke were analyzed in a secondary 
analysis. When assessing bleeding outcomes, focused specifically on gastrointestinal bleeding events, 
with the less-specific major bleeding term being used for secondary analyses. We also used crude 
mortality data from the trial. 
 
3.2.1.3: Exposure Assessment in RE-LY 
In order to facilitate comparison with non-experimental analyses and prevent the large gap in 
warfarin adherence (see section 2.3.2: Non-experimental Studies under Background and Significance) 
from jeopardizing transportability, our main analyses censored individuals at treatment switching or 
discontinuation. 
In order to conduct any non-ITT analysis, we required data on when individuals discontinued or 
switched from drug to which they were randomized. Fortunately, the RE-LY trial tracked individuals to 
see whether they discontinued the study drug across the study period, with a one week grace period 
after permanent discontinuation. In our intention-to-treat secondary analyses, exposure assessment for 





3.2.1.4: Covariate Assessment in RE-LY 
Two types of covariates were assessed in RE-LY in addition to exposure and outcome: 1) effect 
measure modifiers for use in the sampling model and 2) variables associated with discontinuation and 
censoring. Fortunately, RE-LY collected a large quantity of baseline information on variables 
hypothesized to be associated with the outcome in order to examine treatment effects in various 
subgroups that can be leveraged in these analyses. 




 Effect measure modifiers: Potential effect measure modifiers were identified from Figures 8 and 
9, which depict hypothesized causal relationships between sampling, our outcomes of stroke and 
bleeding, and a variety of other variables. These diagrams were built by examining the marginal 
distributions of variables in trial and target populations (including in the literature review) as well as 
review of risk factors for stroke and bleeding for patients with AF. As mentioned in section 2.5.2: 
Weighting Methods, a transport model that renders sampling independent of the outcome should allow 
estimation of an unbiased estimate in the target population. After adjusting for comorbidities, age, sex, 
frailty, and history of past medication use, the only path from sampling to either of our outcomes will be 
via the discontinuation and management node. Fortunately, censoring individuals at discontinuation or 
switching will reduce the potential for differing rates of discontinuation to be problematic. 
Unfortunately, without detailed lab and clinic data in both the trial and target population removing the 
potential for differences in warfarin management is unlikely to be possible. Additionally, several 




variables had large differences between RE-LY and Medicare, likely due to a combination of differing 
sensitivity and specific of our pre-specified code-based algorithms compared to clinical assessment with 
longer lookback (when examining past vitamin K antagonist use) or simply assessing different things 
(when looking at bleeding in the past year vs. bleeding while on a vitamin K antagonist). This made 
weighting by hypertension, history of bleeding, and past use of vitamin K antagonists generate 
extremely large weights that inflated variance unreasonably. Our main analyses omitted these variables, 
though we did explore using an altered definition of hypertension. Still, Aim 2.1 assessed the extent to 
which this or other unmeasured factors may bias our prediction of the outcome in the target 
population. 
 Censoring weight covariates: We used baseline covariates to standardize the population 
continuing treatment to continue to be representative of the population at baseline even if some of the 
effect modifying covariates are associated with censoring (or, in this case, trial discontinuation). This is 
for two reasons: first, there is potential for introduction of confounding after initial randomization. If, for 
example, patients with hypertension are more likely to discontinue treatment with warfarin than 
treatment with dabigatran and hypertension is associated with increased stroke risk, an unweighted 
effect estimate censoring at discontinuation or switching would be biased in favor of dabigatran.107 
Inverse probability of discontinuation weights can help deal with this problem. 
 The second reason is particular to transporting effect estimates that requires continuous 
prescribing and deals with mismatched effect measure modifiers or risk factors in the two populations. 
Suppose that patients in the target population with diabetes in the target population are more likely to 
discontinue their warfarin or dabigatran, while patients in the trial population are not. If we do not 
weight or standardize both populations, we could see differences in our weighted trial effect estimate 
and non-experimental population effect estimates purely because at later time points the trial 
population includes more individuals with the effect measure modifier of diabetes. We could also see 
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differences in our Aim 2.1 assessment of transportability that arise only because of differences we’ve 
induced by requiring individuals to stay on their initial therapy.  
The solution was stabilized inverse probability of censoring (sIPCW) weights. In the RE-LY trial, 
these were estimated with stepwise logistic regression within each treatment arm assessing the 
probability of staying on treatment up to a given time point, then the next time point, then the next, and 
so on. Variables were assessed at baseline, as RE-LY did not have readily available data on post-baseline 
variables. Individuals time periods were then assigned weights according to the following equation 
where Zi is the set of time-varying and baseline covariates associated with sampling and Tx is the 
treatment arm. 
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We included effect measure modifiers as well as confounders that are known in the trial (discussed 
below in the non-experimental section) in the model. Fortunately, warfarin and dabigatran do not cause 
changes in many of these variables, particularly most of the comorbidities and age, so there are few 
mediators we have to worry about conditioning on. 
 
 
3.2.2: Medicare Atrial Fibrillation Population 
3.2.2.1: Medicare Atrial Fibrillation Population Description 
The specific Medicare data used was 20% sample of all Medicare beneficiaries with fee-for-
service coverage of Medicare Parts A, B, and D for at least one month from 2008-2015, available at the 
University of North Carolina through the Sheps Center. We constructed two main study cohorts from 
the Medicare population from 2010 (when dabigatran was approved for use in the United States) to 
October 2015 (when the United States transitioned from ICD-9 to ICD-10 codes) for this analysis: first, a 
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cohort of dabigatran and warfarin initiators; and second, a cohort of dabigatran and warfarin initiators, 
where dabigatran users are allowed to have previously initiated warfarin or switched to dabigatran. 
Patients were eligible for inclusion into the Medicare cohort at their first initiation of warfarin or 
150 mg twice daily dabigatran with a 60-day washout period for use of either drug or another NOAC 
(apixaban, rivaroxaban, and edoxaban), provided they had an inpatient or outpatient AF diagnosis code 
in the 6 months before or 1 week after their prescription (in which case follow-up began at the time of 
diagnosis). This requirement for a recent AF diagnosis code was analogous to the RE-LY trial inclusion 
criteria that required evidence of recent AF. Individuals had to meet the eligibility criteria for RE-LY 
including at least one risk factor for stroke (described in section 3.2.1.1: RE-LY Population Description), 
as represented by at least one diagnosis code in the year prior to initiation (specific codes listed in 
Appendix B) or age over 75. Individuals also needed to have 12 months continuous coverage in 
Medicare parts A, B, and D before this index prescription to enable assessment of eligibility criteria, key 
effect measure modifiers, and potential confounders.  
This period was also used to exclude individuals with identifiable exclusion criteria for the trial, 
including liver disease, severe stroke within the past six months, anemia and thrombocytopenia, valvular 
AF or prosthetic heart valves, and severe renal insufficiency (specific codes listed in Appendix B).  If 
there were multiple eligible initiations, only the first eligible initiation was included. This Medicare 
cohort contributed external validity to the project and allowed insight into the distribution of effect 
modifiers in a general clinical cohort participating in anticoagulation care that may not have been willing 
or able to participate in a trial, critical for Aim 2. It also provided data for the Aim 1 non-experimental 
analyses. 
The Medicare cohort was further divided into four potential target populations: 1) patients 
initiating warfarin for AF that could have been included in RE-LY; 2) patients initiating dabigatran for AF 
that could have been included in RE-LY; 3) patients with less than 15% predicted probability of frailty 
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that initiated warfarin for AF that could have been included in RE-LY; and 4) patients with less than 15% 
predicted probability of frailty that initiated dabigatran for AF that could have been included in RE-LY. 
 
3.2.2.2: Outcome Assessment in Medicare 
Unfortunately, we did not have access to medical records for review by an international blinded 
group of adjudicators for use in this cohort. Instead, we used ICD-9 codes in claims, both inpatient and 
outpatient, to identify ischemic stroke and gastrointestinal bleeding. We used similar ICD-9 codes to 
identify the types of stroke that were used in past non-experimental analyses using claims-based data to 
facilitate comparisons to their results (i.e., by Seeger et al.).18 Medical record review in some databases 
have shown positive predictive value of close to 90% for these codes, suggesting they perform quite 
well.108 The full list of codes for stroke is presented in Appendix A. We specifically examined codes for 
ischemic stroke, with secondary analyses examining all strokes. 
When identifying major bleeding events, we also used ICD-9 codes (presented in the second 
portion of Appendix A) in inpatient and outpatient claims. These definitions were similar to and adapted 
from the definitions used in the other non-experimental studies in claims-based data, particular Seeger 
et al, and map directly to the trial outcomes.18 These codes and definitions have been shown to have 
positive predicted values between 80% and 90% with medical chart review in claims databases, 
particularly in the setting of anticoagulant-associated adverse events.109,110 Than main analysis was 




3.2.2.3: Exposure Assessment in Medicare 
Prescription claims data for Medicare 
beneficiaries were used to identify warfarin and 
dabigatran initiators from 2010 to October 2015. 
Individuals were defined as initiators if the days 
supply from their last prescription for an oral 
anticoagulant ran out at least 60 days prior to the 
initial prescription. In the analysis censoring at 
discontinuation individuals’ follow-up time was 
censored after switching medications as or having a 30-day gap in novel oral anticoagulant coverage or a 
45 day gap in warfarin coverage as shown in Figure 10, with the larger gap for warfarin provided due to 
the fact that pharmacy days’ supply may be out of sync with the way patients are taking warfarin due to 
changes in directions for use at anticoagulation management appointments. To help identify warfarin 
initiators who may start to pay purely out of pocket, CPT codes for INR draws or anticoagulation 
management (CPTs 85610, 99363, and 99364)111 “refreshed” warfarin prescriptions and extended the 
length of follow-up for thirty days from the time of the CPT code. In the intention-to-treat analysis, 
individuals will be followed until death. 
 





3.2.2.4: Covariate Assessment in Medicare 
 We assessed three kinds of covariates in the Medicare cohort: 1) effect measure modifiers, 2) 
confounders, and 3) censoring covariates. 
 Effect measure modifiers: Effect measure modifiers in the Medicare cohort were assessed at the 
date of treatment initiation for the Medicare cohort. We used a lookback period of one year in claims 
data to assess the presence of the variables depicted in the sampling diagrams depicted in Figure 8 and 
Figure 9. Specific ICD-9 codes are listed in Appendix B. 
Confounding variables: Confounding variables were assessed at the date of treatment initiation 
for the Medicare cohort with the same one-year and all-available lookback approaches as the effect 
measure modifiers. The specific variables included were based upon a directed acyclic graph, Figure 11, 
which indicates which variables form a minimally sufficient adjustment set in the Medicare cohort that 




close all open backdoor paths between treatment and the outcomes. Because the set of variables that 
affect treatment choice are identical with respect to both outcomes and ischemic stroke and 
gastroinestinal bleeding events share many risk factors, the same adjustment set was used in each 
analysis. The set of variables can be divided into three main categories: demographics (age, sex, race, 
and socioeconomic status), comorbid conditions (transient ischemic attack, congestive heart failure, 
diabetes, smoking, weight, alcoholism, history of bleeding, and frailty), and past medication use (past 
warfarin use). Definitions and codes used to identify each of these is presented in Appendix B.  
The associations between the demographics, comorbidities, and outcome was built based upon 
literature review of the various epidemiological studies in section 2.3.2: Non-experimental Studies and 
cardiovascular and risk scores including the CHADS2 score112 and the Framingham Risk Score.113 The 
associations between each of these variables and whether a patient might use dabigatran rather than 
warfarin came from questions regarding prescribing preferences to a medical professional working in an 
anticoagulation clinic, section 2.3.2: Non-experimental Studies, and treatment guidelines.5 As can be 
seen in the graph, analyses requiring individuals to stay on treatment in this context involve removing a 
potential mediator of treatment effect (potential for discontinuing the treatment in question). 
 Censoring weight covariates: We also built censoring weights using effect measure modifiers 
and confounders in the Medicare population for use in analyses conditional on staying on initial 
treatment and ensure that the population that continues on treatment is standardized to look like the 
initial population in the Medicare target population; otherwise, as discussed in section 3.2.1.4: 
Covariate Assessment in the RE-LY Trial, selective dropout in this estimate could lead to either bias in 
internal validity (only healthy individuals stay on warfarin, while unhealthy users stay on both 
medication) or external validity (the target and trial populations change differently over time from 
dropout). Weights were estimated separately within the Medicare population from the RE-LY population 
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because the processes leading to discontinuation are likely quite different between the two populations; 












3.2.3: Data Combination 
 Unfortunately, we were not able to combine our two data sets at an individual level (the ideal 
gold standard) for analysis because of data ownership and privacy concerns. Medicare does not allow 
data to leave their server in tables with cell size greater than 11 and is reluctant to allow individuals to 
pull data sets with the exact timing of outcome and censoring events. On the other hand, few drug 
companies are willing to have individual-level patient data leave their system that isn’t being monitored, 
and our original plan to only estimate distributions of effect modifiers did not satisfy their restrictions on 
individual-level data. At first glance, this rendered it difficult to conduct Aim 1 without making 
enormous and potentially incorrect assumptions about correlation between variables, but we used the 
data plan in Figure 12 as a substitute for directly combining data between the populations. 
 First, when estimating our sampling weights and transporting estimates, no data on effect 
modifiers left the Medicare platform. Instead, we took marginal distributions of variouse modifiers and 
Figure 12: Data access plan for combining data from the two populations in Aim 1 and 3. 
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the joint distribution of age and sex and used these to create a simulated cohort of 300,000 individuals, 
which was weighted to resemble the various Medicare target populations using main effects and one-
way interactions for all variables, modeling age with quadratic restricted splines with four knots at the 
20th, 40th, 60th, and 80th percentile. Age was also capped at 90 due to the way trial handled these 
extreme ages. The coefficients from this model were used on a recreated simulant population on the 
trial server, which was in turn used for the target population. While these methods may create issues 
when there are three-way interactions between modifiers, the result did balance marginal distributions 
of modifiers quite well. Additionally, we did not directly export any survival curve data from the 
Medicare server. Instead, we exported the percent of individuals alive at the end of each week and at 
set bench marks (180 days, 365 days, 545 days, and 730 days) for comparison with the trial data in Aim 
2.1. Bootstrapping took all this into account with the modifiers, sampling models, and outcomes all 





3.3: Data Analysis 
We 1) estimated two-year risk differences using non-experimental epidemiologic methods from 
only the Medicare AF population and 2) estimated two-year risk differences comparing warfarin from 
NOACs in the Medicare AF population with transport methods and assessed transportability.  
3.3.1:  Aim 1, Estimating Non-Experimental Treatment Effects in Medicare (Figure 13)  
 Objectives: Aim 1 focused on estimating the treatment effect on the two-year risk of ischemic 
stroke, death, and gastrointestinal bleeding for dabigatran versus warfarin in various Medicare target 
populations using multiple types of non-experimental methods. 
3.3.1.1: Aim 1.1, New User Active Comparator Design 
Objectives: In Aim 1.1 we estimated risk differences of two-year ischemic stroke, death, and 
gastrointestinal bleeding for patients in the cohorts of dabigatran and warfarin initiators using a new 
user active comparator design in the Medicare cohorts to be used as target populations in Aim 2.  
Methods (inverse probability of treatment weights): We balanced the confounding variables 
between dabigatran and warfarin initiators using inverse probability of treatment weighting. To use 
these weights, we estimated the probability of dabigatran initiation based upon the confounders 
described in Figure 11 fitting main effects and additional terms as required to achieve marginal72 
differences as small as possible, with any major confounders with an SMD greater than 0.100 being 
unacceptable (though this is a fairly arbitrary cut point and none came close to this threshold in the 
initial model).114 Stabilized inverse probability of treatment weights (sIPTW) were assigned based upon 
Figure 13: Aim 1 conceptual diagram. 
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the model predicted probabilities.115 Dabigatran initiators were weighted using equation 2 and warfarin 
initiators with equation 3, where Zi represents the confounding variables used in the propensity score 
estimation. 
Equation 2: #-4563 = 7(856395(:5;)7(856395(:5; | <3) 
Equation 3: #-=5:> = +*7(856395(:5;)+*7(856395(:5; | <3) 
 Methods (other statistical considerations): The outcomes of interest were compared by 
contrasting the IPTW and IPCW-weighted survival curves (constructed with Aalen-Johansen methods 
and the above weights for each individual) in the Medicare population at one and two years after 
applying sIPCW. We bootstraped 200 replicates to estimate confidence intervals. Since sIPTW estimated 
the treatment effect in the entire population and we desired treatment effect estimates in the 
dabigatran and warfarin users for comparison with the estimates obtained with sIOSW, we will also use 






3.3.2: Aim 2, Transporting Treatment Effects with Inverse Odds of Sampling Weights (Figure 14) 
 Objectives: Aim 2 was focused on first assessing whether we might be able to transport 
treatment effects and then actually estimating treatment effects on the two-year risk of ischemic stroke, 
all-cause mortality, and gastrointestinal bleeding for dabigatran versus warfarin in the Medicare target 
population using sIOSW. 
 
3.3.2.1: Aim 2.1, Assessing Transportability 
Objectives: For Aim 2.1, we used weighting 
methods to assess the degree to which the 
assumptions necessary for transport of treatment 
effects on the two-year risk of ischemic stroke, 
death, and gastrointestinal bleeding for dabigatran 
versus warfarin have been met in two target 
Figure 14: Aim 2 conceptual diagram. 
Figure 15: Hypothetical graph comparing 
cumulative incidence of bleeding for RE-LY and 
Medicare patients. The groups diverge in 
cumulative incidence quickly. 
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populations with methods from indirect trial comparisons and control arm assessment.96,117  
Methods (initial analysis): The first step in this process was comparison of unadjusted risk of 
stroke, bleeding, and death in the individuals randomized to dabigatran in RE-LY to the unadjusted risk 
of each of the outcomes in the Medicare dabigatran patients (with a similar comparison for the warfarin 
patients in the RE-LY trial and Medicare). This comparison was conducted both visually by overlaying the 
unadjusted Aalen-Johansen cumulative incidence curves (see Figure 16) as well as quantitatively by 
computing risk differences at 6, 12, 18, and 24 months. Variances were obtained with bootstrapping 
with 200 replicates (fewer than the 1000 originally planned due to the time taken by the competing risks 
macro), bootstrapping populations before limiting to complete cases or performing subsample 
validation. For both groups, follow-up was censored at discontinuation or switching and inverse 
probability of selection weights were used to correct for potential bias. 
 Methods (inverse odds of sampling weights): We also assessed whether weighting by measured 
effect measure modifiers reduced the disparity in outcomes between the groups,. We constructed 
weights from a model assessing sampling into the RE-LY trial from the Medicare AF cohort within strata 
of exposure X (where X is either warfarin or dabigatran) in the target population; since exposure was 
randomized within the trial we can treat the trial cohort as having both exposures when building this 
model. Odds weights were necessary so that the trial population is not assumed to be part of the target 
population (see section 2.5.2: Weighting Methods). If individuals were on treatment X in the RE-LY trial, 
they are weighted according to equation 4 with the probabilities being calculated from a logistic 
regression model, where X is either warfarin or dabigatran and EMM represents the set of all selected 
effect measure modifying covariates and interaction terms. 
 = ( #(? − @A  | /)1 − #(? − @A  | /)) ∗ (
1 − #(? − @A  |  !!, /)
#(? − @A  |  !!, /) ) 
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Individuals in Medicare received weights of 1. We used quadratic restricted splines for age when fitting 
the logistic regression models to account for complex types of effect measure modification. 
Other statistical considerations: We repeated the survival analysis using these weights to 
construct the Aalen-Johansen cumulative incidence curves for the RE-LY trial and Medicare cohorts 
(separately for each anticoagulant) and compared them visually and quantitatively with risk differences 
at 6, 12, 18, and 24 months just as we did the crude cumulative incidence curves. Variances were 
obtained with bootstraps of 200 replicates, making sure to bootstrap both populations before taking 
complete cases or conducting any form of imputation or subsample validation.  
If the weighted trial and target population curves differ and there is a non-null treatment effect 
and the outcomes are measured identically, it is impossible to have taken into account all modifiers that 
differ between the groups on both scales, making it less likely all modifiers of the risk difference have 
been controlled for and increasing the possibility that the assumptions necessary for transportability 
have been violated. These analyses were particularly important for evaluating the performance of 
warfarin initiators in Medicare relative to warfarin patients in the RE-LY trial. We also assessed 
transportability after limiting ourselves to patients in the Medicare cohort with under 15% predicted 
probability of frailty based on the frailty prediction algorithm created by Faurot et al.118 to help eliminate 
potential for including individuals in our target populations that were not trial-eligible due to high frailty 
or short life expectancy. Since these frailty-restricted Medicare populations have more similar outcomes 
to the RE-LY trial participants than the original Medicare cohort, they were used for additional target 







3.3.2.2: Aim 2.2, Transporting Treatment Effects 
Objectives: In Aim 2.2, we estimated treatment effects on two-year risk of ischemic stroke, 
death, and gastrointestinal bleeding for dabigatran versus warfarin in various Medicare target 
populations using stabilized inverse odds of sampling weights (sIOSW) and data from the RE-LY trial.  
Weighting methods: Normal inverse probability of treatment weights methods typically 
eliminate confounding by creating exposed and unexposed pseudo-populations with identical 
confounder distributions after estimating the probability of exposure condition on various covariates. 
With IOSW, we instead transformed the RE-LY trial population into a pseudo-population with an 
identical distribution of baseline effect measure modifiers as the Medicare AF population87 by combining 
the joint categorical modifier RE-LY data and Medicare AF data and using logistic regression to identify 
the probability of selection based upon the selected effect measure modifiers. If individuals were 
enrolled in RE-LY, they received stabilized inverse odds of sampling weights (sIOSW) based on this 
equation:  
() = ( #(? − @A )1 − #(? − @A )) ∗ (
1 − #(? − @A  |  !!)
#(? − @A  |  !!) ) 
Unlike in Aim 2.1, Medicare patients received weights of 0 instead of 1 and the estimates were 
no longer conditional on the specific type of treatment received; X has dropped out of the equation. 
When weights became large when including several variables that may have been due to discrepancy in 
measurement or actual differences in distribution (hypertension and vitamin K antagonists), we omitted 
them. In the end we examined the marginal covariate balance using standardized mean differences 
between the target and RE-LY population. 
Follow-up and censoring: To reduce potential issues with differential persistence between the 
trial and target population estimates influencing the comparison, we focused on an analysis censoring 
trial individuals at treatment switching or discontinuation. Stepwise inverse probability of censoring 
weights based upon the set of EMM and confounders as described in 3.2.1.4: Covariate Assessment in 
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the RE-LY Trial and fit separately in the trial and target populations for each treatment were used to 
prevent potential selection bias in this approach. We also explored an intention-to-treat design as a 
secondary analysis. 
Other statistical considerations: The outcomes of interest were compared on the risk difference 
scale by directly comparing the weighted survival curves in the RE-LY trial population (constructed with 
the above weights and Aalen-Johansen methods rather than assuming we can prevent competing 
risks119). The weighting process was bootstrapped with 200 iterations in order to generate 95% 
confidence limits for the risk differences, with both the trial and target populations being bootstrapped 
before any imputation, limitation to complete cases, or subsample validation. This process was repeated 
for each of the target populations of interest (warfarin initiators, dabigatran initiators, and those with 
lower predicted probability of frailty). When these estimates from Aim 2.2 differed from the results of 
the RE-LY trial, it lends credence to the idea that there are meaningful effect measure modifiers in place 
that were differentially selected for by the trial enrollment process.  
 
3.3.2.3: Aim 2.3, Contrasting Effect Estimates 
Objectives: In Aim 2.3 we compared treatment effect estimates for two-year risk of ischemic 
stroke, death, and gastrointestinal bleeding in various Medicare populations obtained using the data 
from the RE-LY trial and the new user active comparator design. 
Methods: The estimates obtained under these Aim 1 were directly contrasted with the 
estimates obtained under Aim 2. This process was repeated for each of the four target populations: 1) 
new users of dabigatran; 2) new initiators of warfarin; 3) less frail new users of dabigatran; and 4) less 
frail new users of warfarin. Comparisons were performed by plotting the point estimates and 95% 
confidence limits of the trial and non-experimental estimates against one another, with particular 
attention paid to shifts in estimate across the null between methods. If the results in Aim 2 differed 
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from those in Aim 1, either additional or incorrectly modeled confounding factors exist (e.g. 
socioeconomic status has an unblocked path to the outcome), additional or incorrectly modeled effect 
measure modifiers exist (e.g. better management in the trial than the target population), different 




3.4: Human Subjects 
 This research was conducted in two large databases and reviewed by the UNC institutional 
review board. We anticipated minimal potential harms to individuals in either of the two databases, 
with the only risk being potential infringement of privacy or identification. To ensure appropriate 
precautions are taken for preservation of patient privacy, data was kept on secure servers at all times. 
When the marginal distribution data was exported from the CTDT platform, it was downloaded directly 
onto the Sheps server. It was never downloaded onto a private computer. Similarly, the weekly 
cumulative incidence from the Medicare cohort was uploaded into the CTDT platform directly from the 
Sheps server, rather than downloaded onto a private computer and transferred. This use of secure 
servers minimized the potential for privacy harms to individuals enrolled in the trial or captured in the 
claims database. Additionally, the survival data and joint distribution data will be deleted from the 





CHAPTER 4: STAYING ON TREATMENT MATTERS: ESTIMATING EFFECTS OF WARFARIN VS 
DABIGATRAN IN MEDICARE 
4.1: Introduction 
Atrial fibrillation affects an estimated 33 million adults worldwide.1 Even if individuals with atrial 
fibrillation are asymptomatic, atrial fibrillation strongly increases stroke incidence and resulting strokes 
are more frequently associated with death, hospitalization, and long-term disability than strokes in 
adults without atrial fibrillation.2,3 Warfarin, the historical standard of care for stroke prevention in atrial 
fibrillation, is difficult to manage therapeutically due to its lengthy half-life and narrow therapeutic 
range.120 To make matters worse, mismanagement can result in catastrophic bleeding events.4 Novel 
oral anticoagulants are comparatively easy to manage (with the necessary adjustments being dosage 
changes in the presence of renal insufficiency) and have been approved after several trials 
demonstrated non-inferiority to warfarin administered with suggested management protocols.5,44,45,47 
One of the first novel anticoagulants to be approved in the United States, dabigatran, appeared more 
effective than warfarin at ischemic stroke prevention (HR 0.76, 95% C.I. 0.60-0.98) in the RE-LY trial, 
though it did cause an increase in gastrointestinal bleeding (HR 1.50, 95% C.I. 1.19-1.89). A small relative 
improvement in all-cause mortality was also observed (HR 0.88, 95% C.I. 0.77-1.00), though it was not a 
primary outcome; this magnitude of protective effect in a population with higher mortality than the trial 
population could result in substantial mortality benefit. 
However, estimates of efficacy in these clinical trials are likely imperfect estimates of 
effectiveness in clinical care.7,8 Patients selected into trials tend to be younger with fewer comorbidities 
than patients in the general population. These differences could modify the population average 
treatment effect.9,10 To address concerns about this potential treatment effect modification in wider 
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populations, studies have used claims data to directly estimate the safety of novel oral anticoagulants 
compared to warfarin in clinical care and observed attenuated efficacy and differing safety profiles.11-20 
While these studies were generally well conducted, gaps in knowledge remain. Most relied on 
propensity score matching of warfarin users to patients taking dabigatran resulting in imperfect 
understanding of treatment effects in the entire population. Most estimated treatment effects on the 
relative scale using hazard ratios rather than the absolute scale, which can be misleading when it comes 
to assesing the overall benefit-harm balance.121,122 Finally, most studies censored individuals at 
treatment discontinuation or switching without assessing whether this was differential with respect to 
treatment; they also refrained from estimating treatment effects taking into account the natural 
switching and discontinuation patterns of real world populations. 
In this study, we aim to estimate absolute-scale treatment effects of dabigatran versus warfarin 
on ischemic stroke, all-cause mortality, and gastrointestinal bleeding considering various patient 






4.2.1: Study Population 
 This study was performed in the 20% sample of Medicare beneficiaries managed by the Centers 
for Medicare and Medicaid Services from 2010 to 2015. Individuals were eligible for the analysis after 
365 days of continuous enrollment in Medicare A, B, and D. All participants were required to be over age 
65 with at least one of the following risk factors for ischemic stroke: hypertension, diabetes, congestive 
heart failure, and past stroke or transient ischemic attack (defined by ICD-9-CM diagnosis codes in any 
position in the past year), and age over 75. Individuals with diagnosis codes indicating prosthetic heart 
valves, endocarditis, primary diagnoses indicating cancer in the past 180 days (as the RE-LY trial 
excluded those with active cancer in the past six months), active liver disease in the past year, or chronic 
kidney disease were excluded. Codes are listed in Appendix B. These inclusion and exclusion criteria 
parallel those used in the RE-LY trial to the extent possible.  
 
4.2.2: Exposure 
 We used an active comparator new user study design. We defined “new use” as having no days’ 
supply of any oral anticoagulant used for atrial fibrillation (warfarin, dabigatran, and the other novel oral 
anticoagulants on the market, apixaban, rivaroxaban, and edoxaban) in the 60 days prior to receipt of a 
warfarin or dabigatran prescription during the study period. To ensure we were examining the dosage of 
dabigatran studied in the RE-LY trial, we limited analyses to the 150 mg dosage in assessing both 
treatment initiation and continuation. Each initiation was analyzed separately for eligibility criteria and 
included only if there was at least one diagnosis code for non-valvular atrial fibrillation present in the 
180 days prior to or 7 days after new use. Only individuals’ first eligible drug initiation of either drug was 
included in the analysis. 
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After identifying new users, we conducted two types of analyses: an analysis in which individuals 
were followed under their initial treatment for each of the outcomes until the end of the study period or 
the end of their Medicare A, B, and D coverage, regardless of whether they continued use of their oral 
anticoagulant (first treatment carried forward analysis, FTCF, analysis); and an analysis where individuals 
were censored after a gap in therapy more than 30 days (dabigatran arm) or 45 days (warfarin arm) 
(adherence adjusted, AA, analysis). Procedure codes for anticoagulation management (listed in 
Appendix D) were used to extend coverage in the warfarin arm for 30 days in the event that warfarin 
claims were unobservable.111 The longer gap in the warfarin arm was to accommodate potential dosage 
changes during warfarin management. Medication stockpiling was not allowed in our analysis as it 
would lead to inaccurate estimates of days’ supply for warfarin users on multiple strengths of the drug.   
 
4.2.3: Outcomes 
 This study examined three main outcomes: ischemic stroke, defined by previously 
validated108,109 ICD-9-CM codes listed in Appendix B; death, defined by the Medicare date of death; and 
gastrointestinal bleeding, defined by previously validated109 ICD-9-CM codes listed in Appendix A. We 
also examined all strokes and major bleeds to compare results with those of the trial and several of the 
past studies. Codes for all outcomes had to appear in the primary position of an inpatient encounter to 
exclude codes for follow-up or medical history of the event, and individuals with day 0 outcomes were 
excluded from that analysis to avoid the possibility of the outcome preceding the initiation. Follow-up 
was outcome-specific; that is, if someone experienced an ischemic stroke, then spent another three 







 In addition to the inclusion and exclusion criteria, we measured a large number of baseline 
covariates (also listed in Appendix B) in this analysis18 using one-year lookback period from the index 
date and estimated the predicted probability of frailty using a Medicare claims-based algorithm 
developed by Faurot et al.118 We constructed directed acyclic graphs123 (Figure 11) for the outcomes 
using expert opinion and a review of the literature. From these graphs, our measured covariates 
(provided they are measured without error) form a sufficient set for estimation of an unbiased effect of 
treatment on the outcome. Age and sex were available for all individuals; since our other covariates 
were defined by the absence of insurance claims, there was no missing data per se. 
 
4.2.5: Statistical Analyses 
 We estimated the predicted probability of dabigatran initiation among new users of dabigatran 
or warfarin conditional on the confounder sets from logistic regression, modeling age and frailty with 
restricted cubic splines with four knots at the 20th, 40th, 60th, and 80th percentiles. The resulting 
probabilities were used to construct inverse probability of treatment weighted (IPTW) dabigatran and 
warfarin cohorts (to estimate treatment effects in the whole population) as well as a standardized 
mortality ratio weighted (SMR weighted) version of the warfarin cohort (to estimate treatment effects in 
the dabigatran initiators).124 We checked to ensure these weights properly balanced covariates by 
assessing whether marginal absolute standardized mean differences between the groups after 
weighting were less than 0.10.114 In adherence adjusted analyses, we implemented inverse probability of 
censoring weights as the inverse probability of not switching or discontinuing (calculating these 
probabilities separately) based on time-varying versions of confounders at the 25th, 50th, and 75th 
percentiles of the censoring distribution.125  Censoring due to end of Medicare A, B, or D enrollment or 
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the end of the study period was treated as random censoring, with no weights constructed for these 
censoring mechanisms. 
After applying weights, we estimated the risk of each outcome via a weighted Aalen-Johansen 
estimator to take into account the competing risk of death68 at one- and two- years for each treatment 
group, using the standard deviations from 200 replicate bootstraps126 to obtain limits for the 95% 
confidence intervals. All statistical analyses were conducted using SAS 9.4 for Windows (Cary, NC, USA). 
 
4.2.6: Sensitivity Analyses 
We conducted a variety of sensitivity analyses. First, we varied the allowable gap between 
prescriptions within a treatment episode to be 7 days or 60 days for both treatment arms. Second, we 
ignored procedure codes rather than using them to refresh warfarin coverage. Third, we excluded 
individuals with any code for stroke in the primary position of an inpatient encounter in the past 6 
months to attempt to emulate RE-LY’s exclusion of those with severe strokes in that time period. Finally, 
we excluded individuals with a predicted probability of frailty over 10% to examine treatment effects in 
a less-frail population. This cut-point was chosen to be more aggressive than that from the frailty score’s 






 Figure 16 provides a flow diagram detailing inclusion and exclusion criteria in the cohort. Of the 
393,684 total new use periods for dabigatran and warfarin, 98,388 met inclusion and exclusion criteria. 
After restriction to the first eligible initiation per individual from 2010-2015, we had a final cohort of 
10,717 dabigatran new users and 74,891 warfarin new users for analysis. The distribution of various 
covariates in these individuals are listed in Table 2. Compared to warfarin new users, dabigatran new 
users were generally younger (28.9% age 80 and over vs 43.3%) and more likely to be women (49.6% vs 
43.3%), with lower predicted probability of frailty (median 0.050 vs 0.074), fewer codes indicating past 
bleeds (8.4% vs 12.8%), and fewer having used warfarin in the past (20.1% vs 35.7%). After IPTW or SMR 
weighting, baseline covariates were more balanced and absolute standardized mean differences 
(ASMDs) for each measured covariate were all less than 0.100 (see Figure 17). The mean of the 
stabilized weights was 1.002, with 15 of the older and frailer dabigatran new users having weights 
greater than 10 and one individual with a particularly high comorbidity burden having a large weight of 
42. 
 Table 3 includes the rates and risks of ischemic stroke, all-cause mortality, and gastrointestinal 
bleeding across the various populations of interest and adherence scenario. Dabigatran users had 
shorter durations of time on treatment (median 152 days vs. median 259 days), with 59% of dabigatran 
users stopping treatment and 16% switching treatment during the study period compared to 44% of 
warfarin users stopping treatment and 8% switching treatment. Outcomes were common in the first 
two years of follow-up in the first treatment carried forward analysis: we observed unadjusted incidence 
rates of 1.37 (dabigatran) vs 1.66 (warfarin) per 100 person-years for ischemic strokes, 5.36 (dabigatran) 
vs 9.51 (warfarin) per 100 person-years for all-cause mortality, and 1.93 (dabigatran) vs 2.05 (warfarin) 
per 100 person-years for gastrointestinal bleeding events. The adherence adjusted analysis showed 
lower rates for ischemic stroke (0.91 (dabigatran) vs 1.56 (warfarin) per 100 person-years) and all-cause 
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mortality (3.59 (dabigatran) vs 8.08 (warfarin) per 100 person-years), but slightly elevated risks of 
gastrointestinal bleeding (2.27 (dabigatran) vs 2.27 (warfarin) per 100 person-years). Figure 18 shows 
IPTW-weighted survival curves for ischemic stroke under FTFC and AA methodologies and illustrates the 
stark shift in adjusted absolute risk for dabigatran patients under the FTFC design compared to the AA; 
Figures 19-22 contain survival curves for the other outcomes.  
Table 4 depicts two-year risk ratios and risk differences under the AA and FTCF follow-up 
methods, both in the crude and after implementing the IPTW, SMR, and inverse probability of censoring 
weights in the AA. In AA analyses, dabigatran new use compared with warfarin new use was associated 
with fewer ischemic strokes (two-year RD: -0.73%, 95% CI -1.40%, -0.06%) and lower mortality (two-year 
RD: -2.98%, 95% CI -5.05%, -0.91%). There was an elevated risk of gastrointestinal bleeding, however 
(two-year RD: 1.79%, 95% CI -0.13%, 3.71%); the larger variance for this outcome is partly due to a 
bleeding event in the person with very large weight.  
In IPTW FTCF analyses, the association between dabigatran new use and all-cause mortality was 
attenuated relative to the AA analyses (two-year RD: -0.84% -2.39%, 0.72%) and risk of ischemic stroke 
actually increased in dabigatran new users (two-year RD: 0.44%, 95% CI -0.22%, 1.09%). The increase in 
the risk of gastrointestinal bleeding was also attenuated compared to the AA analyses (two-year RD: 
1.05%, 95% CI 0.08%, 2.01%). 
SMR-weighted risk differences were similar to the IPTW ones, though they were attenuated for 
AA gastrointestinal bleeding (two-year AA RD: 0.51%, 95% CI -0.30%, 1.31%) and farther from the null 
for the FTCF all-cause mortality outcome (two-year RD: -1.65%, 95% CI -2.32%, -0.98%). 
Risk differences for the outcomes of all stroke and major bleeding are listed in Table 5. The all 
stroke outcome looked similar to ischemic stroke outcome, though farther from the null in AA analyses 
(two-year IPTW RD: -0.94%, 95% CI -1.63%, -0.25%, SMR RD: -0.86%, 95% CI -1.34%, -0.38%), while the 
major bleeding outcome showed increased risk of bleed in the IPTW AA analyses (two-year RD: 1.04%, 
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95% CI -1.06%, 3.15%) but no real difference in the SMR analyses (two-year RD: -0.18%, 95% CI -1.10%, 
0.74%); both estimates were fairly imprecise, however. 
 Changing the allowable gap in medication supply to 7 days resulted in less harmful RDs for 
gastrointestinal bleeding in the IPTW AA analyses (two-year RD: 0.08%, 95% CI -1.19%, 1.36%). A smaller 
attenuation was observed in the IPTW AA gastrointestinal bleeding RD with the 60-day gap analysis (RD 
0.84%, 95% CI -0.04%, 1.73%), as the individual with a weight of 42 was no longer classified as a new 
user of dabigatran. Removing the capacity for procedure codes for anticoagulation management to 
extend treatment episodes attenuated the apparent mortality benefit in the IPTW AA analyses (RD -
2.06%, 95% CI -4.45%, 0.32%). The general trend of FTCF and AA of ischemic stroke RDs on opposite 
sides of the null was preserved through these analyses. The exclusion of anyone with a stroke in the past 
six months diminished the favorable IPTW AA RD for ischemic stroke (RD -0.31%, 95% CI -1.09%, 0.5%). 
Restricting the population to patients with a predicted probability of frailty of less than 10% at baseline 
excluded 42% of patients and reduced the scale of the AA all-cause mortality RD in both the IPTW (RD -
1.13%, 95% CI -2.43%, -0.33%) and SMR (RD -1.63%, 95% CI -2.54%, -0.73%) analyses; FTCF all-cause 
mortality RDs were largely unaffected. Full risks of each outcome and results from sensitivity analyses 





 There is an ongoing shift in stroke prophylaxis for atrial fibrillation patients away from warfarin 
and towards novel oral anticoagulants in the United States,128 but it is difficult to capture the extent to 
which that is improving patient outcomes in the absence of estimates of absolute-scale treatment 
effects. This study is among the first to estimate absolute-scale effects of dabigatran initiation compared 
to warfarin initiation on all-cause mortality, ischemic stroke, and gastrointestinal bleeding in the United 
States population of older adults in Medicare while also comparing adherence-adjusted and first 
treatment carried forward estimates. In adherence-adjusted analyses, we saw decreases in all-cause 
mortality and risk of ischemic stroke among the dabigatran new users with a higher incidence of 
gastrointestinal bleeding. On the other hand, first treatment carried forward analyses showed 
attenuation of the estimated mortality benefits and reversal of the estimated stroke benefits. Estimated 
dabigatran benefits were slightly greater and estimated harms slightly less in the dabigatran new users 
than in the entire population of new users.  
 The adherence-adjusted results of this study generally mirror those of other studies that 
estimated relative scale treatment effects and censored at treatment discontinuation, which had found 
hazard ratios between 0.73 and 0.80 for ischemic stroke and between 1.04 and 1.28 for gastrointestinal 
bleeding where our study found slightly more extreme IPTW risk ratios of 0.70 and 1.48,    
respectively.14-17,19-26 A protective association between dabigatran use and all-cause mortality has been 
universally observed, with hazard ratios of between 0.57 and 0.76 compared to our risk ratio of 0.78. 
Notably, our IPTW results for gastrointestinal bleeding (risk ratio: 1.48) align closely with the hazard 
ratios observed in the RE-LY trial (trial hazard ratio: 1.50), but this is partly due to one dabigatran user 
standing in for a large number of warfarin users in the IPTW analysis; the SMR results (risk ratio: 1.15) 
and many of the sensitivity analyses are attenuated and more comparable to other non-experimental 
studies. Additionally, the adherence-adjusted results for stroke and gastrointestinal bleeding align better 
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with the findings of RE-LY than the first treatment carried forward results. This is not surprising given the 
better persistence in the trial (85% of dabigatran users and 90% of warfarin users on treatment after 1 
year) than in this study (29% of the dabigatran users and 45% of the warfarin new users on treatment 
after 1 year). This suboptimal treatment persistence after initiation is not unique to this study; in an FDA 
analysis conducted in Medicare with a shorter gap period only half of dabigatran and warfarin users 
filled more than 1 prescription for an oral anticoagulant.19  
Divergence between the first treatment carried forward and adherence-adjusted estimates is 
the most interesting finding, particularly for ischemic stroke estimates in all treated patients where the 
first treatment carried forward RD is equal in magnitude to the adherence adjusted but on the opposite 
side of the null. This result persisted across a variety of sensitivity analyses. This, along with the fact that 
median time on treatment was much higher in warfarin than dabigatran patients with more patients 
continuing on treatment, suggests that there may be issues with treatment persistence and adherence 
in the dabigatran users resulting in suboptimal stroke and mortality outcomes; this could be an artifact 
of the way we classified time on treatment, however. Past analyses of trial data and use data from the 
Veteran Affairs medical system also suggest that stroke risk may be elevated immediately after 
discontinuation of novel oral anticoagulants.129,130 In our study, increased ischemic stroke risk after 
switching or a gap in treatment in dabigatran users was elevated relative to those who stayed on 
treatment but without any short-term spikes (even in the 7-day gap analyses); this is likely due to a lack 
of data surrounding exact time of stopping or switching. This may be a target for future research 
estimating per-protocol treatment effects using medical record or lab data that can take into account 
when treatment discontinuation or switching to another medication is clinically appropriate rather than 
motivated by cost concerns or falling out of clinical care.107 
Another point worth discussing is the magnitude of the protective association between 
treatment with dabigatran versus warfarin and all-cause mortality in both the first treatment carried 
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forward and adherence-adjusted analyses. Putting these benefits on the absolute scale gives some 
important context: if these estimates are unbiased, they suggest an adherence-adjusted two-year 
mortality number-needed-to-treat (NNT) with dabigatran to prevent one death of 34 in the general new 
user population and a first treatment carried forward two-year mortality NNT of 57 in dabigatran users. 
As mentioned before, this protective association has also been observed in other studies specifically in 
older adults.131 On the other hand, mortality as an outcome may be subject to more unmeasured 
confounding factors than those measured in claims data, particularly socioeconomic status or frailty, 
resulting in an exaggerated treatment benefit across these and other studies.132-134 Reduced mortality 
benefits in the analyses restricted to those with less than 10% predicted probability of frailty adds some 
support to this hypothesis, though some of this may be due to lower overall risks in those populations. 
This study has several limitations to consider. Variables associated with treatment initiation and 
the outcomes that we were not able to capture in claims data could bias treatment effect estimates. In 
particular, we did not have data on socioeconomic status. Since the generally higher direct cost to 
patients of dabigatran therapy135 may be associated with decreased use among those with lower 
socioeconomic status, if greater wealth improves health above and beyond wealth’s influence on the 
measured confounders, the estimates would overestimate the benefit and underestimate the harm of 
dabigatran provided no other confounding exists. We also did not use race in the main analyses because 
Medicare’s race variables perform poorly for some minority groups and, if our causal diagrams are 
correct, frailty, age, and comorbidity should be sufficient to block the paths from race to outcome.136,137 
When we did include Medicare’s race variable (split into white, African-American, and other categories) 
in a post-hoc analysis, 91.5% of new users were white, and risk differences shifted at most by seven 
hundredths of a percent; our findings may not generalize to minority populations. Additionally, there 
could be unmeasured variables associated with treatment switching and discontinuation; this would 
lead to remaining selection bias in the adherence-adjusted estimates. 
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Outcomes may have been misclassified; for example, hemorrhagic strokes might be recorded as 
ischemic strokes or vice versa. The fact that stroke and bleeding outcomes required diagnoses after 
hospitalization also means that catastrophic strokes that cause death before assistance can arrive or in 
the emergency department might not be captured, which could explain the mortality benefit above and 
beyond stroke prevention. Finally, differential measurement error in exposure due to differing grace 
periods or patterns of use for the two drugs to take into account warfarin dosage changes could result in 
biased adherence-adjusted estimates, as one drug may have more time incorrectly classified as on-
treatment than the other. That would likely make that drug look comparatively safer, but less 
efficacious. That said, sensitivity analyses using alternative grace periods showed generally similar 
results for the mortality and ischemic stroke outcomes, and our adherence-adjusted results were overall 
similar to past non-experimental work with differing grace periods that ignored procedure codes. 
Finally, our results may not apply to younger populations, populations outside the United States, or 
Medicare beneficiaries that enroll in managed care; this is especially our first treatment carried forward 
estimates, where differing cost profiles may result in substantially differing persistence and adherence. 
 These limitations aside, the absolute effect estimates from this study represent a step forward 
in understanding oral anticoagulant treatment in older adults with atrial fibrillation. More and more 
patients (and more and more older adults) with atrial fibrillation are taking novel oral anticoagulants. 
Based on these findings, dabigatran may be a better choice than warfarin in this population as a whole 
when they remain on treatment; lower treatment persistence in the dabigatran users may mean these 
benefits are not being realized in the real world, however. As researchers accumulate data on these 
people, estimating risk and rate differences in addition to hazard ratios and relative risks is critical if we 
want to identify the best treatments for older adults, particularly when we believe treatments may help 
some patients but harm others. Additionally, while it is tempting to conduct only one of an first 
treatment carried forward or adherence adjusted analysis in a study, implementing both can identify 
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how patterns in adherence can shape the potential benefits and harms of treatments, especially in 
settings where the two treatments may differ in patterns of persistence.138,139 Here, conducting both 
first treatment carried forward and adherence-adjusted analyses allowed us to identify differences in 
time on treatment for the two medications that could result in less than optimal outcomes for initiators 
of dabigatran. Further exploration of the effects of both traditional and novel oral anticoagulant 
adherence and persistence that take into account potential bias from treatment switching and 
discontinuation are key to understanding the comparative safety and effectiveness of oral 





Figure 16: Study flow diagram showing study inclusion and exclusion of new use periods identified in the 




Table 2: Distributions of Covariates Included in the Propensity Score Model in New Users of Warfarin and 






Warfarin new users  
N=74,891 (%) 
Absolute Standardized Mean 
Difference (ASMD) 
Age      
65-69 2,249 21.0% 10,295 13.7% 0.192 
70-74 2,859 26.7% 15,442 20.6% 0.143 
75-79 2,514 23.5% 16,666 22.3% 0.029 
80+ 3,095 28.9% 32,488 43.4% 0.305 
Female 5316 49.6% 32430 43.3% 0.127 
Hypertension 10522 98.2% 73340 97.9% 0.018 
Diabetes 3334 31.1% 24329 32.5% 0.030 
Coronary Artery 
Disease 5178 48.3% 37389 49.9% 0.032 
Congestive Heart 
Failure 3839 35.8% 30404 40.6% 0.098 
      
Peripheral Vascular 
Disease 1626 15.2% 14829 19.8% 0.122 
Past Stroke 2522 23.5% 19768 26.4% 0.066 
Past TIA 900 8.4% 6276 8.4% 0.001 
Hyperlipidemia 8973 83.7% 59521 79.5% 0.110 
Atherosclerosis 4883 45.6% 35535 47.4% 0.038 
Obesity 1348 12.6% 7960 10.6% 0.061 
Smoking 739 6.9% 5149 6.9% 0.001 
Cancer 1833 17.1% 11836 15.8% 0.035 
Past Bleed 905 8.4% 9595 12.8% 0.142 
Past Gastrointestinal 
Bleeding 537 5.0% 4863 6.5% 0.064 
Acute Renal 
Dysfunction in the Past 
Year 317 3.0% 4303 5.7% 0.137 
Alcohol Abuse 99 0.9% 677 0.9% 0.002 
Ablation in the Last 
Year 209 2.0% 693 0.9% 0.086 
Cardioversion in the 
Last Year 990 9.2% 3092 4.1% 0.206 
Deep Vein Thrombosis 355 3.3% 8465 11.3% 0.311 
Pulmonary Embolism 98 0.9% 4115 5.5% 0.262 
Previous Warfarin Use 










AA Follow-up (median, 
P25-P75) 
152 (60-382) 259 (117 – 625) NA 
FTFC Follow-up 
(median, P25-P75) 
980 (489-1,386) 846 (355-1,415) NA 




Figure 17: Standardized mean differences in new users in the crude (empty circles), after weighting with 
IPTW (filled squares), and after SMR weights (filled triangles) for covariates with standardized mean 
differences larger than 0.10 in the crude. All measured confounders had absolute standardized mean 








Table 3: Number of Events, Person-Years of Follow-Up, and Risks at One and Two Years By Treatment Group, 
Weighting Methodology, and Type of Follow-Up 








Ischemic Stroke      
Dabigatran new users      
Crude, FTFC 17,259 237 1.37 1.38% 2.57% 
Crude, AA 7,474 68 0.91 0.86% 1.29% 
IPTWa, FTFC 17,113 314 1.84 1.94% 3.29% 
IPTWa, AAb 7,575 108 1.43 1.31% 1.68% 
Warfarin new users      
Crude, FTFC 112,263 1,863 1.66 1.75% 2.91% 
Crude, AA 70,414 1,095 1.56 1.54% 2.48% 
IPTWa, FTFC 112,676 1,823 1.62 1.72% 2.85% 
IPTWa, AAb 70,670 1,068 1.51 1.51% 2.41% 
SMRa weighted to Dabigatran, FTFC 16,539 221 1.34 1.47% 2.41% 
SMRa weighted to Dabigatran, AAb 10,260 127 1.24 1.27% 1.96% 
All-Cause Mortality      
Dabigatran new users      
Crude, FTFC 17,438 934 5.36 5.05% 10.24% 
Crude, AA 7,493 269 3.59 3.92% 6.82% 
IPTWa, FTFC 17,343 1,476 8.51 8.29% 15.65% 
IPTWa, AAb 7,599 484 6.37 6.37% 10.51% 
Warfarin new users      
Crude, FTFC 113,607 10,807 9.51 9.37% 17.14% 
Crude, AA 70,918 5,732 8.08 8.18% 14.02% 
IPTWa, FTFC 114,005 10,385 9.11 8.97% 16.49% 
IPTWa, AAb 71,167 5,653 7.94 7.85% 13.49% 
SMRa weighted to Dabigatran, FTFC 16,714 1,064 6.36 6.24% 11.89% 
SMRa weighted to Dabigatran, AAb 10,326 570 5.52 5.47% 9.78% 
Gastrointestinal Bleeding      
Dabigatran new users      
Crude, FTFC 17,133 330 1.93 1.91% 3.55% 
Crude, AA 7,461 168 2.25 2.18% 4.00% 
IPTWa, FTFC 16,952 438 2.59 2.63% 4.55% 
IPTWa, AAb 7,560 272 3.60 3.42% 5.51% 
Warfarin new users      
Crude, FTFC 111,617 2,288 2.05 2.21% 3.54% 
Crude, AA 70,329 1,597 2.27 2.27% 3.76% 
IPTWa, FTFC 112,028 2,259 2.02 2.18% 3.50% 
IPTWa, AAb 70,574 1,621 2.30 2.24% 3.72% 
SMRa weighted to Dabigatran, FTFC 16,445 294 1.79 1.97% 3.19% 
SMRa weighted to Dabigatran, AAb 10,247 215 2.10 2.07% 3.49% 
AA=adherence-adjusted. FTFC=first treatment carried forward. IPTW = inverse probability of treatment weighted. 
SMR=standardized morbidity ratio weighted. 
aWeighted based upon logistic regression including frailty and age modeled with restricted cubic splines at the 20th, 40th, 
60th, and 80th percentile, sex, diabetes, coronary artery disease, congestive heart failure, hypertension, stroke in the past 
year, transient ischemic attack, cancer, bleed and GI bleed history, past use of vitamin K antagonists, alcohol abuse, acute 
renal problems, atherosclerosis, cardioversion in the past year, deep vein thrombosis in the past year, hyperlipidemia, 
obesity, pulmonary embolism in the past year, peripheral vascular disease and codes indicating smoking. 
bWeighted adherence-adjusted analyses include time-varying inverse probability of censoring weights to account for 





Figure 18: Inverse probability of treatment weighted survival curves for ischemic stroke comparing the 
adherence-adjusted (panel A) and first treatment carried forward (panel B) follow-up schemes. 
 
 
Figure 19: Inverse probability of treatment weighted survival curves for all-cause mortality comparing 





Figure 20: Inverse probability of treatment weighted survival curves for gastrointestinal bleeding 
comparing the adherence-adjusted (panel A) and first treatment carried forward (panel B) follow-up 
schemes. 
  
Figure 21: Inverse probability of treatment weighted survival curves for all stroke comparing the 





Figure 22: Inverse probability of treatment weighted survival curves for major bleeding comparing the 
adherence-adjusted (panel A) and first treatment carried forward (panel B) follow-up schemes. 
 
 




Table 4: Risk Ratios and Risk Differences Comparing Dabigatran New Users to Warfarin New Users for Two-
Year Risks By Outcome, Weighting Method, and Type of Follow-Up 
Estimate 
Two-year adherence-adjustedb: Two-year first treatment carried forward: 
Risk ratio (95% CI) Risk difference (95% CI) Risk ratio (95% CI) Risk difference (95% CI) 
Ischemic Stroke   
Crude 0.52 (0.37, 0.74) -1.19% (-1.67%, -0.71%) 0.88 (0.77, 1.02) -0.34% (-0.71%, 0.02%) 
IPTWa 0.70 (0.49, 1.03) -0.73% (-1.40%, -0.06%) 1.15 (0.94, 1.41) 0.44% (-0.22%, 1.09%) 
SMRa weighted to 
dabigatran 0.66 (0.48, 0.91) -0.67% (-1.10%, -0.24%) 1.07 (0.93, 1.23) 0.16% (-0.20%, 0.52%) 
All-cause Mortality   
Crude 0.49 (0.42, 0.56) -7.20% (-8.13%, -6.27%) 0.60 (0.56, 0.63) -6.90% (-7.59%, -6.21%) 
IPTWa 0.78 (0.64, 0.95) -2.98% (-5.05%, -0.91%) 0.95 (0.86, 1.04) -0.84% (-2.39%, 0.72%) 
SMR weighted to 
dabigatran 0.70 (0.60, 0.81) -2.96% (-3.97%, -1.95%) 0.86 (0.81, 0.91) -1.65% (-2.32%, -0.98%) 
Gastrointestinal 
Bleeding   
Crude 1.06 (0.87, 1.30) 0.24% (-0.49%, 0.98%) 1.00 (0.88, 1.13) -0.00% (-0.43%, 0.44%) 
IPTWa 1.48 (1.05, 2.09) 1.79% (-0.13%, 3.71%) 1.30 (1.05, 1.61) 1.05% (0.08%, 2.01%) 
SMRa weighted to 
dabigatran 1.15 (0.93, 1.41) 0.51% (-0.30%, 1.31%) 1.11 (0.98, 1.26) 0.36% (-0.08%, 0.79%) 
SMR = standardized morbidity ratio. IPTW = inverse probability of treatment weights. 
aWeighted based upon logistic regression including frailty and age modeled with restricted cubic splines at the 20th, 40th, 
60th, and 80th percentile, sex, diabetes, coronary artery disease, congestive heart failure, hypertension, stroke in the past 
year, transient ischemic attack, cancer, bleed and GI bleed history, past use of vitamin K antagonists, alcohol abuse, acute 
renal problems, atherosclerosis, cardioversion in the past year, deep vein thrombosis in the past year, hyperlipidemia, 
obesity, pulmonary embolism in the past year, peripheral vascular disease and codes indicating smoking. 
bWeighted adherence-adjusted analyses include time-varying inverse probability of censoring weights to account for 





Table 5: Risk Ratios and Risk Differences Comparing Dabigatran New Users to Warfarin New Users for Two-Year 
Risks of Stroke and Major Bleeding By Outcome, Weighting Method, and Type of Follow-Up 
Estimate 
Two-year adherence-adjustedb: Two-year first treatment carried forward: 
Risk ratio (95% CI) Risk difference (95% CI) Risk ratio (95% CI) Risk difference (95% CI) 
All Stroke   
Crude 0.53 (0.39, 0.72) -1.4% (-1.93%, -0.87%) 0.85 (0.75, 0.98) -0.47% (-0.85%, -0.09%) 
IPTWa 0.68 (0.48, 0.96) -0.94% (-1.63%, -0.25%) 1.11 (0.93, 1.34) 0.35% (-0.31%, 1.01%) 
SMRa weighted to 
dabigatran 0.65 (0.48, 0.87) -0.86% (-1.34%, -0.38%) 1.03 (0.9, 1.18) 0.09% (-0.29%, 0.46%) 
Major Bleeding   
Crude 0.89 (0.73, 1.10) -0.64% (-1.14%, -0.15%) 0.87 (0.77, 0.97) -0.54% (-1.43%, 0.34%) 
IPTWa 1.20 (0.86, 1.68) 1.04% (-1.06%, 3.15%) 1.11 (0.91, 1.35) 0.53% (-0.52%, 1.58%) 
SMRa weighted to 
dabigatran 0.96 (0.79, 1.18) -0.18% (-1.10%, 0.74%) 0.97 (0.86, 1.09) -0.14% (-0.65%, 0.36%) 
SMR = standardized morbidity ratio. IPTW = inverse probability of treatment weights. 
aWeighted based upon logistic regression including frailty and age modeled with restricted cubic splines at the 20th, 40th, 
60th, and 80th percentile, sex, diabetes, coronary artery disease, congestive heart failure, hypertension, stroke in the past 
year, transient ischemic attack, cancer, bleed and GI bleed history, past use of vitamin K antagonists, alcohol abuse, acute 
renal problems, atherosclerosis, cardioversion in the past year, deep vein thrombosis in the past year, hyperlipidemia, 
obesity, pulmonary embolism in the past year, peripheral vascular disease and codes indicating smoking. 
bWeighted adherence-adjusted analyses include time-varying inverse probability of censoring weights to account for 










risk (7 Day 
gap) 
Two-year 





procedure codes)  
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Ischemic Stroke      
Dabigatran new users      
Crude, FTFC 2.52% 2.49% 2.57% 2.31% 1.92% 
Crude, AA 1.41% 1.48% 1.30% 1.16% 0.91% 
IPTWa, FTFC 3.35% 3.09% 3.44% 2.87% 2.37% 
IPTWa, AAb 1.70% 2.08% 1.76% 1.64% 1.04% 
Warfarin new users      
Crude, FTFC 2.88% 2.92% 2.86% 2.41% 2.01% 
Crude, AA 2.33% 2.54% 2.39% 2.02% 1.64% 
IPTWa, FTFC 2.83% 2.85% 2.81% 2.35% 1.96% 
IPTWa, AAb 2.28% 2.47% 2.34% 1.95% 1.60% 
SMRa weighted to Dabigatran, FTFC 2.39% 2.39% 2.38% 1.95% 1.72% 
SMRa weighted to Dabigatran, AAb 1.84% 1.99% 1.93% 1.53% 1.34% 
All-Cause Mortality      
Dabigatran new users      
Crude, FTFC 10.32% 9.98% 10.20% 9.24% 5.56% 
Crude, AA 5.79% 7.45% 6.72% 6.01% 3.85% 
IPTWa, FTFC 16.22% 14.53% 16.36% 13.18% 6.33% 
IPTWa, AAb 8.81% 10.32% 10.98% 8.49% 4.74% 
Warfarin new users      
Crude, FTFC 17.28% 17.00% 16.84% 15.66% 7.67% 
Crude, AA 12.25% 14.57% 13.51% 12.91% 5.94% 
IPTWa, FTFC 16.68% 16.36% 16.26% 15.07% 7.52% 
IPTWa, AAb 11.82% 14.03% 13.04% 12.43% 5.87% 
SMRa weighted to Dabigatran, FTFC 12.01% 11.74% 11.81% 10.99% 6.66% 
SMRa weighted to Dabigatran, AAb 8.52% 10.16% 9.48% 9.14% 5.48% 
Gastrointestinal Bleeding      
Dabigatran new users      
Crude, FTFC 3.46% 3.57% 3.56% 3.35% 2.81% 
Crude, AA 4.04% 3.81% 3.98% 3.71% 3.02% 
IPTWa, FTFC 4.34% 4.23% 4.67% 3.94% 3.13% 
IPTWa, AAb 3.70% 4.56% 5.64% 4.36% 3.25% 
Warfarin new users      
Crude, FTFC 3.48% 3.56% 3.49% 3.43% 2.82% 
Crude, AA 3.63% 3.75% 3.65% 3.67% 2.98% 
IPTWa, FTFC 3.45% 3.51% 3.45% 3.38% 2.81% 
IPTWa, AAb 3.62% 3.72% 3.62% 3.63% 2.99% 
SMRa weighted to Dabigatran, FTFC 3.19% 3.18% 3.18% 3.06% 2.71% 
SMRa weighted to Dabigatran, AAb 3.50% 3.44% 3.40% 3.38% 3.03% 
SMR = standardized morbidity ratio. IPTW = inverse probability of treatment weights. AA = adherence-adjusted. FTFC = first 
treatment carried forward. 
aWeighted based upon logistic regression including frailty and age modeled with restricted cubic splines at the 20th, 40th, 60th, 
and 80th percentile, sex, diabetes, coronary artery disease, congestive heart failure, hypertension, stroke in the past year, 
transient ischemic attack, cancer, bleed and GI bleed history, past use of vitamin K antagonists, alcohol abuse, acute renal 
problems, atherosclerosis, cardioversion in the past year, deep vein thrombosis in the past year, hyperlipidemia, obesity, 
pulmonary embolism in the past year, peripheral vascular disease and codes indicating smoking. 
bWeighted adherence-adjusted analyses include time-varying inverse probability of censoring weights to account for 




Table 7: Two-year Risk Differences Across Sensitivity Analyses By Outcome, Weighting Methodology, and Type of Follow-Up 
Group 2-year RD (7 Day gap) 2-year RD (60 day gap) 
2-year RD (ignoring 
procedure codes)  
2-year RD (no stroke in 
the past six months) 
2-year RD (low 
predicted probability of 
frailty) 
Ischemic Stroke      
Crude, FTFC -0.36% (-0.69%, -0.03%) -0.43% (-0.81%, -0.04%) -0.29% (-0.61%, 0.03%) -0.10% (-0.45%, 0.25%) -0.09% (-0.44%, 0.26%) 
Crude, AA -0.93% (-1.64%, -0.22%) -1.06% (-1.46%, -0.67%) -1.09% (-1.55%, -0.64%) -0.86% (-1.31%, -0.41%) -0.74% (-1.20%, -0.27%) 
IPTWa, FTFC 0.53% (-0.11%, 1.17%) 0.24% (-0.29%, 0.76%) 0.63% (0.02%, 1.24%) 0.52% (-0.06%, 1.11%) 0.41% (-0.18%, 1.00%) 
IPTWa, AAb -0.58% (-1.47%, 0.32%) -0.39% (-1.07%, 0.29%) -0.58% (-1.24%, 0.09%) -0.31% (-1.09%, 0.46%) -0.56% (-1.15%, 0.02%) 
SMRa weighted to 
Dabigatran, FTFC 0.13% (-0.20%, 0.46%) 0.09% (-0.29%, 0.47%) 0.19% (-0.15%, 0.53%) 0.36% (0.02%, 0.70%) 0.20% (-0.16%, 0.57%) 
SMRa weighted to 
Dabigatran, AAb -0.44% (-1.07%, 0.2%) -0.52% (-0.91%, -0.13%) -0.63% (-1.07%, -0.18%) -0.37% (-0.81%, 0.07%) -0.44% (-0.83%, -0.04%) 
All-Cause Mortality      
Crude, FTFC -6.95% (-7.59%, -6.32%) -7.02% (-7.72%, -6.33%) -6.64% (-7.38%, -5.9%) -6.42% (-7.15%, -5.70%) -2.11% (-2.77%, -1.45%) 
Crude, AA -6.46% (-8.05%, -4.87%) -7.12% (-8.03%, -6.22%) -6.78% (-7.74%, -5.83%) -6.9% (-7.86%, -5.93%) -2.09% (-2.92%, -1.26%) 
IPTWa, FTFC -0.46% (-1.96%, 1.04%) -1.83% (-3.09%, -0.56%) 0.10% (-1.66%, 1.85%) -1.89% (-3.14%, -0.63%) -1.18% (-2.03%, -0.33%) 
IPTWa, AAb -3.01% (-6.46%, 0.44%) -3.71% (-5.37%, -2.04%) -2.06% (-4.45%, 0.32%) -3.95% (-5.87%, -2.02%) -1.13% (-2.43%, 0.16%) 
SMRa weighted to 
Dabigatran, FTFC -1.69% (-2.31%, -1.07%) -1.76% (-2.45%, -1.07%) -1.61% (-2.34%, -0.88%) -1.75% (-2.48%, -1.02%) -1.11% (-1.79%, -0.42%) 
SMRa weighted to 
Dabigatran, AAb -2.74% (-4.42%, -1.06%) -2.72% (-3.71%, -1.73%) -2.76% (-3.76%, -1.75%) -3.12% (-4.22%, -2.03%) -1.63% (-2.54%, -0.73%) 
Gastrointestinal Bleeding      
Crude, FTFC -0.02% (-0.41%, 0.36%) 0.01% (-0.45%, 0.47%) 0.07% (-0.34%, 0.47%) -0.08% (-0.48%, 0.33%) -0.01% (-0.42%, 0.40%) 
Crude, AA 0.41% (-0.76%, 1.57%) 0.05% (-0.52%, 0.62%) 0.33% (-0.36%, 1.02%) 0.04% (-0.65%, 0.74%) 0.04% (-0.68%, 0.76%) 
IPTWa, FTFC 0.89% (-0.27%, 2.05%) 0.71% (0.09%, 1.34%) 1.22% (0.10%, 2.34%) 0.56% (-0.03%, 1.15%) 0.32% (-0.22%, 0.86%) 
IPTWa, AAb 0.08% (-1.19%, 1.36%) 0.84% (-0.04%, 1.73%) 2.01% (-0.40%, 4.43%) 0.73% (-0.42%, 1.88%) 0.26% (-0.91%, 1.44%) 
SMRa weighted to 
Dabigatran, FTFC 0.26% (-0.13%, 0.66%) 0.40% (-0.06%, 0.86%) 0.38% (-0.03%, 0.79%) 0.29% (-0.13%, 0.70%) 0.10% (-0.31%, 0.52%) 
SMRa weighted to 
Dabigatran, AAb 0.55% (-0.76%, 1.86%) 0.37% (-0.31%, 1.04%) 0.58% (-0.20%, 1.36%) 0.33% (-0.51%, 1.16%) 0.00% (-0.95%, 0.94%) 
SMR = standardized morbidity ratio. IPTW = inverse probability of treatment weights. AA = adherence-adjsuted. FTFC = first treatment carried forward. 
aWeighted based upon logistic regression including frailty and age modeled with restricted cubic splines at the 20th, 40th, 60th, and 80th percentile, sex, diabetes, 
coronary artery disease, congestive heart failure, hypertension, stroke in the past year, transient ischemic attack, cancer, bleed and GI bleed history, past use of 
vitamin K antagonists, alcohol abuse, acute renal problems, atherosclerosis, cardioversion in the past year, deep vein thrombosis in the past year, hyperlipidemia, 
obesity, pulmonary embolism in the past year, peripheral vascular disease and codes indicating smoking. 
bWeighted adherence-adjusted analyses include time-varying inverse probability of censoring weights to account for differential censoring and switching across 
treatment arms by measured variables. 
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CHAPTER 5: REWEIGHTING ORANGES TO APPLES: COMPARING TRANSPORTED RE-LY TRIAL AND NON-
EXPERIMENTAL ESTIMATES IN ATRIAL FIBRILLATION 
5.1: Introduction 
  Interest in generalization and transport of estimated intervention effects from study 
populations to external target populations is on the rise across a variety of disciplines, including 
epidemiology.87,89,140-144 Weight-based standardization has been proposed as a method for achieving 
external validity of internally valid treatment effect estimates.88,145,146 Benchmarking the performance of 
these weighting methods against outcomes observed in a subset of the target population has also been 
suggested.117,147 While papers developing methods often include an example or two alongside the 
theoretical basis for this work, these are often single case studies with simple target populations, and 
there is little in-depth discussion about the validity of the transported or generalized study results or 
how they fit with non-experimental evidence. 
 Meanwhile, since the 1990s, warfarin has been used in patients with atrial fibrillation (AF) to 
lower the risk of stroke.36 Use of warfarin requires careful management and dose adjustment to keep 
patients within the therapeutic range given its complicated pharmacokinetics and interactions with food 
and other medications.120 Since 2010, new drugs commonly called novel oral anticoagulants have 
entered the market in the United States and internationally, starting with dabigatran (after the 
Randomized Evaluation of Long-Term Anticoagulants, or RE-LY, non-inferiority trial) and followed by 
several others.6,44,47  
Now that these drugs are on the market, non-experimental studies have been conducted to 
assess whether treatment effects in patient populations in routine care match trial estimates.12,13,15-20 
Unlike the intention-to-treat RE-LY trial analyses that estimate the effect of randomization to treatment 
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under the trial’s observed persistence and adherence, these studies typically censor patients at 
treatment discontinuation; the resulting estimates (often referred to “as-treated” estimates from the 
trial work) are conditional on remaining on treatment.148 Compared to warfarin, investigators 
conducting non-experimental studies of dabigatran have typically found larger survival benefits (HR trial: 
0.88, non-experimental HRs: 0.57-0.76), decreased harms from gastrointestinal bleeding (HR trial: 1.50, 
non-experimental HRs: 1.04-1.28 with one at 1.85) and major bleeding (HR trial: 0.93, non-experimental 
HRs: 0.63-0.82, with one at 1.50), but similar hazards for ischemic stroke. That said, these direct 
comparisons of hazard ratios are comparing apples to oranges. The differences could result from a 
variety of sources, including unmeasured confounding in the non-experimental studies,58 on-treatment 
versus intention-to-treat effect estimates that allow for crossover and discontinuation, or the 
comparatively older and sicker adults in the non-experimental studies experiencing different treatment 
effects.61,124,149 Moreover, these hazard and risk ratios are not readily transformable into risk differences, 
the main parameter of public health interest for interventions and a prerequisite for benefit-harm 
assessment.58,121,122,150 
 In an attempt to disentangle these potential sources of disagreement and obtain absolute effect 
estimates, we conducted two studies, one using weighting methods to transport trial results to a 
population of trial-eligible older adults and another relying entirely on claims data from those older 
adults. By reweighting the trial to resemble the non-experimental target population, we can get closer 
to an apples-to-apples comparison. Medicare often provides data for research purposes and individual-
level data from RE-LY has also been made available for research through a secure online portal. As a 
result, we can apply weighting methods to transport treatment effect estimates to various real-world 
target populations of older adults and benchmark these effect estimates and their variance against 
those obtained in the target. Moreover, the outcome data in Medicare allows benchmarking of the 
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weighted trial population against observed outcomes in the target population to assess whether key 
assumptions for these methods have been met. 
 This study, then, aims to compare on-treatment risks for ischemic stroke, all-cause mortality, 
and gastrointestinal bleeding in separate target populations of Medicare beneficiaries starting 
dabigatran versus warfarin with inverse odds of sampling weights and the RE-LY trial. These estimates 






5.2.1: Parameters of interest 
 We were primarily interested in the causal two-year risk difference for three outcomes 
(ischemic stroke, all-cause mortality, and gastrointestinal bleeding) comparing initiation and persistence 
on dabigatran versus warfarin, allowing for the competing risk of death, in Medicare beneficiaries in 
routine care that met eligibility criteria for the RE-LY trial. We estimated this parameter two ways: first, 
we transported treatment effects from RE-LY trial participants over 65 to the target populations, using 
treatment and covariate data from insurance claims in Medicare (calling these estimates RDTP, where P 
corresponds to the target population); and second, we estimated treatment effects using propensity 
score weighting using only the Medicare claims data (RDOP).  
We were also interested in supplementary parameters, including the causal two-year risk 
differences in the RE-LY participants over 65 without sampling weights, causal two-year risk differences 
for outcomes of all stroke and major bleeding in our target populations, and the two-year risks 
associated with these and primary parameters of interest. 
 
5.2.2: Study Populations 
Trial sample-The RE-LY trial recruited 18,113 participants to assess the non-inferiority of 
dabigatran versus warfarin for the outcomes of stroke and major bleeding in patients with non-valvular 
atrial fibrillation.6 In addition to a diagnosis of atrial fibrillation, patients needed to meet a variety of 
inclusion criteria  including a history of stroke, transient ischemic attack, or systemic embolism; ejection 
fraction less than 40%; symptomatic heart failure; age over 75; or age over 65 and at least one of 
diabetes, documented coronary artery disease, and hypertension requiring medical treatment. 
Participants were randomized to one of three therapies: 150 mg of dabigatran twice daily, 110 mg of 
dabigatran twice daily, or warfarin therapy administered in a systematic protocol. Baseline data on a 
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variety of covariates was collected for potential subgroup analysis and both temporary and permanent 
discontinuation of the study drug was tracked. 
Because we were primarily interested in older adults, we limited analyses to those over 65 
(omitting those younger trial participants with histories of stroke, TIA, or heart failure), and because the 
110 mg twice daily dosage was not approved for use in the United States, we focused on contrasts 
between the 150 mg twice daily arm and the warfarin treatment arm. The trial data was provided by 
Boehringer Ingelheim through Clinical Study Data Request (url: 
https://www.clinicalstudydatarequest.com), a service that provides access to individual-level data from 
randomized controlled trials to researchers through a secure data platform managed by SAS called 
Clinical Trial Data Transparency. 
Target Populations-We were interested in estimating treatment effects in trial-eligible Medicare 
beneficiaries that were new users of dabigatran or warfarin the United States. To estimate the 
distribution of potential covariates modifying treatment effect in this population, we used a 20% simple 
random sample of United States Medicare beneficiaries managed by the Centers for Medicare and 
Medicaid services to construct a cohort of new users of either drug, including only the 150 mg twice 
daily dose of dabigatran. We focused on new users from 2010 (the year dabigatran was approved) to 
October 2015 (the date of diagnosis codes switched from ICD-9 to ICD-10-CM). Individuals were eligible 
for inclusion after 365 days of continuous enrollment on parts A, B, and D. Participants had to be free of 
warfarin or any novel oral anticoagulant for at least 60 days before their qualifying prescription. We also 
required at least one diagnosis for atrial fibrillation in the 180 days before or 7 days after the qualifying 
prescription with follow-up starting at the date of atrial fibrillation diagnosis for those with diagnoses 
after qualifying prescription. 
After identifying these eligible new use periods, we screened each for RE-LY trial eligibility using 
diagnosis codes in claims data. To enter our target population, individuals had to be either over age 75 
90 
 
or over 65 with evidence of at least one of hypertension, diabetes, congestive heart failure, coronary 
artery disease, and history of stroke or transient ischemic attack in the year before their qualifying 
prescription. We applied exclusions for active cancer in the past 180 days, and any of endocarditis, 
severe or chronic kidney failure, valve replacement, and active liver disease in the past 365 days. The full 
list of the codes used to assess these conditions, previously used by Seeger et al., is in Appendix B.18 In 
our main analyses we also used a predicted probability of frailty greater than 15% from a claims-based 
frailty prediction algorithm as a proxy for excluding individuals with a low life expectancy, though we 
also explored omitting this exclusion.118 We chose 15% to be slightly more conservative and ensure 
there were fewer potentially-frail individuals in our targets than the 20% cutoff used in the initial 
validation of the frailty score. 
In total, we constructed four potential target populations from Medicare that appeared eligible 
for the RE-LY trial: first, new users of dabigatran with less than 15% predicted probability of frailty at 
treatment initiation (P1); second, new users of warfarin with less than 15% predicted probability of 
frailty initiation (P2); third, all new users of dabigatran (P3); and fourth, all new users of warfarin (P4). In 
sensitivity analyses, we also considered dabigatran or warfarin users without a code for stroke in the 
primary inpatient position in the past 180 days (to mimic RE-LY’s exclusion of those without a severe 




Trial sample: In the main on-treatment analyses, we used assigned treatment as exposure and 
followed participants for 2 years, death, the end of their study participation, or six days after recorded 
permanent cessation of assigned treatment, whichever came first (this was the safety interval defined in 
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the trial protocol). This meant that individuals who were assigned to a treatment arm but did not initiate 
it were included for the purposes of constructing sampling weights. 
Medicare sample: we followed individuals until receipt of another type of oral anticoagulant 
with an allowed gap of 30 days’ supply for dabigatran users and 45 days’ supply for warfarin users. 
Different grace periods were due to concerns about frequent changes in dosage amongst warfarin users. 
We also allowed procedure codes for anticoagulation management (listed in Appendix D) to “refresh” 
days’ supply of warfarin for 30 days under the assumption patients may pay out-of-pocket for the 
medication or, again, have their dose frequently adjusted. 
 
5.2.4: Outcomes 
We assessed two-year cumulative incidence of the first occurrence of five outcomes after 
treatment initiation: ischemic stroke, all-cause mortality, gastrointestinal bleed, all stroke, and major 
bleeding. In this paper we present results for the first three outcomes due to their more specific nature 
and greater similarity between the trial and target populations; results for the final two outcomes are 
included in supplemental material. We used the original adjudicated outcomes from the RE-LY trial 
when analyzing the trial data. When obtaining estimates of cumulative risk in the Medicare population, 
we relied on ICD-9 codes from the primary position in inpatient hospitalizations under the assumption 
that these outcomes are all severe enough to qualify for hospitalization stays. The full list of codes for 
each outcome, validated for positive predictive value in previous claims-based studies109 and used in 
past non-experimental work, is listed in Appendix A. 
 
5.2.5: Covariates 
We used data collected during the conduct of the RE-LY trial on a wide set of potential modifiers 
of treatment effect (to estimate sampling weights) and variables associated with remaining on 
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treatment (to estimate censoring weights). These baseline variables included age (with those over 89 
combined in one category for privacy reasons), sex, use of other medications, current smoking, diabetes, 
congestive heart failure, coronary artery disease, past stroke, past transient ischemic attack, and past 
cancer. We also used trial variables on heavy alcohol use, hypertension, major or moderate bleeding 
while on warfarin, and past use of warfarin in the censoring weights. 
In the Medicare patients, we used diagnosis and procedure codes as well as drug prescriptions 
to identify the presence or absence of analogous variables, as well as even more variables for use for 
censoring weights and confounding control (which did include past use of warfarin during the 
individual’s time in claims). We used 1-year lookbacks for all covariates except for past use of warfarin 
(which used all potential lookback time). The full list of codes and criteria for each modifier is presented 
in Appendix B. In addition to its role restricting the target populations, the predicted probability of 
frailty was used to construct weights for censoring and confounding control. 
The set of variables we included in our sampling model was built from both the trial subgroup 
analyses and clinical knowledge about the variables associated with outcome. Assuming the sampling 
diagrams in Figures 8 and 9 are correct, the covariates included will render sampling and outcome 
independent except through hypertension, heavy alcohol use, past use of warfarin, and bleeding history. 
89,105 Rather than use linear age or predicted probability of frailty in our sampling and censoring models, 
we used semiparametric restricted quadratic splines with knots at the 20th, 40th, 60th, and 80th 
percentiles. The major covariates missing (heavy alcohol use, general history of major bleeding, 
hypertension, and past warfarin use) appeared to be captured poorly or measured differently in the trial 
and target populations: hypertension required medical treatment in the trial compared to our pre-
specified more sensitive hypertension code set; bleeding history outside of warfarin use was not 
available in RE-LY; prevalence of heavy drinking in Medicare appeared vastly lower, suggesting 
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differences in sensitivity; and past use of warfarin could not be assessing prior to enrollment onto 
Medicare, while it was assessed over the life course in RE-LY. 
 
5.2.6: Statistical Analysis 
 Analyses without sampling weights: Risk differences in those over 65 in the trial were estimated 
from cumulative incidence and survival curves in both the trial and target populations using the Aalen-
Johansen estimator119 to take into account the competing risk of death for all of our non-mortality 
outcomes. This estimator was unweighted when assessing the intention-to-treat effect of treatment 
randomization. When estimating the effect of being randomized and remaining on treatment, we 
accounted for differential discontinuation and switching by covariates using cumulative inverse 
probability of censoring weights estimated from the probability of remaining uncensored between 
quartiles of the censoring distribution, estimating those probabilities using multivariable logistic 
regression.125 Due to data constraints, we used baseline versions of all covariates in the trial but allowed 
target population versions of covariates to vary over time. 
 Sampling weights (in the trial): Our first method for estimating the main parameters of interest 
was transporting the RE-LY trial results was combining the above censoring weights with inverse odds of 
sampling weights.88 We were unable to directly combine individual-level RE-LY trial date with the 
Medicare data due to stipulations in our data sharing agreements, so these weights could not be 
calculated directly. Instead, we took an alternate approach involving simulating data and exporting 
coefficients described in detail in Section 3.2.3. Estimated covariate-conditional odds from the final 
multivariable logistic regression sampling models were used to calculate inverse odds of sampling 
weights stabilized to the number of overall participants in the trial. We then created a trial population 
with similar covariate distributions as the target population. These weights were combined with the 
inverse probability of censoring weights to estimate on-treatment survival curves and risk differences 
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for each outcome. The models were deemed successful if absolute standardized mean differences 
between distributions of all the covariates in the sampling model for the inverse odds of sampling 
weighted trial and target populations were less than 0.10.114 
Non-experimental effect estimates: The second method for estimating our main parameters of 
interest was the use of standardized morbidity ratio (SMR) weights combined with inverse odds of 
censoring weights.151 Based on the directed acyclic graphs relating exposure and the outcomes in the 
target population (Figure 11), crude estimates of treatment effect using the non-experimental data 
should be biased. To account for this confounding, we estimated the probability of initiating dabigatran 
rather than warfarin conditional on a set of covariates that should render treatment and outcome 
independent with multivariable logistic regression (these included a variety of comorbid conditions used 
in past non-experimental studies). These probabilities were transformed to odds, with the inverse of 
those odds being the SMR weights. We conducted separate analyses weighted to the dabigatran new 
users and the warfarin new users as potential target populations. These propensity score models were 
deemed successful if absolute standardized mean differences between the two groups of new users in 
the Medicare population were less than 0.10 after weighting. These final SMR weights were then 
combined with inverse probability of censoring weights for use in an Aalen-Johansen estimator. 
Comparing estimates: We compared the estimated two-year risk difference for the three 
primary outcomes comparing dabigatran and warfarin initiators transporting trial results to the non-
experimental treatment effect estimates in each target population. 
Diagnostic assessment of transportability: In addition to comparing treatment effect estimates, 
we also assessed the extent to which the weighted survival curves differed from inverse probability of 
censoring-weighted survival in the target population.117,147 We compared survival curves and calculated 
risk differences at 730 days. If there was a large gap between the two, then the chance our main 
parameters of interest are not being estimated in the transported or non-experimental results 
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increased: either the sampling model does not render them independent, and the effect estimate will be 
biased on at least one scale; the way the exposure is administered differs between the two populations, 
and the effect estimate may be biased; or the outcome itself is measured differently in the 
populations.144 We considered the plausibility and implications of each of these potential sources of 
error for each outcome. 
 
5.2.7: Sensitivity analyses 
We conducted two main types of post-hoc sensitivity analyses: targeting additional populations 
(individuals with no stroke in the primary position of an inpatient encounter in the past 180 days, 
individuals with less than 10% predicted probability of frailty) and including additional or changing 
variables from the sampling model in the main analyses (measured past warfarin use and a modified 
version of hypertension requiring treatment with non-beta-blockers, as well as another model with 
quadratic age). 
All statistical analyses were performed in SAS 9.4 for Windows (Cary, NC). This study was 





 Study populations: Figure 23 is a flow diagram describing study inclusion and exclusion. Of the 
18,113 participants included in the original RE-LY trial, there were 15,132 over the age of 65 that were 
used in the transportability analyses. Of these, 10,115 were randomized to the warfarin (N= 5,069) or 
dabigatran 150 mg twice daily arms (N=5,046) and had no missing data on covariates in any of the 
sampling and censoring models. In Medicare, we identified 10,717 dabigatran new users, 74,891 
warfarin new users, 8,586 dabigatran new users with less than 15% predicted probability of frailty, and 
50,650 warfarin new users with less than 15% predicted probability of frailty. In the main results we 
focus on the frailty-restricted target populations due to potential lack of positivity. Results without the 
frailty restriction are included in supplemental material. 
Table 8 presents the distribution of potential modifiers in the trial participants randomized to 
the treatments of interest and the frailty-restricted target populations. Figure 24 graphically shows the 
standardized mean difference for each of these potential modifiers compared to the trial. Generally, 
patients in the target populations were older with more cardiovascular comorbidities, including history 
of stroke. Table 9 provides similar information for the populations that were not restricted by predicted 
probability of frailty; differences between these two groups were even greater. 
Within-trial effect estimates (unweighted): Risks of mortality and ischemic stroke were lower in 
the on-treatment than the intention-to-treat even after applying censoring weights (see Table 10 for 
two-year risks and rates). Risk differences, however, were similar in intention-to-treat and inverse 
probability of censoring weighted on-treatment analyses. Dabigatran remained protective for both 
ischemic stroke (on-treatment two-year risk difference: -0.74%, 95% CI -1.63%, -0.14%) and all-cause 
mortality (on-treatment two-year risk difference: -0.64%, 95% CI -1.3%, 0.1%), but harmful for 
gastrointestinal bleeding (on-treatment two-year risk difference: 1.37%, 95% CI 0.66%, 2.08%). 
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 Transported trial effect estimates: The distributions of each covariate included in the sampling 
model in the weighted trial populations and the target populations are presented in Table 11. Absolute 
standardized mean differences for all covariates were balanced considerably better after weighting with 
all falling below 0.100 when contrasting the weighted trial with its corresponding target. Table 12 
presents a similar breakdown for the unrestricted target populations; the unrestricted warfarin target 
population still had large differences in age, sex, past stroke, and past transient ischemic attack after 
weighting. 
 Figure 25 shows cumulative incidence curves for ischemic stroke in the trial without sampling 
weights (left), the trial weighted to the dabigatran users (middle, P1), and the trial weighted to the 
warfarin users (right, P2). The cumulative incidence is higher in both weighted trial arms compared to 
the original trial. Figure 26 shows cumulative incidence curves for the unrestricted target populations, 
and Figures 27-30 show cumulative incidence curves for other outcomes of interest. 
 Table 13 presents person-time at risk, events, incidence rates, two-year risks, and two-year risk 
differences for ischemic stroke, all-cause mortality, and gastrointestinal bleeding when weighting to 
target populations P1 and P2. Table 14 provides results for all stroke and major bleeding events, while 
Table 15 shows results when weighting to P3 and P4. 
After applying sampling weights, the estimated RD for ischemic stroke in P1 was about the same 
as the original trial (RDT1: -0.78%, 95% CI -1.69%, 0.14%), and P2’s RD was slightly larger in magnitude 
(RDT2: -0.91%, 95% CI 1.93%, 0.11%). RDs for all-cause mortality changed more after applying sampling 
weights: while the weighted estimate in P1 was about the same as the original trial (RDT1: -0.57%, 95% CI 
-1.83%, 0.68%), the RD for P2 was considerably attenuated (RDT2: -0.16%, 95% CI -1.71%, 1.39%). Finally, 
the results for gastrointestinal bleeding were straightforward: across both P1 and P2, the sampling 
weighted RDs were slightly greater than those the original trial (RDT1: 1.75%, 95% CI 0.76%, 2.74%; RDT2: 
1.85% (95% CI 0.65%, 3.04%). 
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SMR-Weighted Non-experimental Results: When the parameters of interest were estimated 
using claims data alone with propensity scores and SMR weights, the two-year RDO1 for ischemic stroke 
was -0.45% (95% CI -0.85%, -0.06%) and RDO2 was -0.55% (95% CI -1.21%, 0.12%). RDO1 for two-year 
mortality was -1.94% (95% CI -2.85%, -1.04%) and RDO2 was -0.40% (95% CI -2.68%, 1.89%) and RDO1 and 
RDO2 for gastrointestinal bleeding were 0.14% (95% CI -0.76%, 1.03%) and 0.57% (95% CI -0.70%, 1.83%), 
respectively. Table 16 includes non-experimental RDs for all outcomes and target populations. Estimates 
of the two-year RD for ischemic stroke were similar across trial transport and non-experimental study 
approaches, but estimates of RDs for mortality in P1 and gastrointestinal bleeding in both P1 and P2 
differed. Figure 31 plots the non-experimental estimates and 95% confidence limits on the horizontal 
axis and the transported trial estimates and 95% confidence limits on the vertical axis, with each point 
representing a different target population and each panel representing a different outcome (Figure 32 
provides an analog for the unrestricted target populations).  
Assessing Transportability: Two-year risk differences between the weighted trial populations 
and the target populations of less-frail dabigatran and warfarin users for all five outcomes are presented 
in Table 17 (a version for the unrestricted populations can be found in Table 18). Weighting appeared to 
put the trial dabigatran users at slightly higher risk of ischemic stroke than the Medicare dabigatran 
users (RD for Medicare vs. weighted trial: -0.57%, 95% CI -1.20%, 0.05%) and trial warfarin users at 
slightly higher risk of ischemic stroke than  Medicare warfarin users (RD: -0.69%, 95% CI -1.48%, 0.09%), 
with similar results for all stroke.  
Risk of gastrointestinal bleeding also appeared higher in the weighted trial than Medicare 
dabigatran users (RD: -0.90%, 95% CI 2.05%, 0.25%), though it was about the same when weighting to 
Medicare warfarin users (RD: 0.36%, 95% CI -0.41%, 1.13%). Major bleeding was much lower in both 
target populations than the corresponding weighted trial (RD for dabigatran users: -4.76%, 95% CI -
6.23%, -3.29%; RD for warfarin users: -4.05%, 95% CI -5.13%, -2.98%).  
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Finally, Medicare dabigatran users and the weighted trial dabigatran users experienced similar 
mortality (RD: 0.18%, 95% CI -1.07%, 1.44%), though the trial warfarin users had a marked mortality 
advantage over the Medicare warfarin users (RD: 2.02%, 95% CI 0.84%, 3.20%). 
 Sensitivity analyses: Table 19 and Table 20 show the results of the sensitivity analyses. Excluding 
those with a stroke within the past 180 days and further frailty restriction appeared to make RDT2 more 
favorable for dabigatran, particularly with respect to mortality and major bleeding; this lends further 
credence to the idea that mortality benefits of dabigatran (or the harms of warfarin) may vary across 
population. Including the modified hypertension definition and history of warfarin use in the sampling 
model appeared to attenuate the ischemic stroke benefits in when targeting dabigatran users, though 






This work represents an important step in assessing the extent to which trial and non-
experimental findings really disagree about treatment effects of dabigatran versus warfarin in patients 
with atrial fibrillation and outlines many of the difficulties encountered when trying to compare 
transported trials to real-world evidence in target populations of interest. Absolute-scale on-treatment 
effect estimates for initiating dabigatran versus warfarin were generally similar whether estimates were 
obtained by transporting trial results or using claims data with propensity score methods. On the other 
hand, transported estimates were closer to the null compared to non-experimental estimates of 
treatment effect on mortality for dabigatran initiators and farther from the null than non-experimental 
estimates of treatment effects for gastrointestinal bleeding. Weighting was able to standardize the RE-
LY trial to Medicare target populations of warfarin and dabigatran new users with low predicted 
probability of frailty (P1 and P2), but problems standardizing to target populations that were not 
restricted based on frailty may reflect a lack of positivity for these older and sicker in the original 
randomized control trial. 
Contextualizing and understanding these results and how they relate to each outcome is key, 
especially as our non-experimental estimates are generally in line with past non-experimental research. 
Perhaps the most encouraging finding from the study is that the absolute-scale effects on ischemic 
stroke obtained via sampling weights were equal to or greater than those from non-experimental work, 
especially as thrombotic strokes are the main reason to prescribe dabigatran and warfarin.22 That the 
weighted trials absolute-scale effects of dabigatran versus warfarin on mortality are attenuated (and 
close to the null) when targeting less-frail warfarin users could either reflect confounding in the non-
experimental estimates or different patterns of warfarin management in RE-LY compared to the general 
population that result in meaningfully different care.71-74,78 Meanwhile, non-experimental treatment 
effect estimates for gastrointestinal bleeding being closer to the null could be due to a lack of data on 
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bleeding risk factors when transporting trial results or differences in treatment effects, or could be due 
to differing definitions of the outcome in the two studies. 
Results from transportability assessment were mixed. The fact that the less-frail dabigatran 
users and the weighted trial dabigatran users had very similar risks of mortality at two years is 
reassuring. The other findings all have many potential explanations. Differences in mortality between 
Medicare warfarin users and weighted trial warfarin users could reflect overall better warfarin 
management in the trial or it could reflect differences in unaccounted for modifiers.70 Using claims-
based data for stroke outcomes can be difficult.152 While our other outcomes were validated for positive 
predictive value, there is less available data on their sensitivity, which is key when juxtaposing trial and 
target population outcomes. The weighted trial versus target differences in ischemic stroke risk could 
plausibly be due to a combination of lower sensitivity for these outcomes in Medicare claims data (a 
more inclusive algorithm still only had 82% sensitivity)153 and the fact that strokes or bleeds that caused 
death before hospitalization would not be captured in Medicare. Additional lowering of all stroke in the 
warfarin users in routine care may reflect that hemorrhagic strokes are less likely to occur due to 
underanticoagulation in routine care or that hemorrhagic strokes are even more poorly captured in 
claims data (75% sensitivity with a more inclusive algorithm).153 The differences in gastrointestinal 
bleeding risk could reflect the fact that we could not use general bleeding history for standardization 
alongside a lower sensitivity, and the large differences in major bleeding most likely means the outcome 
codes in Medicare are not equivalent to RE-LY’s adjudication method. 
It’s important to understand the limitations of our findings. While restricting to those eligible for 
the RE-LY trial was necessary to allow for positivity when transporting treatment effects, those patients 
still represent an important segment of the treated population; our findings may not apply to them. The 
codes and covariates defined using claims data were assumed to map to and reflect the clinical 
covariates obtained during the RE-LY study with minimal misclassification. While we attempted to put as 
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many covariates from the trial into the sampling model as we reasonably could, any effect measure 
modifiers missing from it could bias transported estimates of treatment effects. Furthermore, we were 
not able to include any interaction terms in our sampling model; this could be problematic if some effect 
measure modifiers need to both be present to result in altered treatment effect.145 We relied on our 
inverse probability of censoring weights to mitigate the potential for time-varying confounding; 
however, it is possible these models also omitted key covariates and that residual bias remains. Finally, 
requiring fee-for-service Medicare coverage to observe prescription exposure to dabigatran restricts the 
study population and the resulting covariate distributions may differ from the ideal target 
populations.154 
 Overall, this is one of the first applications of inverse odds of sampling weights to understand 
the extent to which trial and non-experimental findings of treatment effects disagree about treatment 
effects in target populations of interest after taking into account treatment effect heterogeneity. As 
data from trials and clinical practice populations becomes more available for health research, 
researchers should make sure to specify target populations when considering whether treatment effect 
estimates agree with one another. While it may require additional data and analysis, comparing apples 





Figure 23: Consort diagram for the study (RE-LY) and target (Medicare) populations. Subjects in A were 
required to match the inclusion and exclusion criteria of RE-LY. T1 and T4 represent the various target 
populations used in the analysis, with T1 and T2 referring to the main populations analyzed. All trial 
participants in B were used to calculate inverse odds of sampling weights. Population W and D were 






Table 8: Distribution of selected potential modifiers in RE-LY trial participants randomized to dabigatran 150 mg twice 
daily or warfarin and the target populations identified in the 20% random Medicare sample from 2010 through 2015 
after restricting to individuals with less than 15% predicted probability of frailty. 
Variable 
In RE-LY and randomized to 
either treatment, N=10,115 
Medicare dabigatran new 
users, N=8,586 (P1) 
Medicare warfarin new 
users, N=50,650 (P2) 
Age (Median, P25-P75) 74 (70-78) 74 (70-79) 76 (71-81) 
Male Sex 6,171 (61.0%) 4,418 (51.5%) 23,691 (46.8%) 
Smoking N (%) 615 (6.1%) 523 (6.1%) 3,100 (6.1%) 
Past stroke N (%) 1147 (11.3%) 1,484 (17.3%) 8,630 (17.0%) 
Hypertensiona N (%) 8152 (80.6%) 8,418 (98.0%) 49,488 (97.7%) 
Past TIA N (%) 871 (8.6%) 511 (6.0%) 2,575 (5.1%) 
CHF N (%) 2637 (26.1%) 2,730 (31.8%) 17,519 (34.6%) 
CAD N (%) 2916 (28.8%) 3,896 (45.4%) 23,171 (45.7%) 
DM N (%) 2319 (22.9%) 2,506 (29.2%) 15,487 (30.6%) 
Cancer N (%) 1207 (11.9%) 1,459 (17.0%) 7,784 (15.4%) 
Past warfarin usea N (%) 6894 (68.2%) 1,565 (18.2%) 18,053 (35.6%) 
Amiodarone use N (%) 994 (9.8%) 888 (10.3%) 5,020 (9.9%) 
PPI use  1500 (14.8%) 2,229 (26.0%) 12,764 (25.2%) 
P1=Target population 1. P2 = target population 2. CHF=Congestive heart failure. CAD = coronary artery disease. DM = 
diabetes mellitus. PPI = proton pump inhibitor. 
aThese variables may not be equivalent across data sources, as hypertension in the trial is treated hypertension while 
hypertension in the targets is treated or untreated hypertension, and past use of vitamin K antagonists in the target 
populations can only be examined during their time in Medicare. 
 
Table 9: Distribution of selected potential modifiers in RE-LY trial participants randomized to dabigatran 150 mg twice 
daily or warfarin and the target populations identified in the 20% random Medicare sample from 2010 through 2015 
that were not restricted by frailty probability. 
Variable 
In RE-LY and randomized to 
either treatment, N=10,115 
Medicare dabigatran new 
users, N=10,717 (T3) 
Medicare warfarin new 
users, N=74,891 (T4) 
Age (Median, P25-P75) 74 (70-78) 75 (70-80) 78 (72-84) 
Sex 6,171 (61.0%) 5,316 (49.6%) 32,430 (43.3%) 
Smoking N (%) 615 (6.1%) 739 (6.9%) 5,149 (6.9%) 
Past stroke N (%) 1147 (11.3%) 2,522 (23.5%) 19,768 (26.4%) 
Hypertensiona N (%) 8152 (80.6%) 10,522 (98.2%) 73,340 (97.9%) 
Past TIA N (%) 871 (8.6%) 900 (8.4%) 6,276 (8.4%) 
CHF N (%) 2637 (26.1%) 3,839 (35.8%) 30,404 (40.6%) 
CAD N (%) 2916 (28.8%) 5,178 (48.3%) 37,389 (49.9%) 
DM N (%) 2319 (22.9%) 3,334 (31.1%) 24,329 (32.5%) 
Cancer N (%) 1207 (11.9%) 1,833 (17.1%) 11,836 (15.8%) 
Past warfarin usea N (%) 6894 (68.2%) 2,154 (20.1%) 26,725 (35.7%) 
Amiodarone use N (%) 994 (9.8%) 1,160 (10.8%) 7,606 (10.2%) 
PPI use  1500 (14.8%) 3,018 (28.2%) 21,915 (29.3%) 
P3=Target population 3. P4 = target population 4. CHF=Congestive heart failure. CAD = coronary artery disease. DM = 
diabetes mellitus. PPI = proton pump inhibitor. 
aThese variables may not be equivalent across data sources, as hypertension in the trial is treated hypertension while 
hypertension in the targets is treated or untreated hypertension, and past use of vitamin K antagonists in the target 







Figure 24: Plot of standardized mean differences (SMDs) for covariates when comparing the RE-LY 
population participants over 65 to the Medicare target populations restricted to less than 15% predicted 
probability of frailty. Negative values indicate increased prevalence or mean in the target population 
compared to the trial, while positive values indicate traits that were more common in the trial than the 
target. The squares are SMDs between the trial and dabigatran users (P1) and the triangles are SMDs 





Table 10: Person-years, event numbers, two-year risks, and two-year risk differences for ischemic stroke, mortality, 
gastrointestinal bleeding, all stroke, and major bleeding in the intention-to-treat and as-treated analyses of the RE-LY 
trial participants over 65. 
Outcome and 
treatment arm 
Person-years Events Two-year risk Two-year risk difference 
(95% CI) 
Ischemic stroke-ITT     
Warfarin 8,751 720 2.39% Ref. 
Dabigatran 150 mg 8,764 650 1.75% -0.64% (-1.3%, 0.01%) 
All-cause mortality-ITT     
Warfarin 8,823 336 7.44% Ref. 





Warfarin 8,739 724 2.25% Ref. 
Dabigatran 150 mg 8,661 715 3.62% 1.37% (0.66%, 2.08%) 
All stroke-ITT     
Warfarin 8,736 703 3.31% Ref. 
Dabigatran 150 mg 8,758 648 2.10% -1.21% (-1.97%, -0.45%) 
Major bleeding-ITT     
Warfarin 8,549 849 7.57%  





Warfarin 7,976 1,321 2.14% Ref. 





Warfarin 8,025 579 4.39%  





Warfarin 7,969 1,331 2.10% Ref. 
Dabigatran 150 mg 7,465 1,308 3.64% 1.54% (0.82%, 2.25%) 
All stroke-OT, IPCW     
Warfarin 7,973 1,317 3.00% Ref. 





Warfarin 7,846 1,835 7.14% Ref. 
Dabigatran 150 mg 7,379 1,718 7.76% 0.62% (-0.54%, 1.77%) 
CI = confidence interval. ITT=intention-to-treat. OT=on-treatment.  
 
 
Table 11: Distributions of the covariates included in the sampling model in each of the four target populations in Medicare and the associated weighted trial 





Trial weighted to P1, 
N=10,113.57 
SMDs (P1 weighted 




P2 weighted trial, 
N=10,073.6 
SMDs (P2 weighted 
Trial vs P2) 
Age (Median, P25-P75) 74 (70-79) 74 (70-79) 0.043 76 (71-81) 76 (71-81) -0.008 
Sex N (%) 4418 (51.5%) 5233.7 (51.7%) 0.005 23691 (46.8%) 4864.5 (48.2%) 0.029 
Smoking N (%) 523 (6.1%) 589.7 (5.8%) -0.011 3100 (6.1%) 572.5 (5.7%) -0.018 
Past stroke N (%) 1484 (17.3%) 1735.2 (17.2%) -0.004 8630 (17%) 1697.6 (16.8%) -0.004 
Past TIA N (%) 511 (6%) 574.7 (5.7%) -0.014 2575 (5.1%) 485.8 (4.8%) -0.013 
CHF N (%) 2730 (31.8%) 3041.7 (30.1%) -0.037 17519 (34.6%) 3153.9 (31.3%) -0.071 
CAD N (%) 3896 (45.4%) 4581.2 (45.3%) -0.002 23171 (45.7%) 4567.8 (45.3%) -0.008 
DM N (%) 2506 (29.2%) 2917.7 (28.8%) -0.008 15487 (30.6%) 2979.4 (29.5%) -0.023 
Cancer N (%) 1459 (17%) 1817.9 (18%) 0.026 7784 (15.4%) 1737.6 (17.2%) 0.050 
Amiodarone use N (%) 888 (10.3%) 1015 (10%) -0.009 5020 (9.9%) 894.7 (8.9%) -0.035 
PPI use  2229 (26%) 2655.4 (26.3%) 0.006 12764 (25.2%) 2648.4 (26.3%) 0.024 
P1=Target population 1. P2 = target population 2. CHF=Congestive heart failure. CAD = coronary artery disease. DM = diabetes mellitus. PPI = proton pump 
inhibitor. 
 
Table 12 Distributions of the covariates included in the sampling model in each of the four target populations in Medicare and the associated weighted trial 
populations in the RE-LY trial. 
Variable 
Dabigatran new 
users, N=10,717 (P3) 
Trial weighted to P3, 
N=9,991.26 
SMDs (P3 weighted 




Trial weighted to 
P4, N=7,980.4 
SMDs (P4 Weighted 
Trial vs P4) 
Age (Median, P25-P75) 75 (70-80) 75 (70-81) 0.061 78 (72-84) 74 (72-75) -1.459 
Sex N (%) 5316 (49.6%) 5,089.6 (50.9%) 0.027 32430 (43.3%) 4,299.9 (53.7%) 0.210 
Smoking N (%) 739 (6.9%) 633.6 (6.3%) -0.023 5149 (6.9%) 675.1 (8.4%) 0.058 
Past stroke N (%) 2522 (23.5%) 2256.6 (22.6%) -0.022 19768 (26.4%) 1754.2 (21.9%) -0.105 
Past TIA N (%) 900 (8.4%) 734 (7.3%) -0.039 6276 (8.4%) 439.1 (5.5%) -0.115 
CHF N (%) 3839 (35.8%) 3290.1 (32.9%) -0.061 30404 (40.6%) 2931.3 (36.6%) -0.082 
CAD N (%) 5178 (48.3%) 4746 (47.5%) -0.016 37389 (49.9%) 3938.4 (49.2%) -0.014 
DM N (%) 3334 (31.1%) 2961.7 (29.6%) -0.032 24329 (32.5%) 2536.6 (31.7%) -0.017 
Cancer N (%) 1833 (17.1%) 1860.8 (18.6%) 0.040 11836 (15.8%) 1332 (16.6%) 0.023 
Amiodarone use N (%) 1160 (10.8%) 1030.8 (10.3%) -0.016 7606 (10.2%) 764.6 (9.6%) -0.022 
PPI use  3018 (28.2%) 2841.1 (28.4%) 0.005 21915 (29.3%) 2207.2 (27.6%) -0.038 
P3=Target population 3. P4 = target population 4. CHF=Congestive heart failure. CAD = coronary artery disease. DM = diabetes mellitus. PPI = proton pump 
inhibitor. 
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Figure 25: Cumulative incidence of ischemic stroke during two years of follow-up and censoring after 
discontinuation and applying censoring weights in A) the on-treatment trial population without sampling 
weights, B) the trial population weighted to the less-frail initiators of dabigatran in Medicare (P1), and C) 
the trial population weighted to the less-frail initiators of warfarin in Medicare (P2). The solid line shows 




Figure 26: Cumulative incidence of ischemic stroke during two years of follow-up and censoring after 
discontinuation and applying censoring weights in the as-treated A) trial population without sampling 
weights, B) trial population weighted to initiators of dabigatran in Medicare (P3), and C) trial population 
weighted to initiators of warfarin in Medicare (P4). The solid line shows survival for dabigatran users and 




Figure 27: Cumulative incidence of all-cause mortality during two years of follow-up and censoring after 
discontinuation and applying censoring weights in A) the on-treatment trial population without sampling 
weights, B) the trial population weighted to the less-frail initiators of dabigatran in Medicare (P1), C) the 
trial population weighted to the less-frail initiators of warfarin in Medicare (P2), D) the trial population 
weighted to initiators of dabigatran in Medicare (P3), and E) the trial population weighted to initiators of 
warfarin in Medicare (P4). The solid line shows survival for dabigatran users and the dashed line 




Figure 28: Cumulative incidence of gastrointestinal bleeding during two years of follow-up and censoring 
after discontinuation and applying censoring weights in A) the on-treatment trial population without 
sampling weights, B) the trial population weighted to the less-frail initiators of dabigatran in Medicare 
(P1), C) the trial population weighted to the less-frail initiators of warfarin in Medicare (P2), D) the trial 
population weighted to initiators of dabigatran in Medicare (P3), and E) the trial population weighted to 
initiators of warfarin in Medicare (P4). The solid line shows survival for dabigatran users and the dashed 




Figure 29: Cumulative incidence of all stroke during two years of follow-up and censoring after 
discontinuation and applying censoring weights in A) the on-treatment trial population without sampling 
weights, B) the trial population weighted to the less-frail initiators of dabigatran in Medicare (P1), C) the 
trial population weighted to the less-frail initiators of warfarin in Medicare (P2), D) the trial population 
weighted to initiators of dabigatran in Medicare (P3), and E) the trial population weighted to initiators of 
warfarin in Medicare (P4). The solid line shows survival for dabigatran users and the dashed line 





Figure 30: Cumulative incidence of major bleeding during two years of follow-up and censoring after 
discontinuation and applying censoring weights in A) the on-treatment trial population without sampling 
weights, B) the trial population weighted to the less-frail initiators of dabigatran in Medicare (P1), C) the 
trial population weighted to the less-frail initiators of warfarin in Medicare (P2), D) the trial population 
weighted to initiators of dabigatran in Medicare (P3), and E) the trial population weighted to initiators of 
warfarin in Medicare (P4). The solid line shows survival for dabigatran users and the dashed line 




Table 13: Person-years, event numbers, two-year risks, and two-year on-treatment risk differences for ischemic 
stroke, mortality, and gastrointestinal bleeding in RE-LY trial participants over 65 after reweightinga to resemble 
dabigatran initiators (P1) or warfarin initiators (P2) in Medicare with less than 15% predicted probability of frailty. 
Outcome and target 
population Person-years Events Two-year risk 
Two-year risk difference 
RDTP (95% CI) 
Ischemic stroke-P1     
Warfarin 7,951 1,457 2.40% Ref. 
Dabigatran 150 mg 7,508 1,240 1.62% -0.78% (-1.69%, 0.14%) 
Ischemic stroke-P2       
Warfarin 7,911 1,522 2.54% Ref. 
Dabigatran 150 mg 7,489 1,389 1.63% -0.91% (-1.93%, 0.11%) 
All-cause mortality-P1       
Warfarin 8,003 630 4.79% Ref. 
Dabigatran 150 mg 7,535 544 4.22% -0.57% (-1.83%, 0.68%) 
All-cause mortality-P2       
Warfarin 7,967 661 5.07% Ref. 
Dabigatran 150 mg 7,518 625 4.90% -0.16% (-1.71%, 1.39%) 
Gastrointestinal 
bleeding-P1       
Warfarin 7,944 1,469 2.48% Ref. 
Dabigatran 150 mg 7,435 1,479 4.23% 1.75% (0.76%, 2.74%) 
Gastrointestinal 
bleeding-P2       
Warfarin 7,900 1,546 2.80% Ref. 
Dabigatran 150 mg 7,391 1,689 4.65% 1.85% (0.65%, 3.04%) 
CI = confidence interval. P1= the population of less-frail dabigatran initiators. P2=the population of less-frail warfarin 
initiators. 
aWeighted with inverse odds of sampling weights including age modeled with restricted cubic splines at the 20th, 40th, 
60th, and 80th percentile, sex, use of amiodarone or proton pump inhibitors, current smoking, diabetes, congestive 





Table 14: Person-years, event numbers, two-year risks, and two-year on-treatment risk differences for all stroke and 
major bleeding in RE-LY trial participants over 65 after reweightinga to resemble dabigatran initiators (P1) or warfarin 
initiators (P2) in Medicare. 
Outcome and target 
population Person-years Events Two-year risk 
Two-year risk difference  
RDTP (95% CI) 
All stroke-P1     
Warfarin 7,941 1,468 3.32%  
Dabigatran 150 mg 7,506 1,232 1.81% -1.52% (-2.52%, -0.51%) 
All stroke-P2       
Warfarin 7,898 1,533 3.53%  
Dabigatran 150 mg 7,488 1,377 1.83% -1.70% (-2.80%, -0.59%) 
Major bleeding-P1       
Warfarin 7,780 2,054 7.90%  
Dabigatran 150 mg 7,329 1,910 8.73% 0.83% (-0.63%, 2.29%) 
Major bleeding-P2       
Warfarin 7,726 2,145 8.38%  
Dabigatran 150 mg 7,270 2,126 9.59% 1.2% (-0.45%, 2.86%) 
CI = confidence interval. P1= the population of less-frail dabigatran initiators. P2=the population of less-frail warfarin 
initiators.  
aWeighted with inverse odds of sampling weights including age modeled with restricted cubic splines at the 20th, 40th, 
60th, and 80th percentile, sex, use of amiodarone or proton pump inhibitors, current smoking, diabetes, congestive 





Table 15: Person-years, event numbers, two-year risks, and two-year as-treated risk differences for ischemic stroke, 
mortality, and gastrointestinal bleeding in RE-LY trial participants over 65 after reweighting to resemble dabigatran 
initiators (P3) or warfarin initiators (P4) in Medicare. 
Outcome and target 
population Person-years Events Two-year risk 
Two-year risk difference 
RDTP (95% CI) 
Ischemic stroke-P3     
Warfarin 7,772 1,556 2.65% Ref. 
Dabigatran 150 mg 7,462 1,437 1.72% -0.92% (-2.02%, 0.17%) 
Ischemic stroke-P4       
Warfarin 6,476 1,301 2.52% Ref. 
Dabigatran 150 mg 5,827 842 2.7% 0.18% (-2.05%, 2.41%) 
All-Cause mortality-P3       
Warfarin 7,832 671 5.27% Ref. 
Dabigatran 150 mg 7,497 644 5.01% -0.26% (-1.92%, 1.39%) 
All-Cause mortality-P4       
Warfarin 6,530 574 5.02% Ref. 
Dabigatran 150 mg 5,858 292 3.15% -1.87% (-3.36%, -0.37%) 
Gastrointestinal 
bleeding-P3 
    
  
Warfarin 7,769 1,566 2.73% Ref. 
Dabigatran 150 mg 7,375 1,701 4.51% 1.78% (0.6%, 2.96%) 
Gastrointestinal 
bleeding-P4 
    
  
Warfarin 6,485 1,304 1.91% Ref. 
Dabigatran 150 mg 5,788 924 4.01% 2.1% (0.51%, 3.69%) 
All stroke-P3       
Warfarin 7,758 1,569 3.67% Ref. 
Dabigatran 150 mg 7,460 1,427 1.96% -1.71% (-2.92%, -0.51%) 
All stroke-P4       
Warfarin 6,468 1,356 3.14% Ref. 
Dabigatran 150 mg 5,826 844 2.77% -0.37% (-2.62%, 1.88%) 
Major bleeding-P3       
Warfarin 7,592 2,162 8.31% Ref. 
Dabigatran 150 mg 7,245 2,172 9.58% 1.26% (-0.53%, 3.06%) 
Major bleeding-P4       
Warfarin 6,343 1,734 6.79% Ref. 
Dabigatran 150 mg 5,721 1,198 7.12% 0.34% (-1.78%, 2.45%) 
CI = confidence interval. P3= the population of all dabigatran initiators. P4=the population of warfarin initiators. 
aWeighted with inverse odds of sampling weights including age modeled with restricted cubic splines at the 20th, 
40th, 60th, and 80th percentile, sex, use of amiodarone or proton pump inhibitors, current smoking, diabetes, 




Table 16: Two-year risk differences for the three main outcomes obtained using SMR weighting in all four main target 
populations. 
Outcome 
SMR two-year RD in 
less-frail dabigatran 
new users, RDO1 (95% 
CI) 
SMR two-year RD in 
less-frail warfarin new 
users, RDO2 (95% CI) 
SMR two-year RD in 
dabigatran new users, 
RDO3 (95% CI) 
SMR two-year RD in 
warfarin new users, 
RDO1 (95% CI) 
Ischemic Stroke -0.46% (-0.88%, -0.03%) -0.55% (-1.22%, 0.13%) -0.67% (-1.10%, -0.24%) -0.74% (-1.47%, -0.01%) 
Mortality -1.94% (-2.92%, -0.97%) -0.39% (-2.68%, 2.09%) -2.96% (-3.97%, -1.95%) -3.00% (-5.23%, -0.74%) 
Gastrointestinal 
bleeding 0.14% (-0.82%, 1.09%) 0.57% (-0.70%, 1.83%) 0.51% (-0.30%, 1.31%) 1.97% (-0.15%, 4.08%) 
CI = Confidence interval. SMR = standardized morbidity ratio. RD = risk difference. RDOP = the SMR-weighted risk difference 
using non-experimental data in target population P. 
aWeighted based upon logistic regression including frailty and age modeled with restricted cubic splines at the 20th, 40th, 
60th, and 80th percentile, sex, diabetes, coronary artery disease, congestive heart failure, hypertension, stroke in the past 
year, transient ischemic attack, cancer, bleed and GI bleed history, past use of vitamin K antagonists, alcohol abuse, acute 
renal problems, atherosclerosis, cardioversion in the past year, deep vein thrombosis in the past year, hyperlipidemia, 




Figure 31: Each panel plots the estimated risk differences from the transported RE-LY trial on the vertical 
axis against the estimated risk differences from non-experimental methods in those same populations 
on the horizontal axis, with each panel corresponding to a different outcome (panel A is ischemic stroke; 
panel B is mortality; and panel C is gastrointestinal bleeding) and each point representing a different 
target population (circles are the target population of less-frail dabigatran users, squares are the target 
population of less-frail warfarin users). The closer the point estimates are to the reference line at 45 
degrees, the more similar the findings are. If the horizontal line crosses that line, 95% confidence limits 
of the non-experimental estimate include the weighted trial estimate; if the vertical line crosses that 




Figure 32: Each panel plots the estimated risk differences from the transported RE-LY trial on the vertical 
axis against the estimated risk differences from non-experimental methods in those same populations 
on the horizontal axis, with each panel corresponding to a different outcome (panel A is ischemic stroke; 
panel B is mortality; and panel C is gastrointestinal bleeding) and each point representing a different 
target population (circles are the target population of dabigatran users, squares are the target 
population of warfarin users). The closer the point estimates are to the reference line at 45 degrees, the 
more similar the two results are. If the horizontal line crosses that line, 95% confidence limits of the 
non-experimental estimate include the weighted trial estimate; if the vertical line crosses that line, 95% 
confidence limits of the weighted trial estimate include the non-experimental estimate.  
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Table 17: Two-year risks and risk differences comparing ischemic stroke, mortality, gastrointestinal bleeding, all stroke, and 
major bleeding in arms of the weighted RELY trial to the observed risks in dabigatran (T1) and warfarin (T2) users in 
Medicare with less than 15% predicted probability of frailty, 
Outcome and target 
population 
Two-year risk for the weighted 
RE-LY population on the 
correspondinga drug, RT 
Observed two-year risk in the 
Medicare population on the 
correspondinga drug, RO 
Two-year risk difference for 
RT-RO (95% CI) 
Ischemic stroke    
Dabigatran users (P1) 1.62% 1.05% -0.57% (-1.20%, 0.05%) 
Warfarin users (P2) 2.54% 1.85% -0.69% (-1.48%, 0.09%) 
All-cause mortality    
Dabigatran users (P1) 4.22% 4.4% 0.18% (-1.07%, 1.44%) 
Warfarin users (P2) 5.07% 7.09% 2.02% (0.84%, 3.20%) 
Gastrointestinal 
bleeding   
 
Dabigatran users (P1) 4.23% 3.33% -0.90% (-2.05%, 0.25%) 
Warfarin users (P2) 2.8% 3.16% 0.36% (-0.41%, 1.13%) 
All stroke    
Dabigatran users (P1) 1.81% 1.38% -0.43% (-1.18%, 0.32%) 
Warfarin users (P2) 3.53% 2.22% -1.31% (-2.16%, -0.45%) 
Major bleeding    
Dabigatran users (P1) 8.73% 3.97% -4.76% (-6.23%, -3.29%) 
Warfarin users (P2) 8.38% 4.33% -4.05% (-5.13%, -2.98%) 
CI=confidence interval. 
aFor the target population P1 of dabigatran users, this risk is the risk in dabigatran users in the weighted RE-LY or Medicare 
population in the left and right column, respectively. For the population P2 of warfarin users, this is the risk in warfarin users 
in the weighted RE-LY or Medicare population. 
 
Table 18: Two-year risks and risk differences comparing ischemic stroke, mortality, gastrointestinal bleeding, all stroke, and 
major bleeding in arms of the weighted RELY trial to the observed risks in all dabigatran and warfarin users in Medicare. 
Outcome and target 
population 
Two-year risk for the weighted 
RE-LY population on the 
correspondinga drug, RT 
Observed two-year risk in the 
Medicare population on the 
correspondinga drug, RO 
Two-year risk difference for 
RT-RO (95% CI) 
Ischemic stroke    
Dabigatran users (P3) 1.72% 1.29% -0.43% (-1.12%, 0.26%) 
Warfarin users (P4) 2.52% 2.48% -0.04% (-1.12%, 1.04%) 
All-cause mortality    
Dabigatran users (P3) 5.01% 6.82% 1.81% (0.16%, 3.45%) 
Warfarin users (P4) 5.02% 14.02% 9.00% (7.71%, 10.29%) 
Gastrointestinal 
bleeding   
 
Dabigatran users (P3) 4.51% 4% -0.51% (-1.78%, 0.75%) 
Warfarin users (P4) 1.91% 3.76% 1.85% (1.14%, 2.56%) 
All stroke    
Dabigatran users (P3) 1.96% 1.59% -0.37% (-1.15%, 0.41%) 
Warfarin users (P4) 3.14% 2.99% -0.15% (-1.29%, 0.99%) 
Major bleeding    
Dabigatran users (P3) 9.58% 4.64% -4.94% (-6.62%, -3.26%) 
Warfarin users (P4) 6.79% 5.19% -1.60% (-3.01%, -0.20%) 
CI=confidence interval. 
aFor the population P3 of dabigatran users, this risk is the risk in dabigatran users in the weighted RE-LY or Medicare 
population in the left and right column, respectively. For the population P4 of warfarin users, this is the risk in warfarin users 





Table 19: Risk differences for various outcomes from sensitivity analyses after applying additional exclusion criteria and 
further frailty restrictions. 
Outcome 
Two-year RD (95% CI) 
after weighting to 
≤10% PPF dabigatran 
new users 
Two-year RD (95% CI) 
after weighting to 
≤10% PPF warfarin 
new users 
Two-year RD (95% CI) 
after weighting to 
dabigatran new users 
with no stroke in 180 
days 
Two-year RD (95% CI) 
after weighting to 
warfarin new users 
with no stroke in 180 
days. 
Ischemic stroke -0.93% (-1.82%, -0.04%) -0.72% (-1.67%, 0.24%) -0.82% (-1.77%, 0.13%) -0.19% (-1.30%, 0.91%) 
Mortality -0.64% (-1.80%, 0.51%) -2.17% (-3.52%, -0.82%) -0.28% (-1.67%, 1.10%) -1.67% (-3.77%, 0.43%) 
Gastrointestinal 
bleeding 
1.71% (0.77%, 2.66%) 0.72% (-0.37%, 1.81%) 1.63% (0.51%, 2.76%) 1.96% (0.30%, 3.62%) 
All stroke -1.63% (-2.60%, -0.67%) -1.36% (-2.4%, -0.33%) -1.47% (-2.48%, -0.46%) -0.66% (-1.83%, 0.50%) 
Major bleeding 0.89% (-0.50%, 2.28%) -0.76% (-2.28%, 0.77%) 0.96% (-0.61%, 2.53%) 0.30% (-1.83%, 2.44%) 
PPF = predicted probability of frailty. CI = confidence interval. 
 
Table 20: Risk differences for various outcomes from sensitivity analyses including altered hypertension and past 
vitamin K usage or a quadratic term for age in the sampling model. 
Outcome 
Two-year RD (95% CI) 
after weighting to 
≤15% PPF dabigatran 
new users with 
additional covariates 
Two-year RD (95% CI) 
after weighting to 
≤15% PPF warfarin 
new users with 
additional covariates 
Two-year RD (95% CI) 
after weighting to 
≤15% PPF dabigatran 
new users with 
quadratic age term 
Two-year RD (95% CI) 
after weighting to 
≤15% PPF warfarin new 
users with quadratic 
age term 
Ischemic stroke -0.33% (-1.90%, 1.23%) -0.63% (-2.15%, 0.90%) -0.82% (-1.70%, 0.05%) -0.97% (-1.94%, -0.01%) 
Mortality -0.73% (-2.62%, 1.15%) -0.60% (-2.76%, 1.55%) -0.53% (-1.73%, 0.66%) -0.13% (-1.59%, 1.32%) 
Gastrointestinal 
bleeding 
1.60% (-0.03%, 3.23%) 1.46% (-0.19%, 3.10%) 1.82% (0.88%, 2.76%) 1.97% (0.84%, 3.10%) 
All stroke -1.03% (-2.68%, 0.63%) -1.38% (-2.96%, 0.20%) -1.56% (-2.53%, -0.59%) -1.76% (-2.82%, -0.71%) 
Major bleeding 0.44% (-1.96%, 2.83%) 0.78% (-1.41%, 2.96%) 0.91% (-0.54%, 2.36%) 1.28% (-0.33%, 2.90%) 
PPF = predicted probability of frailty. CI = confidence interval. 
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CHAPTER 6: CONCLUSIONS 
6.1: Main findings 
 We had two main goals in this work: first, estimate treatment effects of dabigatran vs warfarin 
on a variety of outcomes with propensity score methods and a new user active comparator design 
entirely using non-experimental data; and second, estimate analogous treatment effects using inverse 
odds of sampling weights and data from a randomized trial combined with target population data. In the 
first goal, we also explored differences in effects of initiating and staying on treatment (adherence-
adjusted or on-treatment design) versus initial treatment assignment (first treatment carried forward or 
intention-to-treat design). 
In the first goal, we relied entirely on data from a 20% random sample of Medicare beneficiaries 
provided by the Centers for Medicare and Medicaid Services. We used outcome and covariate data from 
the dabigatran and warfarin initiators we were intending to use as target populations in the first goal to 
estimate both as-treated and intention-to-treat effects. Unlike the transported trial, which focused on 
estimating effects in warfarin and dabigatran initiators separately, the non-experimental work estimated 
treatment effects in the entire population (estimated using inverse probability of treatment weights, 
IPTW) as well as treatment effects in initiators of dabigatran and warfarin separately (estimated using 




As-treated estimates of treatment effect in all initiators were similar to past non-experimental 
work: dabigatran appeared protective for ischemic stroke (two-year IPTW RD, RDIPTW: -0.73%, 95% CI: -
1.40%, -0.06%), strongly protective for mortality (RDIPTW: 2.98%, 95% CI: -5.05%, -0.91%), and harmful for 
gastrointestinal bleeding (RDIPTW: 1.79%, 95% CI: -0.13%, 3.71%). Gastrointestinal bleeding harms 
appeared weaker in initiators of dabigatran (two-year SMR RD, RDdabi: 0.51%, 95% CI: -0.30%, 1.31%), 
but effects on mortality (RDdabi: -2.96%, 95% CI  -3.97%, -1.95%) and ischemic stroke (RDdabi: -0.67%, 95% 
CI: -1.10%, -0.24%) stayed relatively constant. 
 Intention-to-treat estimates, however, told a very different story. Dabigatran actually appeared 
to be harmful with respect to ischemic stroke in all users (RDIPTW: 0.44%, 95% CI -0.22%, 1.09%), and 
mortality benefits were greatly attenuated (RDIPTW: -0.84%, 95% CI: -2.39%, 0.72%). Gastrointestinal 
bleeding effects were also attenuated (RDIPTW: 1.05%, 95% CI: 0.08%, 2.01%). Targeting dabigatran 
initiators reduced, but did not eliminate, the change in estimates for ischemic stroke (RDdabi: 0.16%, 95% 
CI -0.20%, 0.52%), mortality (RDdabi: -1.65%, 95% CI -2.32%, -0.98%) and gastrointestinal bleeding (RDdabi: 
0.36%, 95% CI -0.08%, 0.79%). These differences in intention-to-treat and as-treated estimates remained 
across a variety of sensitivity analyses. While it’s theoretically possible that this could be due to an open 
backdoor path through factors predicting treatment adherence biasing intention-to-treat estimates but 
not as-treated estimates, it does emphasize the potential for loss of clinically relevant information when 
we only examine effects in those that remain on treatment. 
 Meanwhile, to accomplish the second goal, we leaned heavily on both the Randomized 
Evaluation of Long-Term Anticoagulation (RE-LY) trial and the 20% random sample of Medicare 
beneficiaries. After reweighting the trial participants to resemble two target populations of dabigatran 
initiators and warfarin initiators in the target population and censoring at treatment discontinuation, 
there was evidence of issues with positivity towards the edges of the the sampling distribution and 
inability to match mortality in the target population.  
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After restricting ourselves to Medicare initiators with less than 15% predicted probability of 
frailty to mimic trial exclusion criteria, however, these issues diminished, and we were able to obtain as-
treated estimates of treatment effect for ischemic stroke (RDdabi: -0.77%, 95% CI -1.69%, 0.14%; RDwarf: -
0.91%, 95% CI -1.93%, 0.11%), all-cause mortality (RDdabi: -0.57%, 95% CI -1.83%, 0.68%; RDwarf: -0.16%, 
95% CI -1.71%, 1.39%), and gastrointestinal bleeding (RDdabi: 1.75%, 95% CI 0.76%, 2.74%; RDwarf: 1.85%, 
95% CI 0.65%, 3.04%). Even in this restricted population, however, differences remained in mortality for 
warfarin users relative to Medicare initiators, and after applying those weights we saw more stroke and 
gastrointestinal bleeding events in weighted trial patients than observed in our targets. Differences in 
warfarin therapy, differences in outcome sensitivity and specificity, and missing information on the key 
effect measure modifier of bleed were all potential causes of these differences. 
 To have appropriate benchmarks for comparing the non-experimental estimate to the 
transported estimates, we also re-analyzed the non-experimental data limiting ourselves to initiators 
with less than 15% predicted probability of frailty and specifically targeting the two populations of 
dabigatran and warfarin users. These SMR weighted estimates in the non-experimental study showed 
very similar estimates of effect on ischemic stroke risk to the reweghted trial (RDdabi: -0.46%, 95% CI -
0.88%, -0.03%; RDwarf: -0.55%, 95% CI -1.22%, 0.13%), but estimates of effects on mortality were larger 
for dabigatran users (RDdabi: -1.94%, 95% CI      -2.92%, -0.97%; RDwarf: -0.39%, 95% CI -2.68%, 2.09%) and 
estimates of effects on gastrointestinal bleeding were reduced (RDdabi: 0.14%, 95% CI -0.82%, 1.09%; 
RDwarf: 0.57%, 95% CI -0.70%, 1.83%). These differences in mortality and gastrointestinal bleeding 
estimates could be due to unmeasured confounding, measurement error, differences in distributions of 





 With the ongoing phasing out of warfarin in favor of dabigatran and other novel oral 
anticoagulants in patients with atrial fibrillation, understanding the advantages and disadvantages of 
each of these new drugs is key. The differences in intention-to-treat and as-treated estimates from the 
non-experimental work reemphasize the importance of remaining on a stabilized treatment for patients 
receiving oral anticoagulants. While it is tempting to limit ourselves to estimating one of these two 
intervention effects, the context gained from estimating both is vital to simulaneously improve clinician 
decision-making and public health. 
This work is provides the first absolute-scale effect estimates from RE-LY including censoring 
weights and some of the first absolute-scale effect estimates in Medicare as whole. Additionally, this is 
the first time the trial data has been reweighted to take into account differing distributions of risk 
factors in older adults receiving routine care for atrial fibrillation. Differences in effects on 
gastrointestinal bleeding and mortality in even the frailty-restricted trial and non-experimental study 
lends significant context the large mortality benefits from this and other non-experimental work, though 
it is possible those benefits are concentrated heavily in the frailer patients and based on differing 
patterns of warfarin therapy.  
Finally, we also observed potential differences in treatment effect across target populations of 
warfarin users and dabigatran users, suggesting that prescribers may have been successful in steering 




6.3: Future directions 
We plan to use this work as a case study illustrating the potential impact of misclassification and 
missing data for transporting trial results to target populations. This could help contextualize the extent 
to which problems we observed in the differential classification of effect measure modifiers we wanted 
to include in our sampling models (e.g. hypertension, history of major bleeding, and past vitamin K 
antagonist use) could bias results in this and future studies. We also hope to use this scenario to assess 
potential exaggeration of chance confounding after randomization by effect modifiers. We further hope 
to contrast transported effects in all dabigatran new users with transported effects in individuals 
switching to dabigatran.  Finally, examining per-protocol treatment effects with a more complex 
treatment rule, rather than simply requiring individuals stay on treatment, could provide additional 
insight into treatment effects, as could digging further into the components of the censoring models and 
attempting to understand the differential experience of warfarin and dabigatran switchers and stoppers. 
We strongly suggest that future non-experimental pharmacoepidemiologic studies assessing 
long-term treatments consider estimating both intention-to-treat and as-treated treatment effects. 
Determining and providing in publications which drug had longer follow-up time in the as-treated 
approach is similarly vital. This is especially important in an active comparator new user design where 
one drug may have radically differing adherence and persistence patterns relative to the other. Knowing 
when differential stopping or switching rates cause overall worse performance is key to public health. 
As a result of this, additional work in understanding the best ways to transport intention-to-
treat effect estimates is key. Can trial populations with much lower rates of discontinuation and re-
initiation be used to stand-in for target populations that stop, switch, and restart treatment at double 
the rate? Can and should this be done routinely for trials with run-in periods or restrictions designed to 




We recommend future work transporting study results to other populations where outcome 
data is available should make sure to assess whether the weighted populations experience similar 
outcomes to those from the original to identify when key covariates may be unavailable for the sampling 
model. Researchers should also be sure to assess how covariates in the source and target populations 
have been measured differently when determining whether the fits of their sampling models are 
plausible. Additional work on methods for identifying whether covariates are necessary for a sampling 
model would also help precision. 
Finally, we suggest comparisons of non-experimental and trial data in both this and other 
settings should do their best to move beyond direct comparisons of point estimates and assuming there 
is no heterogeneity of treatment effect, particularly when there may be issues of non-positivity in the 
trial. When non-experimental data and trial data conflict, it’s vital to address as many potential sources 
of error as possible, including standardizing both target population and intention-to-treat versus as-
treated estimands. Once that’s done, considering the plausibility of confounding, measurement error, 





APPENDIX A: OUTCOME CODING 
Outcome Hospital Discharge Codes 
Ischemic stroke As primary discharge diagnosis: 
433.x1 Occlusion and stenosis of precerebral 
arteries 
434.x1 Occlusion and stenosis of cerebral arteries 
with cerebral infarction 
All stroke As primary discharge diagnosis: 
431.x Intracerebal hemorrhage 
433.x1 Occlusion and stenosis of precerebral 
arteries 
434.x1 Occlusion and stenosis of cerebral arteries 
with cerebral infarction 
436.x Acute but ill-defined cerebrovascular 
events 
Gastrointestinal bleeding: As primary discharge diagnosis: 
 
Upper gastrointestinal bleed: 
531.0x Acute gastric ulcer with hemorrhage with 
or without obstruction 
531.2x Acute gasric ulcer with hemorrhage and 
perforation with or without obstruction 
531.4x Chronic or unspecified gastric ulcer with 
hemorrhage with or without obstruction 
531.6x Gastric ulcer with hemorrhage and 
perforation with or without obstruction 
532.0x Acute duodenal ulcer with hemorrhage 
with or without obstruction 
532.2x Acute duodenal ulcer with hemorrhage 
and perforation with or without obstruction 
532.4x Chronic or unspecified duodenal ulcer 
with hemorrhage with or without obstruction 
532.6x Chronic or unspecified duodenal ulcer 
with hemorrhage and perforation with or without 
obstruction 
533.0x Acute peptic ulcer of unspecified site with 
hemorrhage with or without obstruction 
533.2x Acute peptic ulcer of unspecified site with 
hemorrhage and perforation with or without 
obstruction 
533.4x Chronic or unspecified peptic ulcer of 
unspecified site with hemorrhage with or without 
obstruction 
533.6x Chronic or unspecified peptic ulcer of 
unspecified site with hemorrhage and perforation 
with or without obstruction 
534.0x Acute gastrojejunal ulcer with 
hemorrhage with or without obstruction 
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534.2x Acute gastrojejunal ulcer with 
hemorrhage and perforation with or without 
obstruction 
534.4x Chronic or unspecified gastrojejunal ulcer 
with hemorrhage with or without obstruction 
534.6x Chronic or unspecified gastrojejunal ulcer 
with hemorrhage and perforation with or without 
obstruction 
578.0 Hematemesis 
ICD-9 procedure code 44.43 Endoscopic control 
of gastric or duodenal bleeding 
CPT code 43255 Upper gastrointestinal 
endoscopy including esophagus, stomach and 
either the duodenum and/or jejunum as 
appropriate with control of bleeding, any method 
 
Lower and unspecified G.I. bleeds: 
562.02 Diverticulosis of small intestine with 
hemorrhage 
562.03 Diverticulitis of small intestine with 
hemorrhage 
562.12 Diverticulosis of colon with hemorrhage 
562.13 Diverticulitis of colon with hemorrhage 
569.3x Hemorrhage of rectum and anus 
569.85 Angiodysplasia of intestine with 
hemorrhage 
578.1x Blood in stool 
578.9 Hemorrhage of GI tract, unspecified 
 
Major bleeding As primary discharge diagnosis: 
 
Intracranial bleeding: 
430.x Subarachnoid hemorrhage 
431.x Intracerebral hemorrhage 
432.x Other and unspecified intracranial 
hemorrhage 
 
Upper gastrointestinal bleed: 
531.0x Acute gastric ulcer with hemorrhage with 
or without obstruction 
531.2x Acute gasric ulcer with hemorrhage and 
perforation with or without obstruction 
531.4x Chronic or unspecified gastric ulcer with 
hemorrhage with or without obstruction 
531.6x Gastric ulcer with hemorrhage and 
perforation with or without obstruction 
532.0x Acute duodenal ulcer with hemorrhage 
with or without obstruction 
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532.2x Acute duodenal ulcer with hemorrhage 
and perforation with or without obstruction 
532.4x Chronic or unspecified duodenal ulcer 
with hemorrhage with or without obstruction 
532.6x Chronic or unspecified duodenal ulcer 
with hemorrhage and perforation with or without 
obstruction 
533.0x Acute peptic ulcer of unspecified site with 
hemorrhage with or without obstruction 
533.2x Acute peptic ulcer of unspecified site with 
hemorrhage and perforation with or without 
obstruction 
533.4x Chronic or unspecified peptic ulcer of 
unspecified site with hemorrhage with or without 
obstruction 
533.6x Chronic or unspecified peptic ulcer of 
unspecified site with hemorrhage and perforation 
with or without obstruction 
534.0x Acute gastrojejunal ulcer with 
hemorrhage with or without obstruction 
534.2x Acute gastrojejunal ulcer with 
hemorrhage and perforation with or without 
obstruction 
534.4x Chronic or unspecified gastrojejunal ulcer 
with hemorrhage with or without obstruction 
534.6x Chronic or unspecified gastrojejunal ulcer 
with hemorrhage and perforation with or without 
obstruction 
578.0 Hematemesis 
ICD-9 procedure code 44.43 Endoscopic control 
of gastric or duodenal bleeding 
CPT code 43255 Upper gastrointestinal 
endoscopy including esophagus, stomach and 
either the duodenum and/or jejunum as 
appropriate with control of bleeding, any method 
 
Lower and unspecified G.I. bleeds: 
562.02 Diverticulosis of small intestine with 
hemorrhage 
562.03 Diverticulitis of small intestine with 
hemorrhage 
562.12 Diverticulosis of colon with hemorrhage 
562.13 Diverticulitis of colon with hemorrhage 
569.3x Hemorrhage of rectum and anus 
569.85 Angiodysplasia of intestine with 
hemorrhage 
578.1x Blood in stool 




Other major bleeds: 
285.1x Acute posthemorrhagic anemia 
423.0x Hemopericardium 











APPENDIX B: ELIGIBILITY CRITERIA AND CODING 
Variable Related ICD-9 codes 
Inclusion:  
Atrial fibrillation 427.31 



















Past TIA ICD-9 code: 
435.x 
Diabetes 1 hospital discharge or 2 outpatient ICD-9 for DM 
250.x 
OR 
Dispensing of metformin, sulfonylureas, insulin, 
or other direct antidiabetic agent 
Hypertension ICD-9 diagnosis codes: 
401.x-405.x 
OR 
Dispensing of CCB, ACEI, ARB, BB, thiazide 
diuretic, or other direct antihypertensive agent 







Valvular heart disease and heart valve 
replacement 

































ICD-9 procedure codes: 
39.1 
42.91 
Cancer within the last 6 months ICD-9 diagnosis codes: 
140.x-208.x 
230.x-239.x 





















Predicted probability of frailty > 15% Calculated from Faurot et al.118 
Other covariates  
Systemic embolism ICD-9 codes: 
444.x 
Deep vein thrombosis 451.x, 453.x 
Pulmonary embolism 415.11, 415.12, 415.19 





Statins or other antihyperlipidemic 





















35256, 35286, 35351, 35355, 35361, 35363, 
35371, 35372, 35381, 35454, 35456, 35459, 
35470, 35473, 35474, 35482, 35483, 35485, 
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35492, 35493, 35495, 35521, 35533, 35541, 
35546, 35548, 35549, 35551, 35556, 35558, 
35563, 35565, 35566, 35571, 35621, 35623, 
35641, 35646, 35647, 35650, 35651, 35654, 
35656, 35661, 35663, 35666, 35671  






































APPENDIX C: PROCEDURE CODES FOR ANTICOAGULATION MANAGEMENT 
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